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Abbreviations  
The abbreviations of the amino acids and their derivatives are written according to the 
recommendations of the IUPAC-IUBMB Joint Commission on Biochemical 
Nomenclature (JCBN) using the three or one letter code. Unless otherwise indicated, all 
amino acids and their derivatives have L-configuration. Abbreviations of chemical 
compounds are taken from the relevant references like Methods of Organic Chemistry 
(Houben-Weyl), March's Advanced Organic Chemistry and Greene's Protective Groups 
in Organic Synthesis. 
 
Å Ångstrom (1Å = 10-10 m) 
Ac acetyl 
HOAc acetic acid 
ACN acetonitrile 
Am amidine 
AcOxAm acetylhydroxyamidine 
Amba 4-amidinobenzylamide 
Abu α-aminobutyric acid (homoalanine) 
Bzls benzylsulfonyl 
Boc tert.-butyloxycarbonyl 
Bzlu benzylurea 
calcd calculated 
Cbz benzyloxycarbonyl 
Chxu cyclohexylurea 
Dbzg dibenzylglycine 
DIPEA diisopropylethylamine 
Dpheg diphenylethylglycine 
(Boc)2O di-tert-butyl dicarbonate 
DCM dichloromethane 
DMF N,N-dimethylformamide 
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DMSO dimethylsulfoxide 
Et ethyl 
EtOAc ethyl acetate 
EDCI 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
฀equiv equivalent 
EtO ethoxy 
fXa factor Xa 
Fig. figure 
h hour 
OxAm hydroxyamidine 
HAT human airway trypsin-like protease 
HATU O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
hexafluorophosphate 
HBTU 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HOBt 1-hydroxybenzotriazole 
hPhe homophenylalanine 
hTyr homotyrosine 
Ki dissociation constant for the enzyme inhibitor complex 
Km Michaelis-Menten-constant 
MMPs matrix metalloproteinases 
MeOH methanol 
MeO methoxy 
MS mass spectrometry 
n.d. not determined  
NMM N-methyl morpholine 
NMR nuclear magnetic resonance spectroscopy 
Nva norvaline 
Pbf 2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl 
Pd/C palladium on activated charcol 
Phg phenylglycine 
Abbreviations 
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Phe(3-CN) 3-cyanophenylalanine 
PDB protein data base 
Pip piperidide 
pNA para-nitroanilin 
ppm parts per million  
PAR-2 proteinase-activated receptor 2 
Pra propargylglycine 
PyBOP benzotriazol-1-yl-N-oxy-tris(pyrrolidino)phosphonium hexafluorophosphate 
Pyr pyridyl 
Rf retardation factor (TLC) 
RP-HPLC reversed phase-high performance liquid chromatography 
RT room temperature 
tBu tert.-butylester 
TEA triethylamine 
TFA trifluoroacetic acid 
Tfa trifluoroacetyl 
THF tetrahydrofuran 
TLC thin-layer chromatography 
TMPRSS2 transmembrane protease serine 2 (epitheliasin) 
TMS trimethylsilane 
Tris tris(hydroxymethyl)aminomethane 
TTSP-II type II transmembrane serine protease 
uPA urokinase-type plasminogen activator 
Vmax maximum velocity of non-inhibited enzyme reaction 
Cbz-OSu N-(benzyloxycarbonyloxy)succinimide 
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1 Introduction 
1.1 Cancer 
Cancer is medically known as a malignant neoplasm, which is a group of diseases 
characterized by uncontrolled growth and the spread of abnormal cells. It may also 
extend to more distant parts of the body through the lymphatic system or bloodstream. 
Cancer is caused by a multistep process of alterations in several oncogenes due to either 
the damage of genes or to genetic faults within cells in tumor-suppressor genes and 
microRNA genes. Oncogenes encode proteins that control cell proliferation, apoptosis, 
or both. They can be activated by structural alterations resulting from mutation or gene 
fusion.[1, 2] Oncogenes produce six broad groups of products: transcription factors, 
chromatin remodelers, growth factors, growth factor receptors, signal transducers, and 
apoptosis regulators. These products are involved in the initiation and progression of 
tumors and have become important targets for the development of new anticancer 
drugs.[2] The alterations in genes occurred as a result of internal factors, such as 
inherited mutations, hormones and immune conditions; and environmental/acquired 
factors such as tobacco, diet, radiation, and infectious organisms, (Fig. 1.1). The 
contribution of genetic factors and environmental factors towards cancer risk is 5–10% 
and 90–95%, respectively. The evidence indicates that of all cancer-related deaths, 
almost 25-30% are caused by tobacco, as many as 30-35% are linked to diet, about 15-
20% are due to infections, and the remaining percentage are due to other factors like 
radiation, stress, physical activity, and environmental pollutants, etc.[3] 
 
Fig. 1.1 The role of genes and environment in the development of cancer. A: The percentage contribution 
of genetic and environmental factors to cancer. B: Percentage contribution of each environmental factor. 
The percentages represented here indicate the attributable-fraction of cancer deaths due to the specified 
environmental risk factor (figure adapted from Anand, 2008[3]).  
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The international agency for research on cancer (IARC) considered cancer as one of the 
leading causes of death in economically developed countries and the second leading 
cause of death in developing countries.[4] About 12.7 million cancer cases and 7.6 
million cancer deaths are estimated to have occurred in 2008 worldwide, with 56% of 
the cases and 64% of the deaths in the countries of the third world. Breast, lung, 
colorectal, and cervix cancers in females and lung, liver, colorectal, and prostate cancers 
in males are the most frequently diagnosed cancers and the leading cause of cancer 
death worldwide.[5] Cancer cells possess a broad spectrum of migration and invasion 
mechanisms. These include both individual and collective cell-migration strategies. The 
ability of a cancer cell to undergo migration and invasion allows it to change position 
within the tissues. For example, cell-migration processes allow neoplastic cells to enter 
lymphatic and blood vessels for dissemination into the blood stream, afterwards the 
cells undergo metastatic growth in distant organs.[6] To spread within the tissues, tumor 
cells use migration mechanisms, where the cell must modify its shape and stiffness to 
interact with the surrounding tissue. Hereby, the extracellular matrix (ECM) provides 
the substrate, as well as a barrier towards the advancing cell body. Proteases in general, 
including type II transmembrane serine proteases (TTSPs), play a potential role in 
degrading components of the ECM and thus give tumor cells the ability to migrate and 
spread within living tissues. In recent years, numerous studies focused on the expression 
of individual TTSPs including matriptase during tumor progression; and on the possible 
functions of these enzymes in tumor cell proliferation, migration and invasion.[7] For 
these reasons, inhibition of such enzymes in the initiating steps of cancer might have 
clinical importance in tumor development and this offers a new rational strategy for 
cancer treatment. 
1.2 Proteases and their roles in tumorgenesis and tumor suppression 
Proteases are a class of enzymes that play fundamental roles in multiple biological 
processes and are associated with a wide variety of pathological conditions, including 
cancer. They act as processing enzymes, catalyze the cleavage of specific substrates and 
influence cell behavior, survival and death.[8] In the 1970s various proteases of the 
serine, cysteine, and metalloproteases families with pro-metastatic activities began to be 
identified. Intracellular and extracellular proteases can operate as signaling molecules in 
various cellular processes that are essential for cancer biology. These protease-regulated 
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processes include proliferation, adhesion, migration, differentiation, angiogenesis, 
senescence, autophagy, apoptosis and immune response. In addition, proteolytic 
processing is necessary in nearly every stage of cancer growth and progression, from 
angiogenesis to extracellular matrix remodeling, cell-to-cell signaling, and metastasis.[9, 
10] 
Intracellular proteases 
In many cases the function of intracellular proteases in signaling cascades is associated 
with the removal of damaged or undesirable products, e.g., lysosomal cysteine and 
aspartyl cathepsins mediate the degradation of endocytosed proteins.[11] The 
intracellular cysteine proteases of the caspase family play a role in regulation of 
proteolytic activities that result in apoptosis.[12, 13] For instance, CASP8 is found to be 
inactivated by somatic mutations in malignancies including head, neck, lung, and 
gastrointestinal carcinomas. This might represent an additional strategy for cancer 
progression. In addition, the loss of CASP8 was found to increase the risk of metastasis 
in neuroblastoma patients. That result has led to the assumption that this protease is a 
metastasis suppressor that regulates the survival and invasive capacity of neuroblastoma 
cells.[14, 15] Another cysteine protease family, the autophagins, contribute to the ‘self-
eating’ effect that is found during starvation conditions,[16] and deubiquitylases (DUBs) 
are responsible for removing ubiquitin from ubiquitinylated proteins and peptides.[17, 18] 
Extracellular proteases 
Extracellular proteases belong to different clans including metalloproteases such as 
MMPs, ADAMTSs (a disintegrin and metalloproteinases with thrombospondin 
domains) and neprilysin (MME), the cysteine cathepsins, and several serine proteases 
like kallikreins, testisin (PRSS21), prostasin (PRSS8) and dipeptidyl peptidase-4 (DPP-
4).[19] These extracellular proteases are thought to be actively involved in facilitating 
tumorigenesis since they promote tumor progression and metastasis. They are 
frequently overexpressed in malignant tissues. This aspect led to the development of 
small-molecule inhibitors for the treatment of cancer, in particular of molecules 
targeting matrix metalloproteinases (MMPs) and plasminogen activators.[8] By contrast, 
other clinical studies have shown in some cases that the inhibition of metalloproteinases 
causes an acceleration of tumor growth. This suggests that some extracellular and 
pericellular proteases of all major catalytic classes might have anti-tumor roles and 
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suppress tumor progression. MMPs have long been associated with cancer invasion and 
metastasis owing to their ability to degrade the extracellular matrix.[10] However, recent 
studies have shown that several members of this family, including collagenase 2 
(MMP8), macrophage metalloelastase (MMP12) and matrilysin 2 (MMP26) provide a 
protective effect in different stages of cancer progression. Furthermore, other MMPs 
such as stromelysin 1 (MMP3), gelatinase B (MMP9), stromelysin 3 (MMP11) and 
MMP19, which were originally recognized as pro-tumorigenic proteases, might also 
function as protective enzymes in some specific situations.[10, 20] Examples of the 
extracellular serine proteases with tumor suppressing activity are testisin and prostasin 
which are members of the glycosylphosphatidylinositol (GPI)-anchored proteases with 
trypsin-like activity. Prostasin can suppress tumor growth and invasion of prostate and 
breast cancer cells,[21] e.g., it is downregulated in prostate cancer.[22] Furthermore, the 
ectopic expression of testisin in testicular tumor cells was found to suppress their 
tumorigenicity,[23] although opposing results appeared in ovarian cancer cells.[24] 
Urokinase, a serine protease that is frequently associated with cancer progression, might 
also delay tumor development in specific cancer models.[25] Dipeptidyl peptidase-4 
(DPP-4) is a cell surface serine protease that was first reported to suppress the 
malignant phenotype of melanocytic cells,[26] and it has subsequently been found to 
have protective functions for different human malignancies.[27] By contrast, DPP-4 
inhibitors a class of oral hypoglycemic drugs, such as sitagliptin or vildagliptin have 
been in clinical use for the treatment of diabetes mellitus type 2 for several years. 
Moreover, several other serine proteases that are generally associated with cancer 
progression have been reported to have a protective function in specific instances. These 
examples highlight the dual roles of some proteases, depending on the cellular source 
and cancer microenvironment.[7, 28] 
1.3 Trypsin-like serine proteases  
The family of trypsin-like serine proteases consists of approximately 70 members. 
These enzymes have been found to play a major role in a variety of physiological 
processes including digestion, blood coagulation, regulation of blood pressure, 
fibrinolysis, pathogen-host interaction, wound healing, immune responses, tumor 
growth, invasion, and metastasis, and they have been implicated in the etiology of a 
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number of human diseases related to these systems.[29] In recent years, subgroups of 
these enzymes have been identified, which are anchored directly to plasma membranes, 
either by a carboxy-terminal transmembrane domain (Type I), an amino-terminal 
transmembrane domain with a cytoplasmic extension (Type II or TTSP), or through a 
GPI linkage. An additional mechanism is used by uPA (urokinase), which is fixed to the 
cell surface via binding to a specific uPA-receptor.[30] These trypsin-like serine 
proteases have a common catalytic mechanism for the cleavage of specific substrates 
and are frequently involved in consecutive proteolytic reactions or protease cascades, 
where one protease precursor (zymogen) is the substrate of an active protease. This 
shared mechanism confers the advantage that a single signal may be specifically and 
irreversibly amplified at each step, when a downstream zymogen is activated, providing 
the capacity for unleashing a burst of proteolytic potential.[31] 
1.4 Type II transmembrane serine proteases 
TTSPs are serine proteases defined by a hydrophobic single-pass transmembrane 
domain located near the amino terminus of the protein that separates a short intracellular 
domain from a larger extracellular portion. The extracellular part of the molecule 
contains a highly variable stem region and a carboxy-terminal trypsine-like serine 
protease domain of the chymotrypsin S1 fold.[32-34] Localization to the cell surface gives 
these enzymes an excellent opportunity to mediate signal transduction between the cells 
and their extracellular environment, and to regulate various cellular responses. 
The TTSPs have been divided into four subfamilies based on the phylogenetic analysis 
of the serine protease domains and the domain structure of the extracellular stem region. 
These are the human airway trypsin-like protease HAT/DESC-, the Hepsin/TMPRSS-, 
the Matriptase- and the Corin-subfamilies. Their schematic structures are shown in 
Figure 1.2.[32, 33, 35] The first described TTSP; enteropeptidase has an essential role in 
food digestion and was identified over a century ago by Pavlov. In 1994 the cloning of 
the enteropeptidase cDNA has revealed the presence of a membrane-anchor and 
explained its localization to the plasma membrane.[36] Meanwhile, 19 active members of 
TTSPs have been identified in mice and humans, which have a similar modular 
structure as found in enteropeptidase. They were also found in all vertebrate species and 
in the non-vertebrate species Drosophila.[37] Several members of the family have 
already been assigned important roles in the normal development of human or mouse 
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tissues. Additionally, many of the TTSPs are consistently overexpressed in a great 
variety of tumors, suggesting their potential as novel tumor markers and targets for anti-
cancer therapy.[35]  
 
Fig. 1.2 Predicted domain structures of human type II transmembrane serine proteases. Numbers indicate 
the position of each domain in the amino acid sequence of native, pro-enzyme molecules (figure adapted 
from Szabo and Bugge, 2008[28]). 
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All members of the four TTSPs subfamilies are synthesized as single chain zymogens 
that are activated by proteolytic cleavage after a specific arginine or lysine residue 
within a highly conserved activation motif preceding the catalytic domain. Several of 
the biochemically purified TTSPs, such as HAT, matriptase, matriptase-2, hepsin and 
TMPRSS2 to 4 rapidly undergo autocatalytic activation in vitro.[32]  
All TTSPs contain six conserved cysteine residues within their catalytic domains that 
are predicted to form three intradomain disulfide bonds, as known for all serine 
proteases domain of the S1 fold. TTSPs exhibit a strong preference for substrates that 
contain an Arg or Lys residue in the P1 position and they may be activated by other 
members of the family or be subject to intermolecular autoactivation in vivo.[35] After 
activation, the C-terminal protease domain remains covalently linked to N-terminal 
located domains by a conserved disulfide bond and can develop their activity in cellular 
compartments or on the cell surface.[32]  
Of all TTSPs, the HAT/DESC subfamily exhibits the simplest modular structure of the 
stem region (Fig. 1.2), which consists only of a SEA domain (single sea urchin sperm 
protein, enteropeptidase, agrin domain).[8, 38] The function of this segment is currently 
unknown, but there are indications that the SEA domains are associated with 
glycosylation reactions, and it is known that an additional autocatalytic (proteolytic) 
cleavage in this region of matriptase (see section 2.2) and enteropeptidase is essential 
for subsequent activation of the protease.[39, 40] The SEA domain-containing TTSPs 
were found to be released by a second cleavage within the SEA region from the cell 
surface.[41, 42] This cleavage within the SEA domain allows the shedding of the protease 
from the cell surface where soluble forms of enteropeptidase, HAT, TMPRSS2, and 
matriptase have been detected in vivo.[43, 44] These shed forms may be involved in the 
regulation of TTSP activity and function. The hepsin/TMPRSS/enteropeptidase 
subfamily includes hepsin, MSPL, TMPRSS2–5 and enteropeptidase. With the 
exception of enteropeptidase, members of this subfamily exhibit a relatively short stem 
region containing a SRCR domain (a single scavenger receptor Cys-rich, also 
abbreviated as SR domain), either alone as in hepsin and TMPRSS5 or proceeded by an 
LDLA domain (a single low density lipoprotein receptor class A) in TMPRSS2–4 and 
MSPL. Furthermore, enteropeptidase displays a unique structure with a complex stem 
region consisting of a SEA domain following the signal anchor, a SRCR domain 
preceding the serine protease domain, and two LDLA domains separated by two CUB 
Introduction 
8 
 
domains (bone morphogenic protein 1), and a MAM domain (a meprin, A5 antigen, and 
receptor protein phosphatase μ). In corin, the only member of the corin subfamily, two 
frizzled, eight LDLA, and an SRCR domain were identified in the stem region (Fig. 
1.2).[29, 33] The specific contributions of each stem domain to TTSP proteolytic activities 
have not yet been well defined, although for many TTSPs, the stem domain is required 
for efficient cleavage of their physiological substrates.[8]  
Physiological and pathophysiological functions of the TTSPs 
Many TTSPs show relatively strict patterns of expression and were detected in different 
tissues and cells of the human body. For example, enteropeptidase is expressed on the 
apical surface of enterocytes and goblet cells in the proximal small intestine and is the 
principle trypsinogen activator.[44] Hepsin is mainly found in hepatocytes, while its 
expression has been identified in a number of additional tissues including thymus, 
thyroid, lung, pancreas, pituitary gland, prostate, and kidney, as well as in cultured 
human endothelial cells grown in 3D type I collagen matrices.[45, 46] It is thought to play 
a role in the growth of some cells as well as potently activating the proform of 
hepatocyte growth factor (HGF)[46] and pro-uPA.[47] Corin is highly expressed in 
cardiomyocytes and converts pro-ANP and pro-BNP (atrial and brain natriuretic 
peptides, cardiac hormones that regulate blood pressure and cardiac function by 
promoting natriuresis, dieresis, and vasodilation) into smaller biologically active 
molecules.[48, 49] HAT is mainly localized in human trachea and bronchi, and its 
upregulation is found to be associated with inflammatory environments. It also cleaves 
the surface glycoprotein hemaglutinin (HA) of the human and avian influenza viruses of 
subtypes H1, H2, and H3 at a monobasic cleavage site, which is a prerequisite for 
influenza virus replication.[50, 51] HAT has been demonstrated to have the capacity to 
degrade fibrinogen to activate pro-uPA to activate membrane receptors such as PAR-
2.[52, 53] However matriptase is an exception as it is not restricted to any particular organ. 
An overview of these proteases expression patterns and their physiological functions 
were described and summarized in several review articles.[7, 28, 33] 
Pathophysiologically, some TTSPs are highly expressed during tumor progression and 
play a major role in tumor cell proliferation, migration and invasion. For example, an 
increased expression of hepsin, TMPRSS2 and matriptase was detected in various 
tumor tissues. Hepsin is involved in the pathogenesis of metastatic prostate cancer,[54] 
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ovarian and renal cancers. The overexpression of hepsin was an unfavorable clinical 
forecast in those tumors. Other members of the hepsin/TMPRSS subfamily, TMPRSS2, 
TMPRSS3 and TMPRSS4 are overexpressed in the epithelium of most prostate cancers, 
ovarian cancers and pancreatic tumors respectively.[55, 56] Matriptase is involved in the 
development of a variety of tumors as discussed in section 1.5.[57] Other members of 
TTSPs have not been clearly associated with cancer, while it should be noted that some 
members like matripatse-2 seem to have a tumor suppressing function.[58] 
1.5 Matriptase subfamily 
The matriptase subfamily of the TTSPs consists of three homologous proteases, 
matriptase, matriptase-2, matriptase-3, and a protein with atypical mosaic structure, 
polyserase-1. All matriptases have a similar stem region with one SEA, two CUBs, and 
three (matriptase-2 and matriptase-3) or four (matriptase) LDLA domains (Fig. 1.2). In 
polyserase-1, the transmembrane domain is followed by a single LDLA domain and a 
parallel repeat of three serine protease domains, referred to as serase-1, -2, and a 
catalytically inactive serase-3.[7, 59] Recently, polyserase-2 and -3, two closely related 
proteases with a similar structure, have been found in mice and humans, but both 
proteins lack the transmembrane domain and appear to be secreted.[60] 
The first identified member of this subfamily is matriptase (MT-SP1), which is found in 
the epithelial compartments of most embryonic and adult tissues. Several studies have 
reported the properties and physiological functions of matriptase, which is described in 
section 1.5.1.  
Matriptase-2 (MT2), also known as TMPRSS6, is predominantly expressed in adult and 
fetal liver tissues in humans and mice with minor expression in the kidney, uterus, and 
nasal cavity. It has proteolytic activity toward various macromolecular substrates.[61, 62] 
MT2 suppresses the expression of the hepatic hormone hepcidin, the main regulator of 
systemic iron homeostasis, through cleavage of the bone morphogenetic protein co-
receptor hemojuvelin, which is a key regulator of hepcidin gene activation.[63-65] 
Otherwise, humans with MT2 deficiency suffer from low iron levels and severe 
microcytic anemia.[66, 67] Due to the important role of MT2 in iron homeostasis, the 
enzyme represents a novel target for the development of inhibitors, potentially useful in 
the treatment of the systemic iron overload (hemochromatosis). In contrast to 
matriptase, the expression of MT2 correlates with the suppression of the invasiveness 
Introduction 
10 
 
and migration of breast and prostate cancer cells.[58] However, the precise functions of 
MT2 in cancer remain to be further elucidated.  
Matriptase-3, also named TMPRSS7, revealed expression in brain, skin, eye, salivary 
gland, and the reproductive tissues, including prostate, testis, epididymis, ovary and 
uterus. The recombinant catalytic domain of matriptase-3 can hydrolyse synthetic 
peptide substrates with a strong preference for arginine in the P1 position, and shows 
proteolytic activity toward several macromolecular substrates, including gelatin, casein, 
and albumin.[68] Studies in animals or humans with matriptase-3 deficiency have not 
been reported and its physiological function remains to be determined. 
The polyserase-1, also named TMPRSS9, was detected predominantly in skeletal 
muscle, heart, kidney, liver, placenta, and brain.[60] In addition, a shorter splice variant 
containing only the first of the three serine protease domains of polyserase-1, termed 
serase-1B (Fig. 1.2), has been described in mice and humans, with its highest expression 
detected in liver, small intestine, pancreas, testis, and peripheral blood.[40] Matriptase-
like enzymes have proteolytic activity against a number of polypeptide substrates 
in vitro, including casein, albumin, pro-uPA, and components of the extracellular matrix 
such as fibronectin, fibrinogen, and denatured type I collagen, but their functional 
characterization still awaits further studies.[7, 40, 68]  
1.5.1 Identification of matriptase and its catalytic domain 
Matriptase is also known as membrane-type-serine-protease 1 (MT-SP1),[69] tumor-
associated differentially expressed gene-15 (TADG-15),[70] suppressor of tumorigenicity 
14 (ST14), and as epithin for the mouse analogue.[71] It is an 80- to 90-kDa cell surface 
glycoprotein with a complex modular structure. MT-SP1 was first described and 
isolated by the Dickson group in 1993 with a new gelatinolytic activity in cultured 
breast cancer cells.[72] It is widely expressed in various epithelial compartments of many 
embryonic and adult tissues and in immune cells including mast cells, monocytes and 
macrophages.[73, 74] Matriptase has a small cytoplasmic N-terminus, followed by a short 
transmembrane segment and a large extracellular part containing the protease domain 
on the C-terminus. It is synthesized as an inactive, single chain zymogen and its 
activation is a multistep process.[75] This activation requires two sequential endo-
proteolytic cleavages; the first is after Gly149 within the amino-terminal SEA domain, 
which occurs in the endoplasmatic reticulum or Golgi apparatus. The SEA domain 
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cleaved matriptase is associated with HAI-1 (hepatocyte growth factor activator 
inhibitor-1) and is transported in its complexed form to the cell surface. The second 
cleavage is an autocatalytic process, which occurs in the serine protease domain 
between Arg614 and Val615 within a highly conserved activation cleavage site 
R↓VVGG. This autoactivation appears to be controlled by the stem region, by 
posttranslational modifications and the cellular localization of the protease.[75] However, 
the specific mechanisms that trigger the activation of matriptase are incompletely 
understood. 
The structure of the catalytic serine protease domain of matriptase is similar to other 
proteases of the chymotrypsin family (S1) and is closely related to numerous well know 
trypsin-like serine proteases, such as thrombin and factor Xa. Therefore, the common 
chymotrypsinogen numbering will be used for describing the structure of matriptase in 
the following part. Meanwhile, various X-ray structures of matriptase in complex with 
benzamdine, the Kunitz-type bovine pancreatic trypsin inhibitor (BPTI), two synthetic 
3-amidinophenylalanine-derived inhibitors, and the sunflower trypsin inhibitor-1 have 
been solved. This information can facilitate the design of new matriptase inhibitors.[76-
78] Matriptase contains a Ser190 adjacent to the Asp189, which makes the S1 pocket 
slightly more hydrophilic and narrow than in other trypsin-like serine proteases 
containing an Ala190, such as thrombin or factor Xa.[79] The S1 pocket binds basic 
residues, such as Lys or Arg as found in several substrates or Arg-mimetics used in 
synthetic inhibitors. The matriptase residues 214-220 and 189-195 on the wall of the 
S1-pocket are very similar to the sequences of other trypsin-like serine proteases and 
differ mainly in position 217 and 192. However, the side chain of Asp217 is directed 
away from the S1 pocket. The S2 site is well suited to accommodate small to medium-
sized P2-amino acids such as serine, which was found to be a preferred P2 residue in 
studies using a combinatorial substrate library prepared by phage display technique.[80] 
However, the bulky Phe99, which was expected to restrict the access of sterically 
demanding P2 amino acids, possesses some flexibility and its side chain is significantly 
rotated within the BPTI complex compared to the X-ray structure found with 
benzamidine.[77] Therefore, matriptase also cleaves substrates with larger P2 amino 
acids with high efficiency, such as Phe in pro-uPA or Leu in pro-HGF.[75] 
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Fig. 1.3 Stereo view of matriptase in complex with BPTI (1eaw.pdb).[77] Shown BPTI residues Thr11(I)-
Gly12(I)-Pro13(I)-Cys14(I)-Lys15(I)-Ala16(I)-Arg17(I)-Ile18(I) are disulfide bridged to residues 
Cys38(I)-Arg39(I) and given as sticks with orange carbon atoms. Matriptase residues His57, Asp102, 
Ser195 (catalytic triade) and Asp189 at the bottom of the S1-site are colored with white carbon atoms. 
The amino acids surrounding the S3/4 site (Phe97, Phe99, Gln175 and Trp215) and the amino acids of the 
60-insertion loop are shown in green and yellow, respectively (figure modified and adapted from 
Friedrich, 2002[77]). 
Matriptase possesses a characteristic S3/4-binding site, formed by 3 aromatic amino 
acids, Phe97 on the top, Trp215 at the bottom, surrounded by Phe99 and Gln175. This 
region is reminiscent of the corresponding pocket found in factor Xa that can 
accommodate hydrophobic residues, but it can also act as a cation binding site. 
Probably, both cation/-interactions and an overall negative potential formed by the 
carbonyl groups of amino acids 96-98 and the side chain carbonyl of Gln175 contribute 
to the preferred binding of basic amino acids to this binding site, such as Arg39(I) in the 
matriptase/BPTI complex (Fig. 1.3). 
Matriptase features a unique nine-residue 60-insertion loop with characteristic amino 
acids surrounding it, as shown with yellow carbon atoms in figure 2.1. A 60-insertion 
loop exists also in thrombin; however the segment Tyr60A-Pro60D-Pro60C-Trp60D 
forms a well defined S2 pocket, which contributes to the preference of proline as P2 
residue in thrombin inhibitors and substrates.[81] By contrast, the 60-insertion loop in 
matriptase is rotated away and forms a more open active site. These differences in the 
structures with the large BPTI and small benzamidine revealed that this 60-insertion 
loop has some conformational flexibility and can adapt to the bounded ligand. 
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1.5.2 Potential matriptase substrates in cancer biology 
The substrate specificity of MT-SP1 was determined using a positional scanning-
synthetic combinatorial library and substrate phage techniques. The preferred P4-P1' 
cleavage consensus sequences were found to be (Arg/Lys)-Xaa-Ser-Arg↓-Ala and Xaa-
(Arg/Lys)-Ser-Arg↓-Ala, where Xaa is a non-basic amino acid.[80] Matriptase is also 
able to cleave a series of synthetic chromogenic or fluorescent tripeptide substrates with 
Arg-para-nitroanilide or Arg-7-amido-4-methylcoumarin as P1-P1' segment, which can 
be used for convenient activity measurements.[82] Through many approaches it was 
demonstrated that matriptase cleaves and activates the proforms of hepatocyte growth 
factor (HGF), the G-protein-coupled protease-activated receptor 2 (PAR-2) and the 
soluble urokinase-type plasminogen activator (uPA).[80, 83, 84] Matriptase can also 
efficiently activate receptor-bound pro-uPA on the surface of cultured monocytes and 
human ovarian cancer cells, and thereby act as an initiator of the plasminogen activation 
system. Activated bound uPA promotes the extracellular proteolysis by generating the 
broad spectrum protease plasmin. Plasmin is also a principal activator of MMPs and 
involved in the degradation of extracellular matrix proteins (ECM). By contrast to the 
initiation of the uPA/plasmin/MMP cascade, a direct matriptase-catalyzed activation of 
stromelysin (MMP-3) was shown in vitro.[85] In addition, the uPA/uPAR complex elicits 
a number of cellular responses that include cellular adhesion, differentiation, 
proliferation, and migration in a non-proteolytic fashion.[86, 87] The components of the 
plasminogen activation system are upregulated in several tumor entities and promote 
tumor invasion and metastasis; therefore, the development of specific uPA inhibitors is 
activative strategy for the prevention of metastasis.[88-90] 
Matriptase converts pro-hepatocyte growth factor/scattering factor (HGF/SF) to its 
active form,[84] which binds with high affinity to the receptor tyrosine kinase c-Met. 
Activated c-Met induces multiple signaling pathways leading to the activation of gene 
products required for tumorigenesis and invasive growth (Fig. 1.4).[57, 91, 92] It has been 
demonstrated that the inhibition of the HGF binding to its receptor by antagonists or 
antibodies strongly reduces tumor growth and metastasis.[93-95] Pro-HGF activation by 
matriptase has been studied in prostate and colon carcinoma cell lines, where inhibition 
of endogenous matriptase by small interfering RNAs or synthetic inhibitors impaired the 
conversion of pro-HGF to HGF on the cell surface. It was demonstrated that matriptase 
processes the inactive form of HGF as efficiently as HGFA and that these two proteases 
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are more active than other pro-HGF convertases such as uPA, tPA, a serum protease 
homologous to the coagulation factor XIIa, factor XIIa itself, coagulation factor XIa, or 
plasma kallikrein, which also activate HGF/SF.[96] 
 
Fig. 1.4 Proposed functions of matriptase in invasive growth. Schematic drawing of the two major 
pathways that are hypothesized to mediate the pro-invasive effects of matriptase (figure adapted from K. 
Uhland, 2006[57]). 
An additional candidate substrate of matriptase is the G-protein coupled protease-
activated receptor 2 (PAR2), which is localized on the extracellular surface.[80, 83] PAR2 
mediates cell adhesion, cell mobility and inflammation and has been suggested to 
stimulate metastasis.[97] However, in addition to matriptase, other proteases such as 
trypsin, tryptase or factor Xa have been described as potential PAR2 activators.[98] 
Matriptase is found to be an efficient activator of prostasin, a glycosylphosphatidyl-
inositol-linked membrane serine protease, also abbreviated as CAP1/PRSS8. The two 
proteases colocalize in the epidermis and in a variety of other epithelia. Since pro-
prostasin is incapable of autoactivation, it is likely that matriptase may be a candidate 
activator of its zymogen in various physiological settings.[99] In vitro, matriptase has the 
ability to convert the prostasin zymogen into the active two-chain form, even though its 
cleavage sequence (Ile-Gln-Pro-Arg↓Ile in mice) lacks the second basic amino acid in 
P3 or P4, which is often supposed to be a prerequisite for matriptase substrates.[100] 
Another study has shown that the secreted form of matriptase produced in COS-1 cells 
digested fibronectin and laminin, both are proteins of the ECM and involved in cell 
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adhesion via binding to specific integrin receptors. This finding suggests that matriptase 
participates in the control of epithelial turnover by regulating the cell-substratum 
adhesion.[101] 
Recently, it was shown that several human cell lines and also a purified soluble form of 
matriptase can process the single-chain of insulin-like growth factor (IGF) binding 
protein related protein-1 (IGFBP-rP1) to a two-chain form.[102] The IGFBPs regulate 
cellular proliferation by modulating the effects of insulin and IGF,[103] whereas the 
IGFBP-rPs have low affinity to IGFs/insulin and low structural homology to 
IGFBPs.[104] Several groups demonstrated tumor-suppressive activity for IGFBP-rP1 
in vivo, although its exact biological function remains to be clarified.[105-107] 
The above-mentioned substrates represent proteins with diverse functions. Future studies 
accessing their physiological relevance as matriptase substrates will provide information 
about the importance of matriptase in cancer biology. 
1.5.3 Function of matripatse in the development of epidermal tissues 
Recent studies suggest that the matriptase and prostasin cascade plays an important role 
in the development of several tissues. It contributes to the epidermal tissue 
differentiation, the formation of follicular structures and to the function of skin.[75, 108, 
109] The close relation between both proteases is proved in part by the identical 
phenotypes of matriptase- and prostasin-deficient mice skin, and by the absence of 
active prostasin in a matriptase-deficient epidermis.[100, 110] 
Follicular structures and skin functions were found to be affected by matriptase loss, as 
shown by generalized hypoplasia of pelage hair follicles of null mice. These phenotypes 
were linked to defects in the initiation matriptase mediated, caspase 14, calpain I and 
bleomycin processing the hydrolase of the epidermal polyprotein profilaggrin.[111] 
Profilaggrin is processed into filaggrin monomer units and subsequently, into free 
hygroscopic amino acids, which partake in the formation of the cornified envelope of 
the uppermost layers of the epidermis and serve as a source of water, binding free 
amino acids that contribute to skin hydration.[75, 109, 111, 112] In addition, matriptase-
deficient animals also exhibit a defect in the formation of lamellar granules, specialized 
secretory vesicles that contain lipid material required for the formation of extracellular 
lipid lamellae within the cornified layer, and display impaired formation of epidermal 
tight junctions within the granular layer.[109, 113, 114] Those defects lead to some severe 
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forms of ichthyotic diseases, including lamellar and harlequin ichthyosis.[115-120] In 
conclusion, based on the mouse studies, a complete loss of matriptase activity in 
humans would be expected to be lethal. 
Studies have shown that proteolytic activity of matriptase is strictly regulated during 
embryogenesis by a transmembrane Kunitz-type serine protease inhibitor, called 
hepatocyte growth factor activator inhibitor (HAI-1). HAI-1 is co-expressed with 
matriptase in embryonic and adult tissues through a complex with matriptase.[82, 121, 122] 
The identification of matriptase/HAI-1 complexes was first documented in human 
milk.[43] These complexes were also found in conditioned medium of cultured 
mammary epithelial cells, as well as in a number of cancer cell lines.[123] 
1.5.4 Matriptase in epithelial cancers 
Matriptase has consistent expression in many tumors of epithelial origin. It was first 
found in breast carcinoma[72, 124] and was later detected with high levels in a wide 
variety of other benign and malignant tumors of epithelial origin including prostate 
carcinoma,[125] ovarian cancer,[126] cervical cancer,[127] gastrointestinal cancers, kidney 
tumors,[75, 128] esophageal, oral squamous tumors,[129] head and neck squamous cell 
carcinoma, but it was not expressed in tumors of mesenchymal origin.[57, 75] 
In many carcinomas, tumor progression is associated with a significant increase in 
matriptase mRNA and protein expression. Thus, in ovarian cancer cells, more than 5-
fold overexpression of matriptase was detected, compared to normal ovarian tissues. 
The increased expression of matriptase correlated with the aggressiveness of the tumor, 
whereas it was downregulated in advanced-stage tumors.[126, 130] By contrast, in 
malignant tissue of the gastrointestinal tract, both the expression of mRNA matriptase 
and its cognate inhibitor HAI-1 were decreased in comparsion with the normal 
tissue.[131] In many cases, matriptase was more frequently expressed in stage I/II tumors 
(82%) than in more advanced stage III/IV tumors (55%). However, an increased 
matriptase/HAI-1 ratio was indicative of the poor clinical outcome of advanced-stage 
tumors, indicating that loss of matriptase inhibition may play a role in the late stages of 
the disease.[132] This output leads to the suggestion that an imbalance of the 
matriptase/HAI-1 ratio towards higher enzymatic activity contributes to tumor 
progression, including invasion and metastasis. Furthermore, a clinical study on breast 
cancer patients identified a correlation among expression of matriptase, HAI-1, the 
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putative matriptase substrate pro-HGF, and the cytoplasmic form of the HGF 
receptor/c-Met, suggestive of the pathophysiological relevance of co-expression of 
matriptase with a potential growth factor substrate.[133] Another study has shown that the 
activity of matriptase is also regulated by its glycosylation pattern. Matriptase was 
identified as a substrate for N-acetylglycosaminyltransferase V (GnT-V), which is an 
enzyme that catalyzes the β1-6 GlcNAc branching of N-glycans on the protein surface. 
The overexpression of GnT-V in gastric cancer cells leads to differences in the 
glycosylation pattern and therefore, to an increased matriptase activity due to an 
acquired resistance to its degradation, which contributes to malignant 
transformations.[134] 
1.5.5 The role of matriptase in cartilage destruction in osteoarthritis (OA) 
Recent studies highlighted the importance of serine proteases and MMPs in cartilage 
degradation and collagenolysis.[135] These proteases regulate the turnover of the ECM 
and of its major structural component type II collagen.[136] Therefore, these enzymes 
emerged as potential therapeutic targets.[137] Meanwhile, it was found that matriptase is 
overexpressed in OA cartilage disease and it might be an important mediator of 
catabolic processes through inducement of collagenolysis and activation of 
procollagenases. Studies have confirmed that matriptase activates PAR-2 and 
demonstrated that matriptase-dependent enhancement of collagenolysis from OA 
cartilage is blocked by PAR-2 inhibition.[138-140] PAR-2 activation in OA cartilage 
induces both MMP-1 and MMP-13 at the cell surface and this facilitates the pericellular 
collagenolysis within this focal region of the cartilage.[139] Furthermore, matriptase 
activity in OA cartilage leads to the induction of collagenolytic MMPs (MMP-1, MMP-
3 and MMP-13) by the activation of their proforms. It was suggested that this process 
occurs via PAR-2 activation. Consequently, matriptase is considered as inducer of 
cartilage destruction in OA and becomes an attractive new therapeutic target for 
preventing pathologic cartilage breakdown and OA treatment.[141] 
1.5.6 Natural matriptase inhibitors and their derivatives 
HAI-1 is a potent endogenous inhibitor of the membrane-bound trypsin-like serine 
proteases matriptase, prostasin, HAT, TMPRSS13, and hepsin. It is a type I 
transmembrane protein with a cytoplasmic C-terminus that contains two extracellular 
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Kunitz-type inhibitor domains similar to BPTI (bovine pancreatic trypsin inhibitor, 
aprotinin, Ki = 10 nM for matriptase), which are separated by a low density lipoprotein 
receptor domain.[43, 142-144] It was shown recently that matriptase also forms a stable 
complex with the related kunitz-type inhibitor HAI-2.[145] Kunitz-type protease 
inhibitors bind to the active site of trypsin-like serine proteases forming relatively stable 
enzyme/inhibitor complexes and blocking the proteolytic activity of their target 
proteases.[146] 
Wild-type ecotins are highly potent inhibitors of various serine poteases, isolated from 
the periplasm of Escherichia coli.[147] Ecotin and its double mutant (M84R/M85R) 
inhibit matriptase with Ki values of 782 pM and 9.8 pM, respectively. These optimised 
ecotin variants potentially inhibit the growth of prostatic carcinomas.[69, 148, 149] 
SFTI-1 (sunflower trypsin inhibitor-1) is another natural matriptase inhibitor, which was 
originally isolated from sunflower seeds and found to be a potent trypsin inhibitor. It is 
a bicyclic 14-amino acid long peptide, containing a disulfide bridge and a head to tail 
cyclization. It exhibits strong inhibitory potency against matriptase with a Ki value of 
0.92 nM (SFTI-1 structure 1, Fig. 1.5,). SFTI-1 and several analogues have been 
synthesized by Roller’s group. These bicyclic peptide analogues were used to 
investigate the structural basis of their inhibitory activity using molecular modeling.[150] 
To improve the metabolic stability of the disulfide bridge in SFTI-1, both cysteine 
residues were replaced with allylglycine, followed by cyclization via ring closure 
metathesis. The reduced analogue 2 has a slightly decreased matriptase affinity (Ki = 2.5 
nM). An alternative approach was the insertion of an additional methylene group 
between both sulphur atoms of the disulfide bridge resulting in the less active 
analogue 3 (Ki = 0.16 µM).[151] 
Gly1-Arg-Cys3-Thr-Lys5-Ser
Pro-Phe-Cys11-Ile-Pro-Pro
Asp14 Ile7
S
S
1
Gly1-Arg-Gly3-Thr-Lys5-Ser
Pro-Phe-Gly11-Ile-Pro-Pro
Asp14 Ile7
2
Gly1-Arg-Cys3-Thr-Lys5-Ser
Pro-Phe-Cys11-Ile-Pro-Pro
Asp14 Ile7
3
S
S
(K i 0.92 nM) (K i 2.5 nM) (K i 0.16 µM)  
Fig. 1.5 Structures of SFTI-1 1 and its analogues 2 and 3 including their Ki values against matriptase.[150, 
151] 
Recently, a crystal structure of the SFTI-1/matriptase complex was solved (pdb code: 
3p8f). This complex revealed the binding of the Lys5 from the “reactive loop” of 
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SFTI-1 in the S1 pocket of matriptase. It forms hydrogen bonds with both the Ser190 
carbonyl oxygen and its hydroxyl side chain, as well as with an additional conserved 
water molecule. Surprisingly, no salt bridge to the Asp189 was found. The positively 
charged guanidinium group of Arg2 is directed towards the S3/4 site, forming cation- 
interactions with the aromatic matriptase residues Phe97, Phe99 and Trp215.[76] This 
structure of the SFTI-1/matriptase complex provides a rational start point for designing 
new SFTI-1 derivatives with better potency and selectivity for matriptase and other 
proteases. 
Human monoclonal antibodies (MAbs) were explored as matriptase inhibitor since 
matriptase is expressed on the cell surface, where large molecules can easily access the 
protease domain. As therapeutic reagents, human MAbs can be far less toxic and more 
selective than other types of inhibitors. Meanwhile several therapeutic antibodies, 
mainly directed towards growth factors or their receptors, have been approved as anti-
cancer drugs. A phage display approach enabled the identification of a set of single 
chain variable region fragments (scFv) comprising the heavy- and light-chain variable 
regions (VH and VL), linked together by a peptide spacer.[152] Some of these chimeric 
scFv proteins, having a molecular weight of approximately 30 kDa, efficiently block the 
active site of matripaste with binding constants in the range from 50 pM to 130 nM. 
Some of these analogues were recently characterized as slow tight binding inhibitors of 
matriptase.[153] These antibodies constitute a new class of highly selective protease 
inhibitors that can be used to dissect the biological roles of proteolytic enzymes as well 
as to develop diagnostic and therapeutic reagents. The disadvantage of such antibodies, 
including their smaller fragments or naturally occurring oligopeptidic and protein-like 
protease inhibitors, is their relatively large molecular weight, which prohibits their oral 
bioavailability. To overcome this problem many groups have initiated a search for small 
molecule matriptase inhibitors. 
1.5.7 Synthetic small molecule matriptase inhibitors 
Simple benzamidines, such as 4 and 5 (Fig. 1.6, structure 4, 5), inhibit matriptase with 
Ki values of 390 and 90 µM, respectively. Their affinity was further enhanced by 
dimerization, whereas a sufficient linker length was required to achieve an improved 
potency. The bisbenzamidines 6, containing a hexa methylene linker inhibit matriptase 
with a Ki value of 0.92 µM (Fig. 1.6, structure 6).[154] However, such bisbenzamidines 
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possess poor specificity against other trypsin-like serine proteases, although some 
compounds have a slight selectivity for matriptase over thrombin. A crystal structure of 
the benzamidine/matriptase complex showed that the benzamidine binds into the S1 
pocket and is sandwiched by the segments of Ser190-Gln192 and Trp215-Gly216 as 
expected.[76, 77] 
NH2HN
4
NH2HN
5
NH2
(CH2)6 OO
NH
NH2H2N
HN
6(Ki 390 µM) (Ki 90 µM) (Ki 0.92 µM)  
Fig. 1.6 Simple benzamidine derivatives and their inhibition constants for matriptase.[155] 
Peptide phosphonates are irreversible inhibitors of various serine proteases and can be 
served for the design of the activity-based probes (ABPs).[156, 157] These ABPs can be 
used for labelling of proteases on the surface of cancer cells. Biotinylated peptide 
diphenyl phosphonate probes were recently developed as matriptase inhibitors. A 
crystal structure of one analogue in complex with matriptase has showed that the 
phosphorous atom is covalently bound to the active site Ser195 and that the 
benzamidine is placed in the S1 pocket. The positively charged amidine forms the 
typical double salt bridges to the negatively charged Asp189.[158] 
A series of substrate analogue peptidomimetics, containing a C-terminal arginal residue 
such as CVS-3983 (7) showed a significant improved matriptase affinity. Compound 7 
inhibits matriptase with a Ki value of 3.3 nM and has strongly reduced affinitity towards 
the related proteases factor Xa, plasmin, tPA, and uPA with inhibition constants > 
1 µM.[159, 160] 
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Fig. 1.7 Substrate analogue peptidomimetic matriptase inhibitors.[160, 161] 
Although no structural information is available for matriptase in complex with CVS-
3983 (7), it should be assumed that the arginal moiety forms a transition state analogue 
hemiacetal with Ser195, whereas the basic m-amidinophenyl side chain of the P3 amino 
acid is directed towards the aromatic S3/4 pocket. Most likely, cation/-interactions 
contribute to inhibitor binding, similar to those described before for the binding of 
Arg39 in the BPTI-complex (Fig. 1.3).[77] Several analogues of CVS-3983 were 
synthesized to improve its inhibitory activity and affinity towards matriptase.[159] 
However, all these peptide aldehydes have limited value for clinical development due to 
their reactive P1 group. Therefore, the P1 arginal was replaced by decarboxylated Arg 
mimetics, known from the development of thrombin,[162, 163] factor Xa,[161] and factor 
VIIa inhibitors.[164] This has led to a series of new analogues, in which the P4-P2 
segment was maintained or slightly modified. Several analogues have been disclosed in 
a patent application by Dendrion, e.g., the substituted pyroglutamyl compound 8 (Fig. 
1.7) which inhibits matriptase with a Ki value < 100 nM.[165] During selectivity 
measurements with highly potent substrate analogue fXa inhibitors, several compounds 
with moderate matriptase affinity were found. For example, compounds 9 and 10 inhibit 
matriptase with Ki values of 70 and 110 nM, respectively (Fig. 1.7).[161] 
Another type of matriptase inhibitors are sulfonylated 3-amidinophenylalanine 
derivatives. For instance, WX-UK1 (11, Fig. 1.8) inhibits matriptase with a moderate 
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Ki value of 0.37 µM, and was originally described as uPA inhibitor.[166] Compound 11 
inhibits other trypsin-like serine proteases, such as thrombin and plasmin with 
comparable efficacy (Ki ≈ 0.5 µM).[166] In preclinical studies, WX-UK1 effectively 
blocks metastasis formation and primary tumor growth.[167] The oral bioavailable 
hydroxyamidino prodrug of WX-UK1 (or mesupron 12, Fig. 1.8)[168] is presently under 
clinical phase II development, and is used as a single agent or in combination with the 
chemotherapeutic 5-fluorouracil prodrug capecitabine for the treatment of patients with 
breast and pancreatic cancer (www.wilex.de). 
Additional 3-amidinophenylalanine derivatives have been described as matriptase 
inhibitors and possess improved affinity and selectivity in case of the incorporation of a 
C-terminal guanidino group. For instance, the related bibasic derivative 13 (Ki value 57 
nM) inhibits matriptase with at least 5-fold stronger than the analogue 11.[78] The 
elongation of the C-terminal alkyl chain has not altered the potency of inhibitor 14 
(Ki value 61 nM), whereas its cyclization resulted in inhibitor 15 (Ki = 14 nM) with 
enhanced matriptase affinity. An X-ray analysis of 15 in complex with the catalytic 
domain of matriptase (Fig. 1.9A) revealed a strong double hydrogen bond of the distal 
guanidino group to the carbonyl oxygen of Ile60, the first residue of the 60 insertion 
loop. The other interactions are similar to related complexes of arylsulfonylated tertiary 
amides of 3-amidinophenylalanine with trypsin, thrombin, or uPA.[78, 169, 170] The 
inhibitor adopts a compact Y-shaped conformation with the benzamidine segment 
placed in the S1 pocket forming a double salt bridge to Asp189, whereas the backbone 
of the 3-amidinophenylalanine makes antiparallel hydrogen bonds to Gly216. The 
conformation is further stabilized by a hydrogen bond between the sulfonyl oxygen and 
the amide moiety of Gly219. 
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Fig. 1.8 3-Amidinophenylalanine-derived matriptase inhibitors.[78, 167-170]  
Furthermore, an elimination of the C-terminal peptide bond provided compounds, such 
as 16 and 17 (Fig. 1.8) with Ki values of 46 and 42 nM, respectively. A similar overall 
conformation in X-ray studies with inhibitor 16 (Fig. 1.9B) as found for inhibitor 15 
showed that the distal guanidinoethyl group is directed to a so called “cation cleft” 
formed by the initial part of the 60 insertion loop and the active site cleft of matriptase, 
which is lined by the carboxylates of Asp96 and Asp60b and the carbonyls of His 57 
and Ile60. However, due to its truncated length the distal guanidinoethyl group forms 
only water mediated hydrogen bond to the side chain of Asp60b and does not interact 
with Ile60, as found in the complex with analogue 15. In both complexes only loose 
contacts between the hydrophobic arylsulfonyl goups of the inhibitors and the 
matriptase S3/4 subsites were found. This is probably caused by the Arg60c side chain 
of a symmetry related matriptase molecule, which extends into this binding pocket 
under crystallization conditions and prevents a proper binding of the aryl sulfonyl 
group. 
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a) 
 
b) 
 
Fig. 1.9 Stereoview of inhibitors 15 (a, 2gv7) and 16 (b, 2gv6) bound to the active site of matriptase. 
Selected matriptase residues are labeled, and strong hydrogen bonds are shown in green. Only water 
molecules that are involved in strong hydrogen bonding are shown in red balls (figure adapted from 
Steinmetzer, 2006[78]). 
Additional potent analogues of this inhibitor type were obtained by substitution of the 
phenylsulfonyl ring, e.g., inhibitor 18 (Ki value 13 nM, Fig. 1.10). It was also found that 
some tribasic 3-amidinophenylalanines inhibitors with an N-terminal of -alanine 
connected via peptide bond to the m-position of the phenylsulfonyl group have an 
excellent selectivity for matriptase over related trypsin-like serine proteases. For 
instance, compound 19 inhibits matriptase with a Ki value of 3.8 nM, whereas the 
inhibition constants for thrombin, factor Xa, urokinase-type plasminogen activator, and 
plasmin are > 1 µM. The modeled complex of inhibitor 19 in matriptase revealed a 
binding of the -alanyl group into the characteristic S3/4 site of the proteases. It was 
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assumed that the high potency of this inhibitor could be related to the formation of 
hydrogen bonds to carbonyl oxygen atoms of matriptase or cation-π-interactions 
between the protonated amino group and the aromatic residue (Trp215, Phe99, and 
Phe97) in this binding pocket.[78, 171] 
18 19
No. R K i (µM)
20 H 0.110
21 2-Cl 0.029
22 4-Cl 0.026
23 4-EtO 0.006
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Fig. 1.10 Additional 3-amidinophenylalanine-derived matriptase inhibitors.[78, 171] 
Tribasic inhibitors like compound 19 have a negligible oral bioavailability. Although 
several prodrug strategies are known for the amidino group as described for the 
thrombin inhibitors ximelagatran and dabigatran,[163, 172] no convenient prodrugs have 
been described for primary amino groups. Most of the known amino prodrugs are 
relatively stable to enzymatic conversion and therefore, less suitable in practice.[173, 174] 
Therefore, the C-terminal amino group or the N-terminal -alanyl-amide moiety was 
replaced with uncharged residues in additional analogues. 
In a first approach, various substituted biphenyl-3-sulfonyl groups were incorporated at 
the N-terminus.[171] Replacement of the N-terminal -alanyl-amide moiety in inhibitor 
19 by a non-substitued phenyl ring caused ≈ a 30-fold decrease in potency and reduced 
the selectivity. Analogue 20 inhibits matriptase and thrombin with Ki values of 0.11 and 
0.056 µM, respectively. However, a single chlorine substitution, especially in para- and 
ortho-position of the terminal phenyl ring results in a slightly enhanced matriptase 
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affinity, as found for compounds 21 and 22. An alkoxy substitution in different 
positions of this ring in the case of inhibitors 23 and 24, also improved the inhibitory 
potency compared to the non-substituted analogues (Fig. 1.10). The most potent 
matriptase inhibitor is the tribasic analogue 26, which inhibits matriptase with a Ki value 
of 80 pM and was obtained as a side product at the final hydrogenation of inhibitor 25. 
Additional matriptase inhibitors were prepared by a modification of the C-terminal of 
tertiary amide, where 2-aminoethylpiperidide was mainly replaced by neutral residues 
in a related series. Compound 28, still containing the N-terminal -alanine amide 
retained high potency and selectivity against matriptase (Ki value 6.3 nM) and was only 
4-fold less active than inhibitor 27 (Ki value 1.8 nM). By contrast, compound 29 was 
relatively weak inhibitor (Ki value 53 nM).  
In a further series, inhibitors with a C-terminal 4-piperidyl-butanoyl methylamide 
residue and an N-terminal biphenyl-3-sulfonyl residue were synthesized. Some of these 
analogues were found to be even more potent thrombin inhibitors like inhibitor 30, 
which inhibits matriptase and thrombin with Ki values of 28 and 5.5 nM, respectivly. 
Analogue 31 maintains moderate affinity to matriptase with an inhibition constant of 
87 nM, but shows only a weak potency against thrombin with a Ki value 2.05 µM. It 
seems that the more bulky tert-butyl substituted biphenyl group of compound 31 is not 
able to occupy the hydrophobic aryl binding site of thrombin, which is more open in 
case of matriptase. Inhibitor 32 (Fig. 1.11) is a dibasic analogue of inhibitor 26 
containing an N-terminal 3-(6-amino-2,3,4,5-tetrahydropyridin-3-yl)benzenesulfonyl 
group, and found to be a very potent matriptase inhibitor with a Ki value of 0.43 nM.[175] 
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Fig. 1.11 Modifications of the C-terminal residue (27-29), the N-terminal biphenyl moiety (30-32) and 
the P1 residue (33-35).[171, 175] 
The replacement of the 3-amidino group in P1 by an amino methylene residue in 
inhibitor 33 led to a significant decrease in the inhibitory potency. This can be explained 
by partial elimination of important hydrogen/salt bonds to Asp189, Gly219, or Ser190 
at the bottom and both sides of the S1 pocket. The affinity was further reduced by 
incorporation of the aminomethyl group in the para-position (compound 34, Fig. 1.11). 
The elimination of the amidino group in inhibitor 35, containing homophenylalanine in 
P1 position, resulted in a dramatic more than 100,000-fold weaker matriptase inhibition 
compared to the analogue 19 (Fig. 1.10).[171] 
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2 Aim of the work  
Most-likely, matriptase is involved in several physiological and pathophysiological 
functions. It has emerged as a potential target for the development of new anti-
invasiveness drugs for the treatment of cancer. In addition, matriptase seems to be 
involved in osteoarthritis, atherosclerosis and in the activation of certain viral surface 
glycoproteins. Therefore, in the present work new matriptase inhibitors with improved 
properties should be developed using various approaches. 
 A further optimization of tertiary amides of arylsulfonylated 3-
amidinophenylalanine derivatives, which were previously decribed as highly 
potent inhibitors of matriptase, should be performed including modifications in 
the N-terminal biphenyl 3-sulfonyl group and C-terminal amide residue. A few 
additional analogues would be prepared by replacement of the 3-
amidinophenylalanine with other P1 amino acids residues. 
 A model of the binding mode of these new inhibitors in complex with matriptase 
should be established. Due to the insufficient amount of matriptase available, the 
easily accessible thrombin could be used as a kind of working horse for 
crystallization in complex with one of the most potent new inhibitors. The 
experimentally obtained coordinates of the thrombin/inhibitor complex should 
be superimposed with the known crystal structure of matriptase. 
 Due to some similarity of the S3/4 pockets between matriptse and fXa, a new 
lead structure should be developed based on previously described fXa inhibitors 
containing a central D-phenylglycine residue. A 3-amidinobenzoyl residue 
should be incorporated as P1 residue, whereby substituted piperazines could be 
used to address the S3/4 binding pockets of matriptase. 
 Due to the similarity of the S1 pocket of matriptase and uPA, new inhibitors 
should be derived from previously described antranilamide-containing uPA 
inhibitors. 
 Substrate analogues containing 4-amidinobenzylamide as P1 residue are potent 
inhibitors of various trypsin-like serine proteases. Only a few analogues of this 
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type have been previously described as matriptase inhibitors with moderate Ki 
values > 50 nM. Therefore, new substrate analogue inhibitors with improved 
potency and selectivity should be developed. 
 It was recently discovered that matriptase could be a potential activator of the 
surface glycoprotein hemagglutinin of the H9N2 influenza A virus subtype. 
Therefore, in collaboration with the group of Prof. Dr. Garten and Dr. Böttcher-
Friebertshäuser, Institute of Virology, Philipps University Marburg, selected 
compounds should be tested as inhibitors of H9N2 influenza virus propagation. 
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3 Results and discussion  
3.1 Development of new 3-amidinophenylalanine-derived inhibitors1 
Piperidides and piperazines of sulfonylated 3-amidinophenylalanines were originally 
developed as inhibitors of the trypsin-like serine proteases thrombin and urokinase.[166, 
176] Various analogues of this type were later identified as inhibitors of matriptase.[78] 
High potency and selectivity was found for tribasic 3-amidinophenylalanines, such as 
inhibitor 19 (Fig. 1.10, section 2.3),[171] which inhibits matriptase in the low nanomolar 
range and is a relatively poor thrombin inhibitor with a Ki value of 27 µM. To reduce 
their strong basicity associated with poor cell permeability, various substituted 
biphenyl-3-sulfonyl groups were incorporated at the N-terminus,[171] and the C-terminal 
2-aminoethylpiperidide was replaced by uncharged residues in a related series.[175] 
However, both modifications reduced the selectivity of these analogues as matriptase 
inhibitors. For instance, the dibasic inhibitor 18 (Fig. 1.10, section 2.3) inhibits 
thrombin with a Ki value of 56 nM, while the monobasic analogue 30 is even a stronger 
thrombin inhibitor with an inhibition constant of 5.5 nM. To enhance the overall 
performance of these matriptase inhibitors, new analogues of this inhibitor type were 
prepared by further optimizing the N-terminal phenylsulfonyl and the C-terminal amide 
groups by incorporation of uncharged substituents. 
In a first series, new analogues based on modifications of the terminal aryl ring at the 
biphenyl-3-sulfonyl residue were synthesized, whereas two different C-terminal amide 
groups known from previous studies were maintained (Table 3.1).[171, 175] Since it was 
known that a single chlorine (compounds 19 and 20) or alkoxy (compounds 21 and 22, 
section 2.3) substitution at different positions of this ring improved the inhibitory 
potency compared to the non-substituted analogue 18,[171] various new disubstituted 
derivatives were synthesized 213-228 (Table 3.1). 
                                                 
1 This part 3.1 of the dissertation is nearly identical to our recently published paper.[177] 
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Table 3.1: Inhibition of matriptase and related trypsin-like serine proteases by inhibitors of the general 
formula. 
H
N
X
O
S
HN
NH2
R
O O
X1
X2 N
N
O
N
CH3X:
=
=
NH2
H
 
No. X R Ki (µM) matriptase matriptase-2* thrombin fXa 
213 
MI-0403 X1 
F
 
0.12 3.0 0.002 1.1 
221 
MI-0433 X2 0.023 2.1 0.04 0.81 
214 
MI-0404 X1 F
 
0.13 10 0.006 3.05 
222 
MI-0431 X2 0.052 3.2 0.04 3.2 
215 
MI-0405 X1 
F  
0.12 4.4 0.001 0.55 
223 
MI-0434 X2 0.033 3.2 0.005 1.12 
216 
MI-0406 X1 
Cl
Cl
 
0.013 0.35 0.001 0.032 
224 
MI-0432 X2 0.002 0.11 0.02 0.05 
217 
MI-0440 X1 
Cl
Cl
 
0.051 0.75 0.004 0.26 
225 
MI-0441 X2 0.011 0.21 0.020 0.58 
218 
MI-0442 X1 
Cl
Cl
 
0.074 1.6 0.003 0.23 
226 
MI-0443 X2 0.018 0.58 0.03 0.37 
219 
MI-0412 X1 
O Cl  
0.049 1.3 0.03 0.18 
227 
MI-0413 X2 0.013 0.40 0.40 0.17 
220 
MI-0438 X1 
O O
 
0.008 0.77 0.001 0.06 
228 
MI-0439 X2 0.001 0.31 0.03 0.11 
*All Ki measurements of matriptase-2 provided in this thesis were performed in the group of Prof. Dr. 
Michael Gütschow (Rheinische Friedrich-Wilhelms-Universität Bonn). The details of the enzyme kinetic 
measurements with matriptase-2 have been described in recent publication.[177, 178]  
In general, all dibasic compounds containing the C-terminal 2-aminoethylpiperidide are 
approximately 3-6 fold more potent matriptase inhibitors than their monobasic 
analogues, confirming previous studies. A strong matriptase inhibition was obtained for 
the 2′,4′-dichlorobiphenyl inhibitor 224 having a Ki value of 2 nM, whereas the other 
dichloro derivatives 225 and 226 (of matriptase Ki values of 0.011 and 0.018 µM, 
respectively) have a similar potency as found for the mono-substituted analogues. The 
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uncharged C-terminal N-methylamide containing analogues 216-218 inhibit matriptase 
with Ki values ≤ 0.074 µM. In addition, several fluorine-containing inhibitors were 
synthesized. The incorporation of fluorine atoms is a standard strategy to enhance 
affinity, metabolic stability and/or selectivity in pharmaceuticals.[179, 180] Due to its high 
electronegativity, the fluorine atom often interacts with electropositive regions of 
receptor sites and therefore strengthens protein-ligand binding.[181] 
Among inhibitors 221-223, the highest potency against matriptase was found for 
analogue 221 with a terminal 2-fluorophenyl ring with a Ki value 0.023 µM, while 
inhibitors 213-215 similarly inhibit matriptase with a Ki value 0.12 µM. However, 
several of these halogen-substituted analogues were found to be excellent thrombin 
inhibitors with Ki values < 6 nM, especially when they comprise the uncharged 
C-terminal N-methylamide group. This confirms results found by the Diederich group 
with other types of fluorine-substituted inhibitors that interact with the distal S3/4 
pocket of thrombin.[182] The strongest matriptase inhibition with a Ki value of 1 nM was 
found for the dibasic 2,4-dimethoxy inhibitor 228, which possesses an acceptable 
selectivity, as it is at least 20-fold less potent against the other tested proteases. Also in 
that case, its analogue 220 containing the uncharged C-terminal amide is a very potent 
thrombin inhibitor with a Ki value of 1 nM. Surprisingly, a relatively poor potency was 
found for inhibitor 227 (Ki 0.013 µM), which combines the single 4-ethoxy and 
2-chloro substituents used previously. In general, all compounds are significantly less 
efficient factor Xa or matriptase-2 inhibitors. However, the strongest inhibition of both 
enzymes was also found for inhibitors 216 and 224. It seems that their terminal 
2,4-dichlorophenyl group contributes to the binding affinity to all tested trypsin-like 
proteases. As discussed before, most of the matriptase inhibitors summarized in Table 
3.1 are also excellent thrombin inhibitors, which could induce bleeding complications, 
if such compounds would be used in animal experiments. A difference between both 
proteases is the structure of the characteristic 60-insertion loop in thrombin, formed by 
residues Tyr60A-Pro60B-Pro60C-Trp60D. It shields the binding pocket occupied by the 
C-terminal piperidide moiety in this inhibitor type as found in the crystal structure of 
inhibitor 224 with thrombin (Fig. 3.1a, section 3.1.1). By contrast, this binding region is 
relatively open in case of matriptase (Fig. 3.1b), since it contains a 60-insertion loop 
with completely different orientation compared to thrombin. 
Therefore, a second inhibitor series was designed by incorporation of uncharged urea 
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structures in the C-terminal amide residue, which could be obtained by reaction of the 
respective amine precursors with various isocyanates (Scheme 3.2). We assumed that 
some of the rigid urea-containing inhibitors should have a reduced affinity to thrombin 
due to sterical repulsion of its 60 loop, whereby they maintain high affinity as 
matriptase inhibitors. To avoid the limited solubility due to the very hydrophobic 
character of these analogues, a ß-alanylamide substituted phenylsulfonyl group at the 
N-terminus in this series was initially incorporated, as known from inhibitor 19.[78] The 
structures of the synthesized inhibitors, summarized in Table 3.2, differ in their 
C-terminal substituent at the urea moiety and in the distance between the piperidide and 
urea group. 
Table 3.2: Inhibition of matriptase and related trypsin-like serine proteases by inhibitors of the general 
formula. 
H
N
N
O
S
HN
NH2
N
H
O
H2N
O O HN
H
N
O
Rn
H
N
N
O
S
HN
NH2
N
H
O
H2N
O O NH2
n
245:
n = 0, (matriptase K i 21 nM)
n = 2, (matriptase K i 3.8 nM)
19:
 
No. n R 
Ki (µM) 
matriptase matriptase-2 thrombin fXa 
229 
MI-0449 2 H 
0.014 3.3 0.14 13.9 
230 
MI-0451 0 0.035 3.9 9.70 16.9 
231 
MI-0436 2 CH3 
0.007 1.2 0.04 7.07 
232 
MI-0450 0 0.056 1.3 10.8 14.1 
233 
MI-0437 2 CH2-CH3 
0.012 0.46 0.13 4.79 
234 
MI-0452 0 0.039 2.4 15.31 8.89 
235 
MI-0444 2 
 
0.011 1.9 0.44 2.61 
236 
MI-0454 0 0.014 1.3 9.25 3.41 
237 
MI-0445 2 
 
0.023 1.8 0.47 6.45 
238 
MI-0453 0 0.008 0.79 35.9 1.2 
243 
MI-0446 2 
 
0.017 1.3 0.23 5.52 
244 
MI-0455 0 0.026 1.1 7.84 2.45 
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Within the series containing a piperidylethyl-urea portion, the methyl compound 231 
has the highest potency against matriptase with a Ki value of 7 nM, whereas its shorter 
analogue 232 is approximately 8-fold less active. All other analogues have reduced 
affinity, but still inhibit matriptase with inhibition constants < 25 nM. By contrast, in the 
series with the shorter piperidyl-urea portion, the cyclohexyl derivative 238 is the most 
potent matriptase inhibitor; possessing an inhibition constant of 8 nM and shows an 
excellent selectivity with respect to thrombin. However, its longer analogue 237 inhibits 
matriptase only with a Ki value 23 nM. The rigid cyclohexyl-urea group of inhibitor 238 
seems to prevent a proper binding below the 60 insertion loop of thrombin. An 
additional reason for the reduced thrombin affinity in this series is most likely caused by 
the presence of the N-terminal ß-alanylamide residue, because the distal S3/4 binding 
pocket of thrombin is less suited to accommodate charged basic groups. All analogues 
summarized in Table 3.2 show poor affinity to factor Xa and matriptase-2, only two 
compounds (233 and 238) inhibit matriptase-2 with Ki values < 1 µM. 
In a third series (Table 3.3), monobasic inhibitors were obtained by replacement of the 
N-terminal -alanyl amide moiety of the most potent urea inhibitors 231 and 238 with 
the 2,4-dimethoxyphenyl or 2,4-dichlorophenyl group, which were used in the most 
potent biphenyl-3-sulfonyl containing inhibitors 224 and 228.  
Table 3.3: Inhibition of matriptase and related trypsin-like serine proteases by inhibitors of the general 
formula. 
H
N
N
O
S
HN
NH2
O O HN
H
N
O
R
n
X X
 
No. X n R 
Ki (μM) 
matriptase matriptase-2 thrombin fXa uPA HAT* 
239 
MI-0460 CH3O 2 CH3 
0.0018 0.18 0.0008 0.051 4.4 0.11 
240 
MI-0461 Cl 2 0.0009 0.073 0.0002 0.029 3.4 0.17 
241 
MI-0462 CH3O 0 
 
0.0027 1.42 1.23 0.011 18.5 0.83 
242 
MI-0463 Cl 0 0.0051 0.94 0.63 0.02 18.1 2.7 
*Measurements of the Ki values with HAT were performed by Daniela Meyer, as described 
previously.[183] 
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As expected, all four analogues have a slightly higher matriptase affinity compared to 
the -alanyl series, whereas they possess strong differences in their thrombin inhibition. 
The piperidylethyl-urea derivatives 239 and 240 inhibit thrombin with Ki values < 
1 nM, whereas both piperidyl-urea inhibitors substituted by a terminal cyclohexyl group 
(241, 242) have a more than 500-fold reduced thrombin affinity. The X-ray structure of 
inhibitor 224 in complex with thrombin reveals that its C-terminal aminoethyl group is 
long enough to slip out of the 60-loop (Fig. 3.1a), which enables its further modification 
without sterical hindrance. This seems to be impossible in the case of the shorter 
aminopiperidyl inhibitors 241 and 242. Their modification by sterically demanding urea 
structures leads to poor thrombin affinity but is well tolerated by matriptase, possessing 
an open prime site. This tendency is confirmed by the Ki values summarized in Table 
3.2. Inhibitors 239-242 were tested also against the related enzymes uPA and HAT, 
whereby HAT is also a TTSP that belongs to the HAT/DESC subfamily. However, all 
compounds were relatively weak inhibitors of these proteases. 
3.1.1 Modeled complex of inhibitor 224 in matriptase  
Based on previously solved X-ray structures of matriptase in complex with closely 
related 3-amidinophenylalanine derivatives possessing N-terminal 2-naphthylsulfonyl- 
or 2,4,6-triisopropylphenylsulfonyl-groups,[78] we assumed that the terminal 2,4-
dichloro-substituted phenyl ring of inhbibitor 224 binds to the distal S3/4 binding 
pocket of matriptase above the side chain of Trp215, which is covered by Phe99 at the 
right side, Gln175 at the left and Phe97 on the top. To confirm this binding mode we 
were interested to obtain a crystal structure with these biphenyl-3-sulfonyl-3-
amidinohenylalanine-derived inhibitors. Due to the insufficient amount of matriptase 
available we used the easily accessible thrombin as a form of working horse for 
crystallization in complex with inhibitor 224 (Fig 3.1), which inhibits thrombin with a 
Ki value of 20 nM. The determined binding mode is shown in Figure 3.1a, which 
confirms that the biphenyl moiety is directed towards the distal S3/4 binding pocket of 
this related trypsin-like serine protease. The para-chlorine substituent is located 3.5 Å 
above the indole portion of Trp215 suggesting a halogen-π interaction[184] and in a 
distance of 3.2 Å away from the carbonyl oxygen of Asn98, probably making a 
polarized halogen-carbonyl contact.[185] The ortho-chlorine is involved in a van-der-
Waals contact to the -methylene group of Glu217 (3.7 Å). All other interactions, the 
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binding of the amidino group to Asp189 and Gly219, the H-bond of one sulfonyl 
oxygen to the NH of Gly219, as well as the antiparallel -sheet interaction between the 
3-amidinophenylalanine backbone to Gly216 are identical as known from other 
thrombin structures with related inhibitors.[186] This complex was superimposed by an 
rmsd fit of the C-atomic coordinates onto a previously solved crystal structure of 
matriptase inhibited by a 2-naphthylsulfonylated 3-amidinohenylalanine-derived 
inhibitor (Fig 3.1b).[78] Based on this model, the N-terminal biphenyl group of inhibitor 
224 also fits well into the S3/4 pocket of matriptase making a close edge to face contact 
to the aromatic side chain of its characteristic Phe99 ( 3.5 Å), whereas all characteristic 
H-bonds of the P1 3-amidinophenylalanine and one sulfonyl oxygen were maintained 
(Fig. 3.1c). It might be possible that in case of the matriptase complex an additional 
halogen--interaction between the para-chlorine substituent and the adjacent phenyl 
ring of Phe99 ( 3.7 Å) is established, which contributes to the improved binding of 
inhibitor 224. Such contacts are known from many other examples.[184] Calculations of 
the electrostatic potential performed at complexes of factor Xa or thrombin with 
inhibitors containing chloroaromatic P1 groups that interact with Tyr228 at the bottom 
of the S1 pocket reveal a slightly positive charge located at the tip of an aromatic 
chlorine atom, which interacts with -electron systems of the neighbouring aromatic 
amino acid.[187] 
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Fig. 3.1 a) Stereo view of the thrombin/224 complex (4e7r.pdb). Thrombin is shown with its solvent-
accessible surface colored by atom type (carbon in grey, oxygen in red, nitrogen in blue, sulfur in yellow) 
and the inhibitor in sticks. The C-terminal piperidide of inhibitor 224 is located below the characteristic 
60 insertion loop of thrombin, whereby its terminal amino group sticks out from this loop. b) Model of 
inhibitor 224 in matriptase, shown with its surface colored by atom type. This stereo figure was obtained 
by superimposing the thrombin/224 complex with the matriptase coordinates taken from the crystal 
structure with the pdb-code 2gv6,[78] followed by deletion of thrombin. Compared to thrombin, matriptase 
has a relatively open S1 site and possesses a Phe in position 99, which is Leu in thrombin. c) Stereo view 
of thrombin (white carbons) in complex with 224 superimposed with matriptase (orange carbons). 
Hydrogen bonds formed between 224 and matriptase are shown as green lines, which match nearly 
perfectly with those found in thrombin/224 complex. Two additional hydrogen bonds are formed from the 
side chain of Ser190 in matriptase to the amidino group of 224 and to a conserved water molecule at the 
bottom of the S1 pocket, which is Ala190 in thrombin. For clarity, only some important residues of both 
enzymes in the active site are shown and labeled. Identical residues in both enzymes are labeled by the 
common name, specific matriptase and thrombin residues are indicated by an additional M or T, 
respectively. 
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3.1.2 Synthesis of the 3-amidinophenylalanine-derived inhibitors 
The synthesis of the inhibitors shown in Table 3.1 was performed according to 
previously described methods[78, 171, 175] using intermediates 5 and 30,[78] which were 
prepared from the appropriate sulfonyl-protected 3-cyanophenylalanines performing the 
following steps in Scheme 3.1. 
The C-terminal residue, N-methyl-4-(piperidin-4-yl)butanamide was prepared from a 
commercially available 4-(piperidin-4-yl)butanoic acid, which was Boc-protected, 
converted into its methylamide by treating with methylamine × HCl and HBTU as a 
coupling reagent in the presence of DIPEA in to obtain compound 3, followed by 
cleavage of the Boc-group with 1 N HCl in HOAc providing intermediate 4 (Scheme 
3.1). Intermediate 1 was obtained by coupling of 3-bromophenylsulfonyl chloride with 
3-cyanophenylalanine under Schotten-Baumann conditions,[78] followed by coupling 
with the respective piperidines, N-methyl-4-(piperidin-4-yl)butanamide (intermediate 4) 
to obtain compound 5, or with tert-butyl 2-(piperidin-4-yl)ethylcarbamate2 to obtain 
intermediate 30, using PyBOP/DIPEA.  
Intermediates 5 and 30 were treated with various arylboronic acids according to a 
Suzuki coupling protocol. For instance, 2,4-dimethoxyphenylboronic acid was used for 
the preparation of inhibitors 220 and 228, using approximately 1 mol% Pd(OAc)2 and 2 
mol% SPhos in toluene in the presence of Cs2CO3 solution.[78, 171] The conversion of the 
nitrile into an amidine was performed according to the method of Judkins.[188] The 
nitrile in intermediates 13 and 38 were treated with hydroxylamine x HCl and DIPEA in 
ethanol, followed by treatment with acetic anhydride (e.g., intermediate 29 and 54). 
These acetylhydroxyamidine compounds were hydrogenated using (10% Pd/C) as a 
catalyst (Scheme 3.1). In case of chlorine- and flourine-containing derivatives, this step 
was performed with zinc dust in 90% HOAc to avoid a partial removal of the aromatic 
halogen atoms during hydrogenolysis. Intermediates containing a 2-(piperidin-4-yl)-
Boc-ethylamine residue were deprotected by treating with 90% trifluoroacetic acid to 
obtain the related inhibitors. The final inhibitors were purified by preparative HPLC, 
followed by lyophilization from 80% tert-butanol. 
                                                 
2 This compound was available in our group from previous work. 
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Scheme 3.1 Synthesis of inhibitors 220 and 228. Reagents and conditions: (a) 2.1 equiv DIPEA, 1.1 
equiv sulfonyl chloride in dioxane and water (2:1, v/v) at 0 °C and at RT overnight; (b) i: 1 equiv 
intermediate 2, 10 equiv methylamine × HCl, 1.5 equiv HBTU and 4.5 equiv DIPEA in EtOAc at 40 °C 
for 5 h; ii: intermediate 3 dissloved in 1 N HCl in HOAc, 1h; (c) 1.05 equiv PyBOP and 3 equiv DIPEA 
in DMF, 30 min at 0 °C, and 2 h at RT; (d) 1.5 equiv 2,4-dimethoxyphenylboronic acid, 1 mol% 
Pd(OAc)2 and 2 mol% S-Phos in toluene containing 3 equiv 2 M Cs2CO3 solution, 3-4 h reflux; (e) i: 3 
equiv hydroxylamine x HCl and 3 equiv DIPEA, 4 h reflux in ethanol, and stirring overnight at RT; ii: 3 
equiv Ac2O in HOAc, 30 min at RT; (f) H2 and Pd/C as catalyst in 90% HOAc, stirring overnight at RT 
(in case of halogen-containing derivatives this step was performed with zinc dust in 90% HOAc to avoid 
a partial removal of the aromatic halogens during hydrogenolysis); (g) 90% TFA, at RT 1 h. 
The inhibitors summarized in Table 3.2, were prepared from compounds 73 and 77, 
which were synthesized according to Scheme 3.2 as previously described.[78] 
Intermediate 70 was obtained from coupling of 3-nitrophenylsulfonyl chloride with 3-
cyanophenylalanine under Schotten-Baumann conditions, followed by coupling with 
tert-butyl 2-(piperidin-4-yl)ethylcarbamate or with commercially available tert-butyl 
piperidin-4-ylcarbamate × HCl using PyBOP/DIPEA to obtain intermediates 71 and 75, 
respectively. The nitro group was reduced using zinc dust in 90% HOAc providing 
compounds 72 and 76. These intermediates were coupled with Cbz-β-alanine using the 
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mixed anhydride procedure, followed by Boc-deprotection resulted in compounds 73 
and 77. 
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Scheme 3.2 Synthesis of intermediates 73 and 77. Reagents and conditions: (a) 1.1 ml 1N NaOH, 1.1 
equiv sulfonyl chloride in ACN and water (2:1, v/v) at 0 °C and at RT overnight; (b) 1.1 equiv tert-butyl 
2-(piperidin-4-yl)ethylcarbamate or 1.1 equiv tert-butyl piperidin-4-ylcarbamate × HCl, 1.05 equiv 
PyBOP and 3 equiv DIPEA in DMF, 30 min at 0 °C, and 2 h at RT; (c) zinc dust in 90% HOAc 2 h at 
RT; (d) 1 equiv Cbz--alanine, 1 equiv isobutyl chloroformate and 1 equiv NMM, 10 min at -15 °C in 
DMF; 1 equiv intermediate 72 or 76, 1 equiv NMM stirring 1 h at -15 °C and overnight at RT; (e) 90% 
TFA, at RT 1 h. 
For most inhibitors summerized in Table 3.2, 1 equiv of the intermediates 77 or 73 was 
treated with 1.5 equiv of the appropriate isocyanates,[189, 190] e.g., cyclohexyl isocyanate 
for inhibitors 237 and 238, and 2 equiv TEA in DCM according to Scheme 3.3. The 
nitrile containing compounds 87 and 88 were converted into acetylhydroxyamidine to 
obtain intermediates 119 and 120, followed by hydrogenation using the previous 
described procedures providing the final inhibitors 237 and 238 as described in Scheme 
3.1. In case of benzyl-containing intermediates 127 and 128, the conversion of 
acetylhydroxyamidine into amidine was performed with zinc dust in 90% HOAc to 
avoid removal of the benzyl group during hydrogenolysis, followed by the final 
cleavage of the Cbz group with 32% HBr in HOAc to obtain inhibitors 243 and 244. 
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Scheme 3.3 Synthesis of inhibitors 237 and 238. Reagents and conditions: (a) 1.5 equiv cyclohexyl 
isocyanate and 2 equiv TEA in DCM, 3 h at RT; (b) i: 3 equiv hydroxylamine x HCl and 3 equiv DIPEA, 
4 h reflux in ethanol, and stirring overnight at RT; ii: 3 equiv Ac2O in HOAc, 30 min at RT; (c): H2 and 
Pd/C as catalyst in 90% HOAc and stirring overnight at RT (in case of the benzylureas 127 and 128 this 
step was performed with zinc dust in 90% HOAc to avoid removal of the benzyl group during 
hydrogenolysis, followed by cleavage of the Cbz group with 32% HBr in HOAc). 
The unsubstituted urea moiety of inhibitors 229 and 230 was synthesized by reaction of 
the amine intermediate with N-methyl-N-nitrosourea in DCM,[191] whereas the 
methylureas 231 and 232 were prepared by treatment of the amine with N-succinimidyl-
N-methylcarbamate to avoid the use of methylisocyanate.[192]  
Inhibitors 239-242 (Table 3.3) were prepared from compound 30 (Scheme 3.1), or its 
analogue 63 possessing the shorter C-terminal Boc-aminopiperidide residue. These 
compounds were coupled with the appropriate 2,4-dichloro-phenylboronic acid or 
2,4-dimethoxy-phenylboronic acid using a Suzuki coupling procedure (conditions 
according to Scheme 3.1), followed by cleavage of the Boc group using 90% 
trifluoroacetic acid. The intermediates 68 and 69 (Scheme 3.4) were treated with 1.5 
equiv N-succinimidyl-N-methylcarbamate[192] and 2 equiv TEA in DCM to obtain 
compounds 91 and 92. However, the urea moiety of intermediates 93 and 94 was 
obtained by treating compounds 65 and 67 with cyclohexyl isocyanate. The nitrile was 
converted into an amidino group as described previously. 
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Scheme 3.4 Synthesis of inhibitors 239-242. Reagents and conditions: (a) 1.5 equiv N-succinimidyl-N-
methylcarbamate and 2 equiv TEA in DCM, 3 h at RT; (b) 1.5 equiv cyclohexyl isocyanate and 2 equiv 
TEA in DCM, 3 h at RT; (c) i: 3 equiv hydroxylamine x HCl and 3 equiv DIPEA, 4 h reflux in ethanol, 
and stirring overnight at RT; ii: 3 equiv Ac2O in HOAc, 30 min at RT; (d) zinc dust in 90% HOAc, 3 h at 
RT. 
3.1.3 Inhibition of H9N2 influenza virus propagation by matriptase inhibitors3 
The infectivity and replication of influenza viruses depends on the proper cleavage of its 
surface glycoprotein hemagglutinin (HA) that mediates binding to sialic acid-containing 
cell surface receptors and fusion of the viral envelope with the endosomal membrane. 
HA is synthesized as a precursor protein HA0 and needs to be cleaved by a host cell 
protease into the subunits HA1 and HA2 to gain its fusion capacity.[193, 194] 
                                                 
3 These studies on the inhibition of H9N2 virus propagation by matriptase inhibitors were performed in 
the group of Dr. Eva Böttcher-Friebertshäuser and Prof. Dr. Wolfgang Garten in the Institute of Virology, 
Philipps University Marburg. 
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In cell culture experiments, it was demonstrated that some serine proteases, like 
TMPRSS2 and HAT, activate the HA of the H1N1 and H3N2 influenza strains 
containing a monobasic cleavage site.[195] By contrast, matriptase was not able to cleave 
these hemagglutinins of the presently circulating human pathogen influenza strains. 
However, matriptase was recently discovered to be a potent activator of the HA from 
H9N2 influenza A virus subtype (Joanna Baron and Dr. Eva Friebertshäuser, 
unpublished data). The used subtype was first isolated from a quail in China (Province 
Shantou) in 2000. These H9 influenza strains are considered to possess the potency to 
be transformed into a new panademic virus strains.[196] Therefore, the relatively 
selective and potent matriptase inhibitors 19, 224, 241, and 242 were examined for their 
inhibitory effect on the propagation of H9N2 influenza virus in MDCK II cells4 (Fig. 
3.2). These cells strongly express matriptase, which is considered to be the revelant 
protease that specifically activates the HA of influenza virus subtype H9N2 at the 
cleavage site sequence R-S-S-R↓. 
 
Fig. 3.2 Inhibition of H9N2 influenza virus propagation by treatment with matriptase inhibitors in 
MDCK-II-matriptase cells. MDCK II cells were infected with the virus A/quail/Shantou/782/00 (H9N2) 
and incubated with the respective inhibitors at 37° C for 24 h in an incubator to allow virus propagation. 
After 24 h the infected cells and comet-like spread of infection were fixed with 4% paraformaldehyde in 
minimum essential medium. These cells were incubated with specific first antibodies against the viral 
nucleoprotein (NP) of H9N2, followed by conjugation with horse radish peroxidase (HRP) secondary 
antibodies. Infected cells were immunostained using the peroxidase substrate TrueBlue (KPL Inc.) as 
described previously.[50, 195, 197] 
                                                 
4 Madin–Darby canine kidney II (MDCK-II) cells are a kidney epithelial cell line, routinely used for the 
culturing of influenza viruses. It was proven by quantitative PCR that these cells express a relative high 
amount of mRNA for matriptase. These cells allow an efficient H9N2 virus propagation without 
exogenous trypsin treatment. 
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As expected, within 24 hours a multicycles replication of viruses is observed as blue 
comet-like spots in control and DMSO-treated cells in the absence of inhibitors. It is 
assumed that endogenous expressed matriptase is able to activate the newly formed H9. 
For the purpose of evaluation, the comet-like spread of the virus in untreated or DMSO-
treated cells was compared to a concentration-dependent reduced spread in inhibitor-
treated cells. All selected inhibitors and the reference compound 19 strongly suppress 
multicycle virus replication at a concentration of 50 µM (Fig. 3.2). The strongest 
inhibition was found for the cyclohexylurea derivative 241, which is more effective than 
reference 19 containing an N-terminal -alanine residue.[78] Inhibitor 241 completely 
inhibits the virus replication at concentration 50 µM, whereby it has also a strong 
inhibitory effect at reduced concentrations of 10 and 20 µM. It should be noted that 
compound 241 is also a very effective matriptase inhibitor with a Ki value of 2.7 nM. 
The other three compounds inhibited the virus spread slightly less, although they 
possess very similar Ki values. These results demonstrate that the tested matriptase 
inhibitors are effective in suppressing the replication of H9N2 influenza viruses in a 
matriptase-expressing MDCK II cell model. 
3.2 Replacement of the P1 3-amidinophenylalanine 
A few additional analogues were initially synthesized by replacement of the 3-
amidinophenylalanine (Table 3.4), because various other amino acids have been used in 
P1 position of inhibitors prepared for other trypsin-like serine proteases. 
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Fig. 3.3 Structures of known thrombin inhibitors containing different P1 residues.[198-200]  
For instance, an arginine was introduced as P1 residue in the clinically used thrombin 
inhibitor Argatroban.[201] However, the incorporation of a P1-arginine in inhibitor 247, 
which is a direct analogue of compound 28 (Ki value for matriptase 6.3 nM, Fig. 1.11), 
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led to an approximately 100-fold reduction in potency with a Ki value of 0.7 µM. The 
precursor 246, missing the N-terminal β-alanyl residue, is even more than a 1000-fold 
weaker matriptase inhibitor. 
Inhibitors 248 and 249 containing pyridylpropargylglycine derivatives as P1 residue 
were synthesized in analogy to previously described thrombin inhibitors[200] (Fig. 3.3), 
e.g., compound 249 has some similarity to the previously described thrombin 
inhibitor.[199] The elimination of the strongly basic amidino group in these compounds 
results in more than a 10000-fold weaker matriptase inhibition, most likely due to 
complete or partial elimination of important hydrogen/salt bonds to Asp189, Gly219, 
and Ser190 at the bottom and at both sides of the S1 pocket. In general, all these 
analogues are very poor matriptase inhibitors; therefore, no further analogues were 
prepared. 
Table 3.4: Inhibition of matriptase and related trypsin-like serine proteases by inhibitors of the formula. 
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No. 
Ki (µM) 
matriptase thrombin fXa 
246 
MI-0401 25.4 8.1 >150 
247 
MI-0402 0.7 25.5 141 
248 
MI-0407 >150 2.7 22 
249 
MI-0408 >150 21.5 69 
Synthesis of inhibitors with modified P1-residue 
The inhibitors 246 and 247 were prepared from compound 132 (Scheme3.5), which was 
obtained from reaction of 3-nitrophenylsulfonyl chloride with H-Arg(Pbf)-OH under 
Schotten-Baumann conditions, followed by coupling of N-methyl-4-(piperidin-4-
yl)butanamide (intermediate 4) using PyBOP.[78] The nitro group was reduced by zinc 
dust in 90% HOAc providing intermediate 133. This intermediate was coupled with 
Boc-β-alanine using the mixed anhydride procedure, followed by the removal of the 
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whole protecting group using 90% TFA providing inhibitor 247. Analogue 246 was 
obtained by direct treatment of intermediate 133 with 90% TFA. 
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Scheme 3.5 Synthesis of inhibitors 246 and 247. Reagents and conditions: (a) zinc dust in 90% HOAc 2 h 
at RT; (b) 90% TFA, at RT 2 h.; (c) i: 1 equiv Cbz--alanine, 1 equiv isobutyl chloroformate and 1 equiv 
NMM, 10 min at -15 °C in DMF; 1 equiv intermediate 133, 1 equiv NMM stirring 1 h at -15 °C and 
overnight at RT; ii: 90% TFA, at RT 1 h. 
The synthesis of the inhibitors 248 and 249 was performed according to Scheme 3.6. 
The Tfa-β-alanine 135 was coupled with metanilic acid (predissolved in DMF in the 
presence of 1 equiv NMM) using the mixed anhydride procedure. The sulfonic acid was 
converted into the sulfonyl chloride using 1.2 equiv cyanuric chloride and 1.3 equiv 
TEA in dry aceton to obtain intermediate 137.[78] This sulfonyl chloride intermediate 
was coupled to L-propargylglycine in a mixture of ACN and water in the presence of 
DIPEA providing compound 138. This was coupled with N-methyl-4-(piperidin-4-
yl)butanamide (intermediate 4) using PyBOP to obtain compound 139. 
A Sonogashira cross coupling was used to prepare intermediates 140 and 142. For these 
reactions, 0.025 equiv CuI, 8 equiv TEA, 1 equiv 3-iodopyridine or 2-(Boc-amino)-5-
iodopyridine (141) and 0.025 equiv tetrakis(triphenylphosphine)palladium (0) were 
suspended in ACN and refluxed under argon atmosphere for 1 h. This mixture was 
treated with 1 equiv intermediate 139, dissolved in ACN, and refluxed under argon 
atmosphere for an additional 18 h. Compound 142 was deprotected in 50% TFA in 
DCM. The Tfa-group from compounds 143 and 140 was removed by treatment with 
1 N NaOH in a mixture of dioxane/water (pH ≈ 12) and was stirred for 3 h at RT, 
providing inhibitors 248 and 249. 
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Scheme 3.6 Synthesis of inhibitors 248 and 249. Reagents and conditions: (a) 1 equiv Tfa--alanine 
(135), 1 equiv isobutyl chloroformate and 1 equiv NMM, 10 min at -15 °C in DMF; 1 equiv metanilic 
acid, 1 equiv NMM stirring 1 h at -15 °C and overnight at RT; (b) i: 1 equiv intermediate 136 in dry 
acetone, 1.3 equiv TEA, 1.2 equiv cyanuric chloride, 0.05 equiv 18-crown-6, 20 h reflux; ii: 1 equiv 
L-propargylglycine, 2 equiv DIPEA, 1 equiv sulfonyl chloride intermediate 137 in a mixture of 
ACN/water; (c) 1.1 equiv intermediate 4, 1.05 equiv PyBOP and 3 equiv DIPEA in DMF, 30 min at 0 °C, 
and 2 h at RT; (d) 1 equiv 3-iodopyridine or 1 equiv  2-(Boc-amino)-5-iodopyridine (141), 0.025 CuI, 
0.025 equiv tetrakis(triphenylphosphine)palladium (0), 8 equiv TEA in ACN,1 h reflux under argon, 1 
eqiuv 139 18 h reflux in ACN under argon; (e) DCM and TFA (1:1, v/v), stirring 1 h; (f) 1 N NaOH in 
dioxane/water, pH 12 at RT 3 h, neutralization by 10% TFA. 
Results and discussion 
 
49 
 
3.3 D-Phenylglycine derivatives 
Derivatives with a central D-phenylglycine residue have been previously described as 
potent fXa inhibitors (Fig. 3.4). In those initial structures, the amino group of the D-
phenylglycine was acylated by a P1 3-amidinobenzoyl residue, whereas its carboxyl 
group was coupled with substituted piperazines or piperidines, which are supposed to 
bind into the hydrophobic S3/4 binding site.[202, 203] Due to some structural similarity 
between matriptase and fXa, this structure type was used for evaluation as matriptase 
inhibitors.[204] The major differences between both proteases exist in the S3/4 pocket. In 
fXa this pocket has a box-shaped hydrophobic/aromatic cavity lined by aromatic side 
chains of Tyr99, Phe174 and Trp215,[205-207] whereas this binding site in matriptase is 
formed by three aromatic amino acids, Phe97 on the top, Trp215 at the bottom, 
surrounded by Phe99 on the right and Gln175 on the left side (section 2.2.1).  
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Fig. 3.4 Structures of known fXa inhibitors containing a central D-phenylglycine.[203, 204] 
The synthesized inhibitors of this type (Table 3.5) vary only in their substituted 
piperazine residue that should bind into the S3/4 pocket of matriptase, whereas the 
3-amidinobenzoyl-D-phenylglycyl segment was maintained. 
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Table 3.5: Inhibition of matriptase and related trypsin-like serine proteases by D-phenylglycyl-derived 
inhibitors with the general formula.  
N
H
O
O
N
N
R
HN NH2  
No. R 
Ki (µM) 
matriptase thrombin fXa 
250 
MI-0415  
18 4.1 0.02 
251 
MI-0418 NC  
18 5.3 0.001 
252 
MI-0420 O
O
 
46 4.6 0.48 
253 
MI-0421 HO  
29 9.2 0.003 
254 
MI-0426  
25 4.5 0.04 
255 
MI-0422 
N
 
1.7 4.2 0.023 
256 
MI-0423 NC  7.4 6.7 0.04 
257 
MI-0427 N
N
 
2.9 8.1 0.07 
258 
MI-0416 N  
1.4 29 0.09 
259 
MI-0417 N  
0.29 17 0.003 
260 
MI-0424 N  
4.5 3.5 0.024 
261 
MI-0419 H2N
HN
 
5.6 4.8 0.02 
262 
MI-0429 
O
H2N  
12 18 0.50 
263 
MI-0430 H2N
O
 
31 21 3.13 
264 
MI-0435 
H
N
O
H2N
NH  
21 12 3.21 
In general, all compounds containing the central D-phenylglycine residue (Table 3.5) are 
weak to moderate matriptase inhibitors, while some of them show high potency against 
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fXa, as known from literature.[203, 204] The best matriptase inhibition was found for the 
pyridin-4-yl inhibitor 259 with a Ki value of 0.29 µM. However, this compound is a 
much stronger fXa inhibitor, having a Ki value of 3 nM. A 6-10 fold reduced potency 
was found for the pyridin-2-yl analogue 255, and the pyrimidin-2-yl derivative 257 with 
matriptase Ki values of 1.7 and 2.9 µM, respectively. However, both analogues are also 
strong fXa inhibitors with Ki values ≤ 0.07 µM. The 1-methylpiperidin-4-yl compound 
258 inhibits matriptase with a Ki value 1.4 µM similarly to analogue 255.  
By contrast, a replacement of the terminal pyridine by phenyl (250), benzyl (254) or by 
substituted phenyl (251 and 253), results in more than a 50-fold less matriptase 
inhibition (Ki ≥ 18 µM). The conversion, in inhibitor 251, of a nitrile into an amidino 
residue (261) slightly improved the inhibitory potency against matriptase (Ki value 
5.6 µM). Inhibitors 262 and 263, containing the N-terminal -alanine amide and glycine 
amide, also show poor potency against matriptase (Ki values 12 and 31 µM, 
respectively). The conversion of the N-terminal amino group of compound 263 into 
guanidine provided analogue 264 possesing a slightly increased matriptase affinity 
(Ki value 21 µM). All of these D-phenylglycine derivatives, summarized in Table 3.5, 
have poor affinity to thrombin with Ki values > 3.5 µM, whereas some compounds are 
excellent fXa inhibitors with inhibition constants in the nanomolar range, like 
compound 251 (Ki value 1 nM for fXa). 
It is known that a 2-chlorothiophene carbonyl group is a very suitable P1 residue for 
fXa inhibitors,[208, 209] which was used for the development of the clinically approved 
fXa inhibitor Rivaroxaban (Fig. 3.5).[210] This chlorothiophene carbonyl residue was 
also incorporated in fXa inhibitors containing a central amino acid in D-configuration 
like D-phenylglycine.[208, 209] 
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Fig. 3.5 Structures of known fXa and thrombin inhibitors containing 2-chlorothiophene and chloro-
aromatic P1 residues.[209-211] 
Therefore, the analogous inhibitor 265 (Fig. 3.6) was synthesized, but this compound 
showed negligible matriptase affinity. 
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Fig. 3.6 Structure of the 2-chlorothiophene-containing inhibitor 256. 
According to present knowledge, these chloro-aromatic groups are only suitable as P1 
residues for inhibitors of the related trypsin-like serine proteases thrombin[211, 212] and 
fXa,[208, 209] which contain an alanine in position 190 next to Asp189 at the bottom of 
the S1 site. However, not all trypsin-like serine proteases containing an Ala190 can be 
efficiently addressed by such inhibitors containing a chloro-aromatic P1 residue, like 
plasma kallikrein (personal information, Prof. Steinmetzer) and HAT.[213] For instance, 
it was found that substrate analogues containing chloro-substituted benzylamides in P1 
position are relatively weak inhibitors of plasma kallikrein and HAT compared to 
4-amidinobenzylamide analogues. 
Results and discussion 
 
53 
 
3.3.1 Modeled complex of inhibitor 259 in matriptase  
In the solved X-ray structure of trypsin in complex with 2-(4-benzoyl-Pip)-D-Phg-3-
benzamidine (leb2. pdb-code, inhibitor c Fig. 3.4), the benzamidine was found to 
occupy the S1 pocket making a bidentate salt bridge to Asp189. The phenyl portion of 
the phenylglycine linker was located above the disulfide bridge between Cys220 and 
Cys191 and the benzoyl piperidine group binds into the S3/4 site with the carbonyl 
pointing upward into the solvent.[203, 204] This trypsin/inhibitor complex was 
superimposed by an rmsd fit to the C-atomic coordinates of matriptase (2gv6. pdb-
code), followed by replacement of the benzoyl group by a 4-pyridine ring used in 
inhibitor 259, which has similar structure to compound c. This matriptase/inhibitor 259 
complex was energy minimized using Moe program and the fold setting (Fig. 3.7). The 
modeled structure of this complex shows that the N-terminal 4-pyridine-piperazine 
group of compound 259 fits well into the S3/4 pocket making a close edge to face 
contact to the aromatic side chain of Phe99 of matriptase, whereas all characteristic H-
bonds of the P1 3-benzamidine were found as known from the complex of inhibitor c 
(Fig. 3.4) in trypsin. 
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Fig. 3.7 Stereo view of the modeled complex of inhibitor 259 in matriptase. a) Matriptase is shown with 
its surface colored by atom type (carbon in grey, oxygen in red, nitrogen in blue and sulfur in yellow). 
The inhibitor is shown in sticks with green carbon atoms. b) Stereo view of the modeled complex 
showing the hydrogen bonds as black lines, formed between 259 and matriptase residue Asp189, Ser190 
and Gly219. 
3.3.2 Synthesis of D-phenylglycine derivatives 
The synthesis of the inhibitors shown in Table 3.5 was performed according to 
previously described methods using intermediate 146.[204] 
D-Phenylglycine was treated with thionyl chloride in MeOH to perform its methyl ester, 
which was coupled with 3-cyanobenzoic acid using the mixed anhydride procedure, 
followed by saponification to obtain intermediate 146. This compound was first coupled 
with Boc-piperazine, followed by deprotection using 1 N HCl in HOAc and coupling of 
Boc-β-alanine. The nitrile-containing compound was converted into the amidine 
according to the procedure of Judkins,[188] as described in Scheme 3.7. The final 
inhibitor 263 was obtained after Boc-deprotection, which was further converted into the 
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guanidine analogue 264 by treatment with 1-H-pyrazole-carboxamidine and DIPEA in 
DMF.[214] 
Intermediate 152 was prepared by the mixed anhydride coupling of compound 146 with 
1-(1-methylpiperidin-4-yl)piperazine, followed by conversion of the cyano group into 
amidine as described previously, to obtain inhibitor 258 (Scheme 3.7). 
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Scheme 3.7 Synthesis of inhibitors 258, 263 and 264. Reagents and conditions: (a) 1 equiv 3-
cyanobenzoic acid, 1 equiv isobutyl chloroformate and 1 equiv NMM, 10 min at -15 °C in DMF; 1 equiv 
intermediate 144, stirring 1 h at -15 °C and overnight at RT; (b) 1 N NaOH in dioxane and water, pH 12, 
3 h at RT, acidified by 5% KHSO4-solution; (c) i: 1.1 Boc-piperazine, mixed anhydride procedure, see 
step a; ii: 1 N HCl in glacial HOAc, 1 h at RT; (d) 1 equiv Boc-β-alanine, 1.25 equiv EDCI, 1.1 equiv 
HOBT in DMF, 3 h at RT (e) i: 3 equiv hydroxylamine x HCl and 3 equiv DIPEA, 4 h reflux in ethanol, 
and stirring overnight at RT; ii: 3 equiv Ac2O in HOAc, 30 min at RT; iii: H2 and Pd/C as catalyst in 90% 
HOAc, stirring overnight at RT; (f) 90% TFA, at RT 1 h; (g) 2 equiv 1-H-pyrazole-carboxamidine x HCl, 
2 equiv DIPEA in DMF stirring 24 h at RT; (h) 1.1 equiv 1-(1-methylpiperidin-4-yl)piperazine, mixed 
anhydride procedure, see step a. 
Initially, the nitrile 146 was directly converted into the amidine 149 and coupled with 1-
(2-Pyr)piperazine to obtain inhibitors 250 and 255 (Scheme 3.8). 
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We assumed that this strategy is more convenient for the preparation of a large inhibitor 
series of this type, since this would require only a single amidine preparation. However, 
this procedure provided only poor yields with several side products during the coupling 
of the free amidino intermediate 149 with the used piperazine derivatives. Therefore, 
most of the inhibitors of this series were prepared as described in Scheme 3.7. 
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Scheme 3.8 Synthesis of inhibitors 250 and 255. Reagents and conditions: (a) i: 3 equiv hydroxylamine x 
HCl and 3 equiv DIPEA, 4 h reflux in ethanol, and stirring overnight at RT; ii: 3 equiv Ac2O in HOAc, 30 
min at RT; iii: H2 and Pd/C as catalyst in 90% HOAc, stirring overnight at RT; (b) 1 equiv 1-(2-
Pyr)piperazine, 1.25 equiv EDCI, 1.1 equiv HOBT in DMF, stirring under argon atmosphere, 3 h at RT; 
(c) 1 equiv 1-phenylpiperazine, 1.05 equiv PyBOP and 3 equiv DIPEA in DMF, 30 min at 0 °C, and 2 h 
at RT. 
Inhibitor 265 was synthesized by reaction of compound 144 with 5-chlorothiophene-2-
carboxylic acid using the mixed anhydride procedure, followed by saponification and 
coupling of 1-(pyridin-4-yl)piperazine (Scheme 3.9).  
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Scheme 3.9 Synthesis of inhibitor 265. Reagents and conditions: (a) i: 1 equiv 5-chlorothiophene-2-
carboxylic acid, 1 equiv isobutyl chloroformate and 1 equiv NMM, 10 min at -15 °C in DMF; 1 equiv 
intermediate 144, stirring 1 h at -15 °C, and overnight at RT; ii:1 N NaOH in dioxane and water, pH 12, 3 
h at RT, acidification by 5% KHSO4-solution; (b) 1-(pyridin-4-yl)piperazine, mixed anhydride procedure, 
see step a. 
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3.4 Antranilamide derivatives 
From an X-ray crystallographic screen, the clinically used antiarrythmic drug 
Mexiletine was identified as a weak uPA inhibitor. It was found that its terminal amino 
group binds into S1 pocket of uPA, makes a salt bridge to Asp189 and hydrogen bonds 
to the carbonyls of Gly219 and Ser190. Further modifications resulted in a series of 
substituted anilides of 4-(2-aminoethoxy)benzoic acid with strongly improved uPA 
affinity (Fig. 3.8).[215] An additional known uPA inhibitor is amiloride containing an 
acylated guanidine that also occupies the S1 binding site.  
These compounds served as a template for the synthesis of para-(guanidinomethyl)-
benzoyl antranilamide derivatives. 
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Fig. 3.8 Structures of non peptidic uPA inhibitors.[215, 216] 
Due to significant structural similarity between matriptase and uPA in their S1 pocket, 
which are both Ser190 proteases, this structure type was used for evaluation of 
matriptase inhibitors. By contrast, the major differences between both proteases exist in 
the S3/4 pocket. Urokinase possesses a two amino acid insertion of Thr97A and 
Leu97B,[217] which partially reduces the size of the S3/4 pocket, whereas matriptase has 
a larger S3/4 pocket than found in uPA. Therefore, the ethoxy group in the known uPA-
inhibitors (compound c, Fig. 3.8)[215] was replaced by larger groups, which should 
interact with this binding pocket. Furthurmore, the aminoethoxy group was replaced by 
a guanidinomethyl residue analogue to the acylguanidine of amiloride (d, Fig.3.8), 
which has a similar length and enable a binding to Asp 189 in the S1 pocket. 
The synthesized inhibitors of this type (Table 3.6) vary in the length of the residue that 
should bind into the S3/4 pocket of matriptase. 
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Table 3.6: Inhibition of matriptase and related trypsin-like serine proteases by inhibitors of the general 
formula. 
O
O
R
OH
N
O
NH
NH2
HN
 
No. R 
 Ki (µM) 
matriptase thrombin fXa uPA 
266 
MI-0409 OCH3 73 26 103 > 30 
267 
MI-0410 
H
N
 
35 27 2.2 > 100 
268 
MI-0411 N
H  
31 7.3 77 > 100 
However, inhibitors 266-268 possess a weak potency against matriptase with Ki values 
> 30 µM. These three compounds are also weak thrombin, fXa and uPA inhibitors. 
Therefore, no further derivatives in this series were prepared. 
Synthesis of anthranilamide derivatives 
4-(Boc-aminomethyl)benzoic acid was coupled with commercially available methyl 2-
amino-4,5-dimethoxybenzoate by the mixed anhydride procedure to obtain intermediate 
175. Deprotection using 1 N HCl in HOAc provided compound 177, which was further 
converted into guanidine 266 by treatment with 1-H-pyrazole-carboxamidine and 
DIPEA in DMF.[214] Alternatively, intermediate 175 was saponified and coupled with 
benzylamine or phenylethylamine using the mixed anhydride procedure to obtain 
compounds 178 and 180. After removal of the Boc-group, amine intermediates were 
converted into guanidino analogues 267 and 268 by treatment with 1-H-pyrazole-
carboxamidine.[214] 
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Scheme 3.10 Synthesis of inhibitors 266-268. Reagents and conditions: (a) 1 N NaOH in dioxane and 
water, pH 12, 3 h at RT, acidified by 5% KHSO4-solution (b) 1 equiv isobutyl chloroformate and 1 equiv 
NMM, 10 min at -15 °C in DMF; 1 equiv benzylamine or 1 equiv phenylethylamine, stirring 1 h at -15 
°C, and overnight at RT; (c) 1 N HCl in glacial HOAc, 1 h at RT; (d) 2 equiv 1-H-pyrazole-
carboxamidine x HCl, 2 equiv DIPEA in DMF stirring 24 h at RT. 
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3.5 Substrate analogue inhibitors  
Substrate analogues containing a C-terminal 4-amidinobenzylamide as a decarboxylated 
P1 arginine mimetic are potent inhibitors of various trypsin-like serine proteases, like 
thrombin, factor Xa, factor VIIa, plasma kallikrein, and uPA.[90, 162-164, 218-220] Such 
inhibitors are stable against degradation by carboxypeptidases and in case of the N-
terminal acylation or sulfonylation they are also resistant against aminopeptidases. Most 
of these inhibitors possess a P3 amino acid in D-configuration. There exist only a few 
potent examples as thrombin inhibitors containing a P3 residue in L-configuration.[221, 
222] Selectivity studies with previously described substrate analogue inhibitors of fXa 
revealed that some of them containing D-homophenylalanine analogues in P3 position 
(9-10) also possess a moderate affinity to matriptase with Ki values > 50 nM (Fig. 
3.9).[161] 
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Fig. 3.9 Known substrate analogue inhibitors of trypsin-like serine proteases.[161] 
The very non-specific analogue MI-0001, containing a D-arginine as P3 residue has 
been previously described as a potent fXa, thrombin and plasma kallikrein inhibitor,[223] 
whereas the D-cyclohexyl alanine analogue MI-0003 was characterized as a highly 
potent thrombin inhibitor.[183, 224] Both analogues were also described as first low 
molecular weight matriptase-2 inhibitors with Ki values of 0.17 µM and 0.46 µM, 
respectively. However, they are also slightly stronger matriptase inhibitors.[178] 
Therefore, an extended screen of matriptase with additional substrate analogues, which 
were available in our group from previous studies[178, 183] was performed. All of these 
inhibitors contain a C-terminal 4-amidinobenzylamide and an N-terminal 
benzylsulfonyl group, but vary in their P2 and P3 residues (Table 3.7).  
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Table 3.7: Screening of substrate-analogue inhibitors of related trypsin-like serine proteases with 
matriptase, which were previously described.[178, 183, 223] 
NH2
NH
H
N
P2
P3
S
OO
 
No. P3 P2 
Ki (µM) 
matriptase Thrombin fXa HAT 
MI-0320 D-hPhe Pro 0.013 0.001 0.014 0.063 
MI-0323 D-hArg Pro 0.03 0.0004 0.003 0.013 
MI-0001 D-Arg Pro 0.033a 0.004 0.0029 0.019 
MI-0322 D-Lys Pro 0.04 0.001 0.052 0.04 
MI-0326 D/l-hAla(2Pyr) Pro 0.073 0.001 0.0022 0.041 
MI-0321 D-Lys(Cbz) Pro 0.2 0.0004 0.017 0.053 
MI-0361 D-Phe(4-Am) Pro 0.3 0.003 0.15 0.17 
MI-0003 D-Cha Pro 0.33a 0.0001 0.035 0.11 
MI-0317 D-Phe- Pro 0.34 0.0001 0.077 0.098 
MI-0354 D-Val Pro 0.77 0.0013 0.012 0.076 
MI-0329 D-Ala Pro 2.76 0.005 0.83 n.d 
MI-0328 Gly Pro 5.91 0.004 5.17 n.d 
MI-0371 D-Arg Ala 0.02 0.075 0.001 0.03 
MI-0360 D-Arg Arg 0.023 n.d. n.d. 0.46 
MI-0381 D-Arg Abu 0.065 0.029 0.002 0.014 
MI-0380 D-Arg Nva 0.12 0.068 0.037 0.015 
MI-0366 D-Arg Ser 0.2 0.5 0.02 0.034 
MI-0377 D-Arg Leu 0.46 n.d. n.d. 0.05 
MI-0378 D-Arg Val 0.57 0.66 0.021 0.022 
MI-0379 D-Arg Phe 0.24 n.d. n.d. 0.06 
MI-0324 Lys Lys 2 n.d n.d 0.2 
MI-0365 D-Phe Ser 4.3 0.02 0.24 0.18 
MI-0362 D-Phe Lys(Cbz) 15 0.0006 0.7 0.67 
aThese matriptase inhibition constants have been previously described.[178]  
In a first series, a proline was maintained as P2 residue, whereby various D-amino acids 
were incorporated in P3 position. All of these analogues are highly potent thrombin 
inhibitors with Ki values ≤ 5 nM, because proline is a preferred P2 residue for this 
trypsine-like protease.[225] MI-0320 was the most potent matriptase inhibitor, which 
could be identified by this screening, possessing a Ki value of 13 nM. This compound 
contains a D-homophenylalanine as P3 residue, similar to several homoamino acids in 
the D-configuration were used for compounds 9-10 (Fig. 3.9). A slightly reduced 
affinity with Ki > 100 nM was found for analogues containing D-homoarginine, D-
lysine, D/L-homo-2-pyridylalanine and D-arginine as previously reported.[178] The found 
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inhibition constants confirm previous results obtained with the 3-amidinophenylalanine-
derived inhibitors that matriptase preferably accommodates aromatic or basic groups in 
its S3/4 pocket. A second series of those previously synthesized analogues contains a 
constant P3 D-arginine, whereas the P2 residue was modified. Among these inhibitors, 
compounds MI-0371 and MI-0360 containing P2 alanine and arginine, respectively, 
have the strongest potency against matriptase; with Ki value close to 20 nM. The 
replacement of P2 proline with other amino acids generally reduces the affinity to 
thrombin. However the alanine derivative MI-0371 and aminobutyric acid derivative 
MI-0381 were found to be excellent fXa inhibitors (Ki ≤ 2 nM).[90, 218, 226] All other 
analogues showed a relatively weak matriptase inhibition. Previous studies with related 
substrate analogue inhibitors revealed that the presence of an N-terminal benzylsulfonyl 
group such as in Bzls-D-Ser(tBu)-Gly-4-amidinobenzyl-amide (a Ki value for fXa 
14 nM) considerably increases the affinity to fXa by a 1000-fold, compared to an 
analogue missing the P4 residue (H-D-Ser(tBu)-Gly-4-amidinobenzyl-amide, Ki value 
for fXa 16 µM). However, this effect was less pronounced with other trypsine-like 
serine proteases, like thrombin, plasmin, uPA, and trypsin,[218] although the Bzls-
derivatives were also more potent with these proteases. To reduce the affinity to fXa, 
several new substrate analogue inhibitors without Bzls-group were prepared (Table 3.8). 
Table 3.8: Inhibition of matriptase and related trypsin-like serine proteases by substrate analogue 
inhibitors. 
N
H NH2
NH
P2
P3
 
No. P3 P2 Ki (µM) matriptase thrombin fXa 
273 
MI-0464 H-hPhe Pro 19.65 7.61 66.36 
274 
MI-0465 H-Phe Pro 46.5 17.64 212.31 
275 
MI-0466 H-D-Phe
a Pro 3.89 0.004 37.53 
276 
MI-0467 H-D-hPhe Pro 0.06 0.072 2.58 
279 
MI-0468 H-D-Arg Pro 0.25 0.69 0.74 
277 
MI-0469 H-D-hPhe Ala 0.044 0.73 1.79 
278 
MI-0470 H-D-hTyr Ala 0.026 0.30 0.57 
aThe inhibitor was previously described as thrombin inhibitor possessing a Kass of 6.8 x 108 L/mol.[162] 
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In addition to inhibitors with D-amino acid in P3 position, two analogues with 
L-configuration were prepared for comparison. However, inhibitors 273 and 274 are 
completely inactive against matriptase and the related trypsin-like serine proteases. 
All compounds are relatively weak fXa inhibitors confirming previous results.[218] The 
P2 proline derivatives in combination with P3 D-phenylalanine (275) and 
D-homophenylalanine (276) retain significant potency against thrombin (Ki values 4 nM 
and 72 nM, respectively), whereas the D-arginine compound 279 is the first substrate 
analogue with stronger affinity to matriptase compared to thrombin and fXa.  
For further reduced affinity to thrombin, the alanine derivatives 277 and 278 were 
synthesized. Based on the screening results (Table 3.7), this modification has slightly 
improved the matriptase inhibition and selectivity. Inhibitor 278 containing 
D-homotyrosin as P3 residue possesses an inhibition constant of 26 nM against 
matriptase, which is more than 10-fold stronger compared to the Ki values against 
thrombin and fXa. Its analogue 277, containing the P3 -D-homophenylalanine, has also 
an acceptable affinity to matriptase (Ki 44 nM) compared to thrombin and fXa. 
Despite it is known that trypsin-like serine proteases prefer P3 residues in 
D-configuration,[227] untill now there exist only some examples of thrombin inhibitors 
with L-amino acids in the P3 position.[221, 222] Therefore, we assumed that it could be 
useful to incorporate also Cα-dialkylated amino acids in P3 position for further 
improvement in affinity to matriptase. Such residues can be considered as a kind of 
chimera between amino acids in D- and L-configuration. However, all of those reported 
analogues contain two different alkyl groups at the P3 Cα-atom resulting in a mixture of 
configuration isomers, which requires a laborious purification to obtain the single 
isomers. To use this strategy and to overcome the synthetic problems, a few analogues 
containing two identical alkyl groups at the P3 Cα-atom were prepared.  
The first compound of this series is inhibitor 269, which contains 4-(pyridin-4-yl)-2-(2-
(pyridin-4-yl)ethyl)butanoyl as an N-terminal acyl residue, and it is missing an amino 
group. This acyl residue was obtained as a side product during malonic ester synthesis 
with 4-vinylpyridine to obtain 4-(pyridin-4-yl)butanoic acid,[228] prepared as a precursor 
for 4-(piperidin-4-yl)butanoic acid, which was incorporated in inhibitors of the 
3-amidinophenylalanine type. However, this compound is a relatively weak inhibitor of 
matriptase, thrombin and fXa (Fig. 3.10). 
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Fig. 3.10 Structure of inhibitor 269. 
We assumed that the weak affinity is mainly related to the missing amino group in the 
P3 position, which normally interacts with the carbonyl oxygene of Gly216. However, it 
should be noted that inhibitor 269 contains two 4-pyridinyl groups; therefore, it is 
difficult to compare this inhibitor with the analogues shown in Tables 3.8 and 3.9. 
The structure of the prepared inhibitors containing Cα-dialkylated amino acids are 
shown in Table 3.9. All of these analogues have a very similar affinity to matriptase as 
found in inhibitor 269, whereas their potency against thrombin was significantly 
enhanced. 
Table 3.9: Inhibition of matriptase and related trypsin-like serine proteases by substrate analogue 
inhibitors of the general formula. 
N
O
H
N
O
N
H
NH
NH2
n
270-272
n
R
 
No. n R 
Ki (µM) 
matriptase thrombin fXa 
270 
MI-0457 1 Tfa 6.6 0.086 22 
271 
MI-0456 0 Tfa 13 0.003 21 
272 
MI-0459 1 H 0.94 0.042 4.2 
The kinetic results for these few examples revealed that the incorporation of 
Cα-dialkylated P3 amino acids is not a suitable strategy for the design of substrate 
analogue matriptase inhibitors. 
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3.5.1 Crystal structure of thrombin in complex with inhibitor 271  
Inhibitor 271 (Tfa-Dbzg-Pro-4-Amba) has a strong potency against thrombin with a Ki 
value of 3 nM. To obtain an impression of its binding mode, it was soaked into 
thrombin/benzamidine crystals and the structure was solved by X-ray crystallography. 
As far as we know, this is the first crystal structure of thrombin in complex with a 
substrate analogue inhibitor containing a Cα-dialkylated P3 amino acid. 
The crystal structure shows that one benzyl group is bound into the distal S3/4 aryl 
binding site, whereas the other benzyl group is directed into the solvent. At present, we 
can not explain the reason for the more than 4000-fold reduced inhibition of matriptase 
by inhibitor 271. However, it should be noted that this preliminary crystal strucrure of 
the complex thrombin/271 is not finally resolved till now and therefore, not submitted 
to the protein data bank. 
However, at the present stage of the refinement, the characteristic interactions of the 
amidine group in the S1 pocket to Asp189, Gly219 and to the characteristic water 
molecule are found, as well as the hydrogen bond between the carbonyl of Ser214 and 
the P1 amide NH (Fig. 3.11). 
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b) 
 
Fig. 3.11 Crystal structure of thrombin in complex with inhibitor 271. a) Thrombin is shown with its 
solvent-accessible surface colored by atom charge (negatively charged atoms in red and positively 
chargeds atom in blue) and inhibitor 271 in sticks. b) Stereo view of the complex in the active site of 
thrombin. 
3.5.2 Synthesis of substrate-analogue inhibitors 
The synthesis of the inhibitors shown in Table 3.8 was performed according to 
previously described methods.[90, 178, 218, 221] Cbz-Pro-(4-acetylhydroxyamidino)benzyl-
amide[221] (provided by Prof. Steinmetzer) was hydrogenated providing intermediate 
194, whereby the analogue Ala-4-amidinobenzylamide was provided by Dr. Frank 
Sielaff. These P2-P1 segments were coupled with various N-protected amino acids 
using PyBOP/DIPEA in DMF. Cleavage of the N-terminal protection group provided 
the final inhibitors 276, 278 and 279 (Scheme 3.11). 
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Scheme 3.11 Synthesis of inhibitors 276, 278 and 279. Reagents and conditions: (a) 1.05 equiv PyBOP 
and 3 equiv DIPEA in DMF, 30 min at 0 °C, and 2 h at RT; (b) 90% TFA, at RT 2 h.; (c) 32% HBr in 
HOAc, 1 h at RT. 
Inhibitor 269 was synthesized according to Scheme 3.12. Intermediate 182 (diethyl 2,2-
bis(2-(pyridin-4-yl)ethyl)malonate) was prepared by treating diethyl malonate with 
sodium hydride in ethanol, followed by treatment with 4-vinylpyridine according to a 
previously described procedure for the preparation of 4-(pyridin-4-yl)butanoic acid.[228] 
To obtain the dialkylated derivative 182, a high excess of the starting material 4-
vinylpyridine was used. This compound was saponified and decarboxylated[229] to 
obtain intermediate 183, which was coupled with H-Pro-4-Amba (194) producing 
inhibitor 269. 
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Scheme 3.12 Synthesis of inhibitor 269. Reagents and conditions: (a) 1.7 equiv NaH, in ethanol at 0 °C, 1 
equiv diethyl malonate, stirring 30 min at 80 °C, the mixture was cooled, 1.1 equiv 4-vinylpyridine, 3 h 
reflux; (b) 3 N NaOH in dioxane and water, stirring 7 h at 95 °C, neutralization with 1 N HCl; (c) 1.05 
equiv PyBOP and 3 equiv DIPEA in DMF, 30 min at 0 °C, and 2 h at RT. 
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The Cα-dialkylated P3 amino acids for inhibitors 270-272 were synthesized by a 
modified strecker synthesis using appropriate symmetric ketones as a starting material, 
according to previously decribed methods.[230] Commercially available 1,3-
diphenylpropan-2-one or 1,5-diphenylpentan-3-one 186, dissolved in MeOH was 
treated with a solution of NH4Cl in water, NaCN and ammonia (Scheme 3.13). The 
mixture was stirred at 50 °C for 32 h, followed by hydrolysing the nitriles 184 and 187 
were hydrolized by 6 N HCl to obtain the amino acids di(phenylethyl)glycine 188 or 
di(benzyl)glycine 185.[231, 232] These glycine derivatives were protected by treatment 
with trifluroacetic anhydride in TFA. Alternatively intermediate 188 could also Cbz-
protected. The protected dialkyled-glycine derivatives were coupled with H-Pro-4-
cyanobenzylamide × HCl (193) using HATU/DIPEA in DCM to obtain intermediates 
195, 198 and 201. These nitriles were converted into amidines as described previously, 
whereby the Cbz-group was cleaved from intermediate 203 during hydrogenation, to 
obtain inhibitosr 270-272. 
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Scheme 3.13 Synthesis of inhibitors 270-272. Reagents and conditions: (a) 3.2 equiv NH4Cl, 2.9 equiv 
NaCN, NH3 in water, 1 equiv 1,3-diphenylpropan-2-one or  1 equiv 1,5-diphenylpentan-3-one dissolved 
in MeOH, 32 h at 50 °C, acidification with 1 N HCl; (b) ≈ 6 N HCl in water, stirring under reflux for 48 
h; (c) i: for Tfa-protection: 2 equiv of trifluoroacetic anhydride in TFA, stirring at 1 h 0 °C, at RT 
overnight; or ii: for Cbz-protection: 2 equiv NMM, 1.1 equiv Cbz-OSu dissolved in ACN, stirring 1h at 0 
°C, 3 h at RT; (d) 1.1 equiv intermediate 193, 1.25 equiv HATU, 2 equiv DIPEA in DCM, stirring 1 h 0 
°C, strirring 2 h at RT; (e) i: 3 equiv hydroxylamine x HCl and 3 equiv DIPEA, 4 h reflux in ethanol, and 
stirring overnight at RT; ii: 3 equiv Ac2O in HOAc, 30 min at RT; (f) H2 and Pd/C as catalyst in 90% 
HOAc, stirring overnight at RT. 
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Despite many attempts, it was impossible to remove the Tfa-protection group by 
treatment with various bases, a similar problem was reported previously.[233]  
The N-terminal Tfa-group was used as an amino protecting group, because it was 
impossible to couple H-Pro-4-cyanobenzylamide × HCl (193) to Boc- or Cbz-
di(benzyl)glycine (185) by various coupling procedures, including the PyBOP, HATU, 
HBTU, PyBrOP, EDCI, or mixed anhydride method. Several examples have 
demonstrated that in peptide chemistry, it is difficult to couple amino components to 
highly hindered dialkylated amino acids, like D-amino isobutyric acid (AIB).[234, 235] By 
contrast, it was possible to couple the H-Pro-4-cyanobenzylamide × HCl (193) to the 
Cbz-protected di(phenylethyl)glycine (190). It seems that this amino acid is sterically 
less hindered than the analogous di(benzyl)glycine-derivative. However, for the 
preparation of all these analogues, relatively poor coupling yields were observed. 
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4 Conclusion and outlook 
In the present work, various types of new matriptase inhibitors were developed. These 
compounds were tested against several trypsin-like serine proteases including 
matriptase, thrombin and fXa. In some cases additional proteases like uPA, matriptase-
2, and HAT were used. Efficient matriptase inhibitors could be useful drugs for the 
treatment of several deseases like cancer, osteoarthritis, atherosclerosis and few types of 
influenza. 
4.1 3-Amidinophenylalanine derivatives 
In a first series, new 3-amidinophenylalanine-derived matriptase inhibitors were 
synthesized. The strongest derivatives of this type possess an N-terminal 2′,4′-dimeth-
oxy or 2′,4′-dichlorobiphenyl-3-sulfonyl with a C-terminal 2-aminoethylpiperidide 
residue (section 3.1, Table 3.1). Both dibasic compounds inhibit matriptase with Ki 
values ≤ 2 nM and possess an acceptable aselectivity against the other tested proteases. 
By contrast, their direct analogues with a neutral C-terminal 4-piperidyl-butanoyl 
methylamide residue have a reduced matriptase affinity and selectivity. Several of these 
monobasic compounds were found to be even more potent thrombin inhibitors with Ki 
values around 1 nM.  
To reduce the strong affinity to thrombin and maintain high affinity as matriptase 
inhibitors, a second inhibitor series was prepared (Table 3.2). These derivatives contain 
a substituted urea residue in the C-terminal amide moiety combined with an N-terminal 
-alanylamide group. Among this series, two matriptase inhibitors with Ki values below 
10 nM could be identified. These analogues, containing a C-terminal cyclohexyl urea or 
methyl urea portions, were further optimized by replacement of their N-terminal basic 
-alanylamide moiety with the most suitable 2,4-dimethoxyphenyl or 2,4-dichloro-
phenyl groups identified from the initial series. This provided the first monobasic 
matriptase inhibitor 241, possessing an N-terminal 2′,4′-dimethoxybiphenylsulfonyl 
group and a C-terminal cyclohexylurea, which retains excellent matriptase affinity with 
an inhibition constant of 2.7 nM exhibiting negligible affinity to thrombin. This 
compound should be well suited to be used in further cell culture or animal studies, 
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probably also in a prodrug form, which are meanwhile well established for various 
benzamidino-drugs. 
The relatively selective and potent matriptase inhibitors 241 and its analogues 
2′,4′-dichlorobiphenyl 242, as well as the dibasic inhibitor 224, were examined for their 
inhibitory effect on the propagation of H9N2 influenza virus strains in MDCK II cells. 
All selected inhibitors could strongly suppress the multicycle virus replication at a 
concentration of 50 µM. The strongest inhibition is found for derivative 241, which also 
showed a strong inhibitory effect at reduced concentrations of 10 µM and 20 µM. These 
results demonstrate that the tested matriptase inhibitors are effective in suppressing the 
replication of H9N2 influenza viruses in a matriptase-expressing MDCK II cell model. 
These matriptase inhibitors could be potential lead structures for the development of 
new drugs against H9 for influenza. 
4.2 Modification of the 3-amidinophenylalanine in P1 position 
All inhibitors of this series have strong reduced affinity to matriptase compared to the 3-
amidinophenylalannine analogues. The incorporation of an arginine in inhibitor 247 
(H-βAla-3-NH-phenylsulfonyl-Arg-4-(piperidin-4-yl)-N-methylbutanamide) reduced 
the potency by approximately 100-fold. All other modifications, e.g., the incorporation 
of propargylglycine-5-(pyridin-3-yl) and propargylglycine-5-(6-aminopyridin-3-yl) 
residues (248 and 249) have completely eliminated any matriptase affinity. 
4.3 D-Phenylglycine derivatives 
Additional inhibitors with a central D-phenylglycine residue, which were previously 
described as potent fXa inhibitors, were prepared and evaluated as matriptase inhibitors 
(section 3.3, Table 3.5). These derivatives differ in their substituted piperazine residue, 
which most likely occupies the S3/4 binding site of matriptase, whereas a constant 
3-amidinobenzoyl-D-phenylglycyl segment was maintained. 
The strongest matriptase inhibiton was found for the 4-pyridinyl-piperazine inhibitor 
259 with a Ki value of 0.29 µM. The replacement of the terminal pyridine by various 
hydrophobic rings, such as benzyl, phenyl and 4-cyanophenyl led to more than 50-fold 
reduced matriptase inhibition (Ki ≥ 18 µM). All of these D-phenylglycine derivatives 
reveal a weak potency against thrombin, and as expected from literatures possess a 
strong fXa affinity. For instance, compound 251 containing an N-terminal 
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4-cyanophenyl-piperazine inhibits fXa with a Ki value of 1 nM. The incorporation of a 
chlorothiophene carbonyl residue in P1 position, which is suitable for fXa inhibitors, 
resulted in a vompound with poor matriptase affinity. 
4.4 Antranilamide derivatives 
Based on some structural similarity between matriptase and uPA, both are Ser190 
proteases, a few matriptase inihibitors, with a para-(guanidinomethyl)benzoyl aniline 
group as a potential P1 residue, were prepared. These compounds were derived from 
uPA inhibitors, like substituted anilides of 4-(2-aminoethoxy)benzoic acid or amiloride, 
which possesses an acylated guanidine as P1 residue. The obtained inhibitors 266-268 
have only weak potency against matriptase and all other tested trypsin-like serine 
proteases. Therefore, no further derivatives were prepared in this series. 
4.5 Substrate analogue inhibitors 
Substrate analogue inhibitors, containing a C-terminal 4-amidinobenzylamide as P1 
residue; a P4 benzylsulfonyl residue; and a P3 amino acid in D-configuration possess 
high potency against various trypsin-like serine proteases. During previous selectivity 
studies with such substrate analogue inhibitors of fXa, a few examples containing 
D-homophenylalanine derivatives in P3 positions were identified as moderate matriptase 
inhibitors. Therefore, a further screen of substrate analogue inhibitors available in our 
group was performed (section 3.5, Table 3.7).  
The strongest affinity was found for Bzls-D-hPhe-Pro-4-amidinobenzylamide 
(MI-0320), which inhibits matriptase with a Ki value of 13 nM. Among a related series 
containing a constant P3 D-arginine residue, a relatively high potency was found for 
analogues with P2 alanine (MI-0371) or arginine (MI-0360). Both compounds inhibit 
matriptase with Ki values around 20 nM. The use of a P2 alanine, instead of proline, 
reduced the affinity to thrombin but maintained high potency against fXa. For instance, 
the alanine analogue MI-0371 and the homoalanyl derivative MI-0381 inhibit fXa with 
Ki values ≤ 2 nM. Other P2 residues were less suitable for matriptase inhibition. 
Additional analogues, missing the N-terminal benzylsulfonyl group were prepared to 
reduce their potency against fXa (section 3.5, Table 3.8). 
This provided inhibitor 278 (H-D-hTyr-Ala-4-Amba), which inhibits matriptase with a 
Ki value of 26 nM, whereas it has more than 10 fold reduced potency against thrombin 
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and fXa. This compound is the first substrate analogue inhibitor with improved affinity 
to matriptase compared to other trypsin-like serine proteases. There also exist a few 
examples of thrombin inhibitors possessing a P3 amino acid in L-configuration. 
Therefore, a few analogues were prepared, which contain a Cα-dialkylated amino acid 
in P3 position. Such residues can be considered as a chimera between a D- and L-amino 
acid. However, the incorporation of these Cα-dialkylated amino acid residues in P3 
position provided only poor matriptase inhibitors. The synthesis of these derivatives 
was much more complicated than the preparation of the classical substrate analogues 
containing D-amino acid as P3 residue. 
Therefore, such dialkylated derivatives provide no further opportunity for the design of 
improved matriptase inhibitors. 
4.6 Summary 
Several new inhibitors were prepared and tested as potential matriptase inhibitors. The 
most potent compounds were found among the tertiary amides of arylsulfonylated-3-
amidinophenylalanines. The incorporation of suitable bis-substituted biphenylsulfonyl 
groups in combination with appropriate C-terminal urea structures provided the final 
strong potent monobasic matriptase inhibitors with acceptable selectivity against related 
trypsin-like serine proteases. Such compounds are suitable candidates for their further 
evaluation in cell culture experiments to elucidate the potential role of matriptase in 
pathophysiological processes. 
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4.7 Zusammenfassung und Ausblick 
Wirksame und selektive Matriptaseinhibitoren sind potentielle Wirkstoffe für die 
Behandlung verschiedener Krankheiten, wie Krebs und Metastasierung, Arthritis, 
Arteriosklerose oder durch H9-Influenzaviren verursachte Grippe. In der vorliegenden 
Arbeit wurden neue Matriptaseinhibitoren entwickelt und gegen verschiedene 
trypsinartige Serinproteasen, wie Matriptase, Thrombin und fXa getestet. Einige 
besonders wirksame Inhibitoren wurden zusätzlich noch auf ihre Hemmwirkung 
bezüglich anderer Proteasen, wie uPA, Matriptase-2 und HAT untersucht. 
3-Amidinophenylalanin Derivate 
Zunächst wurde eine neue Serie an Matriptaseinhibitoren synthetisiert, die sich vom 
3-Amidinophenylalanin ableiten. Die wirksamsten Hemmstoffe dieses Typs besitzen 
eine N-terminale 2′,4′-Dimethoxy- oder 2′,4′-Dichlorbiphenyl-3-sulfonyl-Gruppe und 
einen C-terminalen 2-Aminoethylpiperidid-Rest. Diese bisbasische Verbindungen 
hemmen Matriptase mit Ki-Werten ≤ 2 nM und besitzen eine akzeptable Selektivität 
gegen andere trypsinartiger Serinproteasen. Im Gegensatz dazu besitzen die Analoga 
mit einem neutralen 4-Piperidyl-butanoylmethylamid-Rest am C-Terminus reduzierte 
Matriptaseaffinität und Selektivität. Einige dieser Verbindungen erwiesen sich mit Ki 
Werten um 1 nM sogar als deutlich stärkere Thrombininhibitoren. 
Um die Matriptaseaffinität und Selektivität zu verbessern, wurde eine zweite Serie 
innerhalb dieses Strukturtyps synthetisiert. Diese Verbindungen besitzen am 
C-terminalen Piperididrest substituierte Harnstoffgruppen und am N-Terminus einen 
ß-Alanylamid-Rest. Unter diesen Verbindungen wurden zwei Matriptasehemmstoffe 
mit Ki-Werten unter 10 nM identifiziert, die C-terminal mit einem Cyclohexyl- oder 
Methylharnstoff-Rest modifiziert sind. Um monobasische Inhibitoren zu erhalten, die 
möglicherweise eine bessere Bioverfügbarkeit im Vergleich zu den dibasischen 
Verbindungen besitzen, wurde der N-terminale ß-Alanylamid-Rest durch 2,4-Dimeth-
oxyphenyl- oder 2,4-Dichlorphenyl-Gruppen ausgetauscht, die sich bereits in der ersten 
Serie als besonders wirksam erwiesen hatten. Daraus resultierte der erste monobasische 
Matriptaseinhibitor 241, der eine N-terminale 2′,4′-Dimeth-oxybiphenylsulfonyl-
Gruppe und einen Cyclohexylharnstoff-Rest am C-Terminus besitzt. Diese Verbindung 
inhibiert Matriptase mit einer Hemmkonstanten von 2.7 nM und hat durch die sterisch 
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anspruchsvolle Cycloheyxylharnstoffgruppe vernachlässigbare Affinität zu Thrombin. 
Dieser Matriptaseinhibitor ist ein geeigneter Kandidat für weiterführende in vitro oder 
in vivo Tests, um die biologische Funktion dieser Protease genauer zu untersuchen und 
um pathogene Mechanismen zu hemmen, an denen Matriptase beteiligt ist. So wurde 
beispielsweise der monobasische Matriptaseinhibitor 241, dessen direktes 2,4-Dichlor-
phenyl-Analogon 242, sowie der dibasische Inhibitor 224 eingesetzt, um die 
Vermehrung der H9N2 Influenzaviren in MDCK II Zellen zu inhibieren. Alle drei 
Verbindungen besitzen bei einer Konzentration von 50 µM eine sehr starke 
Hemmwirkung auf die multizyklische Virusvermehrung, wobei Verbindung 241 auch 
bei niedrigeren Konzentrationen von 20 und 10 µM noch einen deutlichen Effekt zeigt. 
Demzufolge könnten diese Verbindungen eine potentielle Leitstruktur für die 
Behandlung von Grippeinfektionen durch H9-Viren darstellung. Denkbar ist auch eine 
Überführung dieser Inhibitoren in ein Prodrug, z.B. in eine Hydroxyamidino-
Verbindung. Es ist bekannt, dass solche Prodrugs häufig eine deutlich bessere 
Bioverfügbarleit besitzen. Im Gegensatz zu den klassischen antiviralen Targets würden 
in diesem Fall stabile humane Zielstrukturen adressiert werden. Es ist davon 
auszugehen, dass sich in diesem Fall keine Wirkstoffresistenzen ausbilden würden. 
Diese Verbindungen könnten prinzipiell auch für eine Kombinationstherapie geeignet 
sein. 
Austausch des 3-Amidophenylalanins in P1-Position 
In einer weiteren Serie wurde das 3-Amidinophenylalanin in P1-Position durch andere 
Aminosäurereste ausgetauscht, jedoch zeigten alle erhaltenen Verbindungen eine 
reduzierte Matriptaseaffinität. Der Einbau eines Arginin, beispielsweise in Inhibitor 247 
(H-βAla-3-NH-phenylsulfonyl-Arg-4-(Pip)-N-methylbutanamide), bewirkte eine ca. 
100-fach geringere Hemmwirkung. Alle weiteren Austausche, wie der Einbau eines P1 
3-Pyr-Propargylglycins in Inhibitor 248 oder des 4-Amino-3-Pyr-Propargylglycins in 
Hemmstoff 249 führten zu völlig wirkungslosen Verbindungen. 
D-Phenylglycin-Derivate 
Verbindungen mit einem zentralen D-Phenylglycin-Rest sind als wirksame fXa-
Hemmstoffe aus der Literatur bekannt. Deshalb wurden analoge Verbindungen 
synthetisiert und erstmals als Matriptaseinhibitoren untersucht (Abschitt 3.3, Tabelle 
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3.5). Die hergestellten Verbindungen besitzen ein konstantes 3-Amidinobenzoyl-D-
Phenylglycin-Segment und unterscheiden sich im substituierten Piperazin-Rest, der 
wahrscheinlich die S3/4-Tasche der Matriptase besetzt. Die stärkste 
Matriptasehemmung mit einem Ki-Wert von 0.29 µM wurde wurde für das 4-Pyridinyl-
Piperazin Derivat 259 gefunden. Der Austausch des endständigen Pyridins durch 
hydrophobe Gruppen, wie Benzyl-, Phenyl- oder 4-Cyanophenyl führte zu einem mehr 
als 50-fachen Abfall der Hemmwirkung (Ki ≥ 18 µM). Diese Verbindungen erwiesen 
sich auch als sehr schwache Thrombininhibitoren, sind jedoch sehr wirksame fXa-
Hemmstoffe, wie aus der Literatur zu erwarten war. Beispielsweise hemmt die 
Verbindung 251 mit einem N-terminalen 4-Cyanophenyl-piperazin-Rest fXa mit einem 
Ki Wert von 1 nM. 
Der aus der Entwicklung von fXa-Hemmstoffen dieses Strukturtyps bekannte Einbau 
eines Chlorthiophencarbonsäure-Restes in P1-Position führte zu drastischem 
Affinitätsverlust auf Matriptase. 
Anthranilamid-Derivate 
Vor kurzem wurden uPA-Hemmstoffe beschrieben, die eine p-Aminoethyloxybenzoyl-
Gruppe als P1-Rest besitzen. Außerdem ist bekannt, dass uPA auch von dem 
Diuretikum Amilorid gehemmt wird und das dessen acyliertes Guanidin in die S1-
Tasche der Protease bindet. Aufgrund struktureller Ähnlichkeiten in der S1-Tasche 
zwischen Matriptase und uPA, beide enthalten einen Ser190-Rest, wurden einige 
Verbindungen mit einem ähnlichen p-Aminoethyloxybenzoyl-Rest synthetisiert. Die 
hergestellten Inhibitoren 266-268 zeigten jedoch nur eine sehr schwache 
Matriptasehemmung und auch vernachlässigbare Affinität bezüglich anderer 
trypsinartiger Serinproteasen. Daher wurden in dieser Serie keine weiteren Derivate 
hergestellt. 
Substratanaloge Inhibitoren 
Substratanaloge Inhibitoren mit einem 4-Amidinobenzylamid in P1-Position und einem 
N-terminalen Benzylsulfonylrest sind sehr wirksame Inhibitoren vieler trypsinartiger 
Serinproteasen, wenn sie mit einem D-Aminosäurerest in P3-Position kombiniert 
werden. Frühere Selektivitätsstudien mit substratanalogen fXa-Inhibitoren zeigten, dass 
einige Verbindungen mit D-Homophenylalanin-Derivaten in P3-Position auch 
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Matriptase mit Hemmkonstanten  70 nM inhibieren. Daher wurden vorhandene 
Substratanaloga aus unserem Arbeitskreis als potentielle Matriptaseinhibition getestet 
(Abschnitt 3.5, Tabelle 3.7). 
Die stärkste Affinität mit einem Ki-Wert von 13 nM wurde für die Verbindung Bzls-D-
hPhe-Pro-4-Amba (MI-0320) gefunden. Ähnliche Derivate mit einem D-Arginin in P3-
Position und Alanin (MI-0371) oder Arginin (MI-0360) als P2-Reste erwiesen sich mit 
Hemmkonstanten um 20 nM ebenfalls als relativ potente Matriptasehemmstoffe. 
Der Austausch des P2-Prolins durch Alanin hatte kaum Einfluß auf die fXa-Affinität, 
bewirkte aber eine deutliche Reduktion der Hemmwirkung auf Thrombin. So hemmt 
beispielsweise das P2-Alaninanalogon MI-0371 mit einem D-Arginin in P3-Position 
fXa mit einem Ki Wert von 1 nM. Andere P2-Reste eignen sich weniger für 
substratanaloge Matriptaseinhibitoren. 
Um die fXa-Affinität zu reduzieren, wurde eine Serie von Verbindungen ohne N-
terminalen Benzylsulfonyl-Rest synthetisiert (Abschnitt 3..5, Tabelle 3.8). Daraus 
resultierte der wirksame Matriptaseinhibitor 278 (H-D-hTyr-Ala-4-Amba, Ki 26 nM), 
der Thrombin und fXa Affinität deutlich schwächer mit Hemmkonstanten  300 nM 
hemmt. Diese Verbindung ist der erste substratanaloge Inhibitor, der Matriptase stärker 
als trypsinartige Serinproteasen hemmt. 
Da auch Thrombininhibitoren mit L-Aminosäuren als P3-Reste bekannt sind, wurden 
einige Analoga mit Cα-dialkylierten Aminosäuren an dieser Position hergestellt. 
Derartige Aminosäuren können als Chimere zwischen D- und L-Aminosäuren angesehen 
werden. Die Synthese und Kopplung dieser Derivate erwies sich jedoch als sehr 
problematisch. Da alle Verbindungen aus dieser Serie nur eine moderate 
Matriptasehemmung zeigten, sind solche Hemmstoffe mit dialkylierten P3-Aminosäure 
keine günstigen Startstrukturen für die Entwicklung substratanaloger 
Matriptaseinhibitoren. 
Zusammenfassung 
Neben dem Screening vorhandener Verbindungen wurden zahlreiche neue 
Proteasehemmstoffe synthetisiert und als Matriptaseinhibitoren untersucht. Die 
wirksamsten Verbindungen sind tertiäre Amide arylsulfonylierter 3-Amidinophenyl-
alanin-Derivate. Der Einbau geeigneter disubstituierter Biphenylsulfonyl-Reste in 
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Kombination mit substituierten C-terminalen Harnstoffen an der Piperididgruppe führte 
zu hochaffinen Matriptaseinhibitoren mit einem relativ günstigen Selektivitätsprofil 
gegenüber anderen trypsinartigen Serinproteasen. Diese Inhibitoren sind geeignete 
Kandidaten für weiterführende Experimente in Zellkultur oder zur Anwendung in 
Tiermodellen, um pathophysiologische Prozesse zu hemmen, die durch Matriptase 
vermittelt werden. 
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5 Experimental part 
5.1 Materials and methods 
5.1.1 Reagents and used materials 
Standard chemicals and solvents were obtained from the companies Acros, VWR, 
Fisher Scientific, Fluka, Sigma-Aldrich, Merck, or Roth. The used solvents had p.a or 
HPLC-grade quality. Dry solvents were stored over molecular sieves. The acetonitrile 
for analytical and preparative HPLC was purchased from VWR (HiPerSolv 
CHROMANORM) or Sigma-Aldrich (CHROMASOLV for HPLC). Ultra pure water 
was prepared using a NOWA pure select system (KSN Water Technology, Nistertal). 
Aqueous solutions of acids, bases or salts were prepared using demineralized water. 
Trifluoroacetic acid was a gift from Solvay. Amino acids and their derivatives were 
purchased from Bachem, Novabiochem, Orpegen Pharma or IRIS Biotech. 
5.1.2 Thin Layer Chromatography 
Reaction control and product purity were monitored by using thin layer chromatography 
(TLC) on precoated "Aluminium oxide 60 F254" plates from Merck. A mixture of n-
butanol/acetic acid/water (4:1:1, v/v/v) was used as a mobile phase. The compounds 
were visualized either by fluorescence detection (λex 254 nm), or by spraying with a 
ninhydrin solution and heating (300 mg ninhydrin dissolved in 100 mL n-butanol and 3 
mL glacial HOAc) followed by incubation in a chlorine gas atmosphere and spraying 
with an o-toluidine solution (150 mg o-toluidine and 2.1 g KI dissolved in 2 mL HOAc 
and 148 mL water and filtered) to reveal the spots. The calculated Rf -values describe 
the relationship between the migration distance of the sample to the solvent front from 
the initial spotting site. 
5.1.3 HPLC  
For all HPLC experiments the following solvents were used: 
 Solvent A: 0.1% TFA in ultrapure water 
 Solvent B: 0.1% TFA in ACN 
Detection at 220 nm.  
HPLC 1: 
Unless otherwise mentioned, all analytical reversed-phase HPLC chromatograms were 
performed using a Shimadzu LC-10A gradient HPLC system consisting of the 
subsystems CTO-10A column oven, LC-10ATvp pumps (2 x), DGU-14A degasser, 
SIL-10Axl autoinjector, SCL-10Avp system controller, SPD-M 10Avp photodiode 
array detector, Shimadzu Class-VP software and a reversed phase column (Nucleodur 
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100-5 C18 ec, 250 mm x 4.6 mm, Macherey-Nagel, Düren, Germany). The detection 
was performed at 220 nm. Solvents A and B served as eluents at a flow rate of 
1 mL/min and a linear gradient of 1 % increase in solvent B/min. Different starting 
conditions (1, 10, 20, 30 and 40% B) were used for analytical HPLC depending on the 
properties of the compounds, which are indicated for each derivative. The given purity 
for all intermediates is based on HPLC detection at 220 nm. 
HPLC 2: 
A few analytical HPLC-chromatograms for reaction monitoring and characterization of 
intermediates were performed using a Shimadzu LC-10A gradient HPLC system 
consisting of the subsystems CTO-10A column oven, LC-10AS pumps(2 x), SCL-
10Avp system controller, SPD-M10A UV-Vis-detector, and a column for fast gradient 
applications (Chromolith® Performance 2 µM C-18 endcapped column, 130 Å, 100 mm 
× 4.6 mm from Merck). The detection was performed at 220 nm. Solvent A and solvent 
B served as eluents at a flow rate of 4 mL/min starting with 1% B and using a linear 
gradient of 10% increase in solvent B/min. In order to distinguish the data in the 
described experiments, this system is named as HPLC 2. 
Preparative HPLC 
The final inhibitors were purified using a preparative HPLC system (pumps: Varian 
PrepStar Model 218 gradient system, detector: ProStar Model 320, fraction collector: 
Varian Model 701). The used columns (of the dimensions 250 mm × 32 mm) were: 
1. Nucleodur 100-5 C8ec, 100 Å, Macherey-Nagel, Düren 
2. Nucleosil, 300-5 C18, 300 Å, Macherey-Nagel, Düren 
3. Prontosil 120-5-C18-SH, 120 Å, Bischoff Chromatography 
All purifications were performed using a linear gradient of acetonitrile/water containing 
0.1 % TFA at a flow rate of 20 mL/min. 
5.1.4 Lyophilization  
All final inhibitors and some intermediates were obtained as TFA salts after preparative 
HPLC followed by lyophilization from water or 80% tert-butanol using a vacuo freeze-
drying system Alpha 2-4 LD plus (Christ, Osterode am Harz, Germany). 
5.1.5 Mass spectrometry 
The molecular mass of the synthesized compounds was determined by a QTrap 2000 
ESI mass spectrometry (Applied Biosystems, USA) or a VG Autospec (Micromass, 
USA). 
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5.2 Enzyme kinetic measurements 
General procedures 
The determination of the inhibition constants (Ki) of the synthesized inhibitors for 
various enzymes was performed using synthetic chromogenic p-nitroanilide substrates 
as described previously.[176] The optical density of the substrate cleavage was measured 
at 405 nm using a microplate IEMS Reader MF 1401 (Labsystems, Helsinki, Finland).  
The used substrates were synthesized in our laboratory. These substrates were dissolved 
in ultrapure water. Stock solutions of the synthesized inhibitors were prepared with a 
concentration of 10 mM in DMSO and Tris·HCl buffer pH 8.0 (containing 0.154 M 
NaCl, 2 % ethanol) to prepare the appropriate concentrations. The used concentrations 
of the inhibitors in the assay were at least 10-fold higher than the enzyme concentration. 
For the calculation of the molecular weight of the inhibitors, one TFA molecule was 
added for each free basic group. The measurements were performed at RT with the 
following volumina: 
- 200 μL 50 mM Tris·HCl buffer pH 8.0 (containing 0.154 M NaCl, 2 % ethanol and 
inhibitor in appropriate concentrations). 
- 25 μL aqueous substrate solution 
- start of reaction with 50 μL enzyme solution  
The measurements were stopped with the addition of 25 µL 50% HOAc after an 
appropriate reaction time, when the absorbance at the highest substrate concentration in 
the absence of an inhibitor had reached a value between 0.15 and 0.18.[176] The Ki 
values were calculated according to the method of Dixon[236] at two different substrate 
concentrations and five different inhibitor concentrations using an EXCEL template 
developed by Stürzebecher. The Ki values are the mean of at least two independent 
measurements. 
The following trypsine like serine proteases and respective substrates were used for the 
measurements (Table 5.1). 
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Table 5.1: Used enzymes and substrates. 
Enzyme 
stock concentration (assay concentration) 
Substrate 
stock concentration, (assay concentration) 
matriptasea (catalytic domain)[78]  
1.44  10-9 M (2.62  10-10 M) 
MeSO2-D-Cha-Gly-Arg-pNA; 
2 mM (182 μM in assay) 
1 mM (91 μM in assay) 
0.5 mM (45.5 μM in assay) 
human factor Xa (fXa)a 
200.35 IE/mg, Enzyme Research South Bend 
2.72  10-9 M ( 4.94  10-10 M) 
CH3OCO-D-Cha-Gly-Arg-pNA, 
2 mM (182 μM in assay) 
1 mM (91 μM in assay) 
0.5 mM (45.5 μM in assay) 
bovine thrombina[237] 
1425 IE/mg 
3.725  10-9 M (6.77  10-10 M) 
MeSO2-D-Cha-Gly-Arg-pNA; 
2 mM (182 μM in assay) 
1 mM (91 μM in assay) 
0.5 mM (45.5 μM in assay) 
human urokinase (uPA) b (HS medac) 
0.06 mg/mL, 240 IE/mL Enzyme 
Bz-ßAla-Gly-Arg-pNA as TFA salt  
2 mM (182 μM in assay) 
1 mM (91 μM in assay) 
0.5 mM (45.5 μM in assay) 
aMatriptase, fXa and thrombin stock solutions were prepared in 0.9% NaCl solution containing 0.1% 
HSA or BSA. buPA stock solution was prepared in 0.9% NaCl solution. 
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5.3 General synthetic procedures 
The following standard procedures A-S were performed as described previously in 
several textbooks[238, 239] for the synthesis of precursors, intermediates, and inhibitors. 
Method A 
Introduction of Boc protecting group[238, 240]5 
1 equiv of the amino component was dissolved in a mixture of dioxane and water (2:1, 
v/v, 5 mL/mmol) at 0 °C. This mixture was treated with 1.1 equiv 1 N NaOH and 1.1 
equiv di-tert-butyl dicarbonate. The pH was adjusted to 8.5-9.5 with 1 N NaOH. The 
mixture was stirred for 3 h at RT, whereby the reaction was controlled by HPLC or 
TLC. If necessary, an additional amount of (Boc)2O and 1 N NaOH were added and the 
mixture was further stirred at RT overnight. The solvent was removed in vacuo. The 
residue was dissolved in EtOAc, washed trice with 5% KHSO4-solution, and trice with 
brine. The EtOAc phase was dried over Na2SO4, filtered and removed in vacuo.  
Method B 
Cleavage of Boc-protecting group by 90% TFA[241]6 
1 equiv of Boc-protected compound was dissolved in 90% TFA (5 mL/mmol) and the 
mixture was stirred for 1 to 2 h at RT. The solvent was removed in vacuo. The product 
was purified by preparative RP-HPLC. Solvents were removed in vacuo and the product 
was lyophilized from water or 80% tert-butanol. 
Method C 
Cleavage of Boc-protecting group by 1 N HCl/acetic acid[241]7 
1 equiv of Boc-protected compound was dissolved in glacial HOAc (1 mL/mmol) and 
treated with 1 N HCl in glacial HOAc (5 mL/mmol). The mixture was shaken several 
times for 1-2 h at RT. The solvent was partially removed in vacuo and the product was 
precipitated by the addition of diethyl ether, filtered, washed with diethyl ether, and 
dried in vacuo. 
Method D 
Introduction of Cbz protectining group[238]8 
1 equiv of the amino derivative was dissolved in ACN (10 mL/mmol) and treated with 2 
equiv NMM. 1.1 equiv Cbz-OSu dissolved in ACN (5 mL/mmol) were added in two 
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portions and the mixture was stirred at 0 °C for 1h. The pH value was set to 8.5-9.5 by 
the addition of NMM and the mixture was stirred at RT for 3 h (HPLC control). If 
necessary, an additional amount of Cbz-OSu and NMM were added and the mixture 
was further stirred at RT overnight. The solvent was removed in vacuo. The residue was 
dissolved in EtOAc and washed trice with 5% KHSO4-solution and trice with brine. The 
EtOAc phase was dried over Na2SO4, filtered, and the solvent was removed in vacuo.  
Method E 
Cleavage of Cbz-protecting group by HBr/acetic acid[241]9 
1 equiv of Cbz-protected compound was dissolved in 32% HBr in glacial HOAc (10 
mL/mmol).The mixture was shaken several times within 1 h at RT. The solvent was 
partially removed in vacuo and the product was precipitated by diethyl ether, filtered, 
washed with diethyl ether, and dried in vacuo. Alternatively, the product was purified 
by preparative RP-HPLC, and lyophilized from water or 80% tert-butanol. 
Method F 
Hydrogenation[241]10 
The compound was dissolved in 90% HOAc and treated with approximately 10 mass 
percent of catalyst (10% Pd/C). The mixture was stirred at least overnight in a hydrogen 
atmosphere. If necessary, the hydrogenation was continued at RT for additional 24 h. 
The catalyst was removed by filtration and the solvent was evaporated. The product was 
purified by preparative HPLC and lyophilized from water or 80% tert-butanol. 
Method G 
Introduction of the Tfa-group[238]11 
1 equiv of the amino component was dissolved in 2 equiv TFA and treated with 2 equiv 
of trifluoroacetic anhydride. The mixture was stirred at 0 °C for 1 h and at RT for 2 h. 
The reaction progress was monitored by HPLC, and if necessary, an additional amount 
of trifluoroacetic anhydride was added and stirring was continued at RT overnight. The 
solvent was removed in vacuo. The remaining residue was dissolved in EtOAc and 
washed trice with 5% KHSO4-solution and trice with brine. The EtOAc phase was dried 
over Na2SO4, filtered and the solvent was removed in vacuo. 
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Method H 
Cleavage of the Tfa-protecting group and saponification of methyl or ethyl esters 
with 1 N NaOH[241]12 
The corresponding ester or a Tfa-protected amino derivative was dissolved in a mixture 
of dioxane and water (1:1, 10 mL/mmol) and the pH was adjusted to 12 using 1 N 
NaOH. The mixture was stirred for 3 h (HPLC control), and if necessary, stirring was 
continued overnight at RT until the end of the reaction. The solution was neutralized by 
the addition of 10% TFA and the solvent was removed in vacuo. The product was 
purified by preparative RP-HPLC and lyophilized from 80% tert-butanol. 
Method I  
PyBOP-coupling[242] 
1 equiv of the salt of an amino component and 1 equiv of the carboxyl derivative were 
dissolved in DMF (5 mL/mmol) and treated with 1.05 equiv PyBOP and 3 equiv 
DIPEA. The mixture was stirred at 0 °C for 30 minutes and at RT for 2 h. The solvent 
was removed in vacuo. The product was purified using preparative HPLC. 
Alternatively, the residue was dissolved in EtOAc and washed trice with 5% KHSO4-
solution, once with brine, trice with saturated NaHCO3-solution, and trice with brine. 
The EtOAc phase was dried over Na2SO4, filtered, and the solvent was removed in 
vacuo. 
Method J  
EDCI, HOBT-coupling[204, 243, 244] 
1 equiv of the amino component and 1 equiv of the carboxyl component were dissolved 
in DMF (5 mL/mmol) and treated with 1.25 equiv EDCI and 1.1 equiv HOBT. The 
mixture was stirred under argon atmosphere at RT for 3 h. The solvent was removed in 
vacuo. The product was purified using preparative HPLC. Alternatively, the residue was 
dissloved in EtOAc and washed trice with 5% KHSO4-solution, once with brine, trice 
with saturated NaHCO3-solution and trice with brine. The EtOAc phase was dried over 
Na2SO4, filtered, and the solvent was removed in vacuo. The product was lyophilized 
from water or 80% tert-butanol. 
Method K  
HATU-coupling[238]13 
1 equiv of the salt of an amino component and 1 equiv of the carboxyl component were 
dissolved in DCM (5 mL/mmol) and treated with 1.25 equiv HATU and 2 equiv 
DIPEA. The mixture was stirred at 0 °C for 1 h. The pH value was maintained at 8-9 by 
the addition of DIPEA and the mixture was continued to be stirred at RT for 2 h. The 
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solvent was removed in vacuo. The residue was dissolved in EtOAc and washed trice 
with 5% KHSO4-solution, once with brine, trice with saturated NaHCO3-solution and 
trice with brine. The EtOAc phase was dried over Na2SO4, filtered, and the solvent was 
removed in vacuo.  
Method L 
Mixed anhydride procedure[78, 239]14 
1 equiv of the carboxyl component was dissolved in DMF (5 mL/mmol) at -15 °C and 
treated with 1 equiv NMM and 1 equiv isobutyl chloroformate. The mixture was stirred 
at -15 °C for 10 min. The mixed anhydride was treated with 1 equiv of the salt of an 
amino component and 1 equiv NMM. The mixture was stirred at -15 °C for 1 h and at 
RT overnight. The solvent was removed in vacuo. The residue was dissolved in EtOAc 
and washed trice with 5% KHSO4-solution, once with brine, trice with saturated 
NaHCO3-solution and trice with brine. The EtOAc phase was dried over Na2SO4, 
filtered, and the solvent was removed in vacuo.  
Method M 
Introduction of sulfonyl groups[229] 
1 equiv of the amino acid was dissolved in dioxane and water or ACN and water (2:1, 
v/v, 15 mL/mmol). The pH was adjusted to 8-9 with ca. approximately 1 equiv DIPEA. 
1.1 equiv sulfonyl chloride was added in several portions at 0 °C and the pH was 
maintained at 8-9 by the addition of DIPEA. The mixture was stirred at 0 °C for 1 h and 
at RT overnight. The solvent was removed in vacuo, the residue was dissolved in water 
and the pH was set to ca. 10 with 1 N NaOH. The water phase was extracted once with 
EtOAc and the pH was set to ca. 2 with 6 N HCl. The water phase was extracted trice 
with EtOAc. The combined EtOAc phase was washed trice with 5% KHSO4-solution, 
trice with brine, dried over Na2SO4, filtered and the solvent was removed in vacuo. 
Method N 
Suzuki coupling procedure[171, 245] 
1 equiv of the intermediates 3-bromophenylsulfonyl-Phe(3-CN)-4-(piperidin-4-yl)-N-
methylbutanamide or 3-bromophenylsulfonyl-Phe(3-CN)-2-(piperidin-4-yl)Boc-ethyl-
amine, 1.5 equiv arylboronic acid and 2 mL/mmol 2M Cs2CO3 were suspended in 
toluene ( 3 mL/mmol). In an argon atmosphere, 1 mol% Pd-(II)-acetate and 2 mol% 2-
dicyclohexylphosphino-2´,6´-dimethoxybiphenyl (S-Phos, Aldrich) were added and the 
mixture was heated under reflux for 3 h. The mixture was centrifuged and the solvent 
was removed from the supernatant in vacuo. The remaining residue was dissolved in 
EtOAc and washed trice with brine. The EtOAc phase was dried over Na2SO4, filtered, 
and the solvent was removed in vacuo. 
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Method O  
Conversion of nitrile into hydroxyamidine[229] 
1 equiv of the benzonitrile derivative was dissolved in absolute ethanol (5 mL/mmol), 
treated with 3 equiv hydroxylamine × HCl, and 3 equiv DIPEA. The mixtrure was 
heated under reflux for 3-4 hours and stirred at RT overnight. The solvent was removed 
in vacuo and the remaining residue was used for method P without further purification. 
Method P  
Acetylation of the hydroxyamidine[188] 
1 equiv of the hydroxyamidine derivative was dissolved in glacial HOAc 
(10 mL/mmol), treated with 3 equiv acetic anhydride and stirred at RT for 1 h. The 
solvent was removed in vacuo (temperature of the water bath has to be < 35 °C to avoid 
1,2,4-oxadiazole formation). The oily intermediate was used for the next step (method F 
or Q) without further purification. 
Method Q 
Reduction of acetylhydroxyamidine- or nitro- derivatives by zinc in acetic acid 
1 equiv of the acetylhydroxyamidine or nitro derivative was dissolved in 90% HOAc 
(50 mL/mmol) and treated with zinc dust. The mixture was stirred at RT for 1-2 h 
(HPLC control). After filtration, the solvent was evaporated in vacuo, and the product 
was purified by preparative HPLC, followed by lyophilization from 80% tert-butanol. 
In the case of the reduction of nitro derivatives, the product was dissolved in EtOAc, 
washed trice with saturated NaHCO3-solution and trice with brine. The EtOAc phase 
was dried over Na2SO4, filtered, and the solvent was removed in vacuo. 
Method R 
Preparation of urea derivatives[190, 191] 
1 equiv of the free amino derivative was dissolved in DCM (15 mL/mmol), treated with 
1.5 equiv isocyanate and 2 equiv TEA. The mixture was stirred at RT overnight. The 
solvent was removed in vacuo, the residue was dissolved in EtOAc, washed trice with 
saturated NaHCO3-solution, and trice with brine. The EtOAc phase was dried over 
Na2SO4, filtered, and the solvent was removed in vacuo.  
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Method S 
Conversion of amino into guanidino group[214] 
1 equiv of the free amino intermediate was dissolved in DMF (10 mL/mmol), treated 
with 2 equiv 1-H-pyrazole-carboxamidine, and 2 equiv DIPEA. The mixture was stirred 
at RT for 24 h (HPLC control) and if necessary, an additional amount of 1-H-pyrazole-
carboxamidine and DIPEA were added, and stirring was continued until completion of 
the reaction. The solvent was removed in vacuo, the product was purified by preparative 
RP-HPLC and lyophilized from water or 80% tert-butanol. 
Experimental part 
 
89 
 
5.4 Synthesis of intermediates 
In this section, the synthesis of the intermediates is described. If needed, these syntheses 
were repeated with larger quantities. Due to the small scale of synthesis in many cases 
the obtained crude intermediates were directly used for the next step without 
purification to homogeneity. Their purity was characterized by HPLC detection at 
220 nm and their yield is only provided in mg without conversion into the amount of 
mmol. 
Compound names in bold were generated by Chemoffice Ultra 12.0 according to the 
IUPAC nomenclature. In the case of amino acid derivatives, additional shorter common 
names are provided in brackets. For simplification, the counter ions are omitted in the 
chemical structures.  
5.4.1 Synthesis of 3-amidinophenylalanine derivatives 
1) (S)-2-(3-bromophenylsulfonamido)-3-(3-cyanophenyl)propanoic acid 
[3-Br-phenylsulfonyl-Phe(3-CN)-OH][171, 245] 
H
N
CN
Br S
O
OH
OO
 
675 mg (3.55 mmol) H-Phe(3-CN)-OH were dissolved in a mixture of dioxane and 
water and treated with 1 g (3.914 mmol) 3-bromophenylsulfonyl chloride according to 
method M. 
Yield: 1.165 g (2.85 mmol, 80.2%), yellowish solid. 
HPLC: 49.5% B (purity: 100%); MS calcd: 407.98, found: 407.09 (M-H)-, 409.10 
(M+H)+. 
2) 4-(1-(tert-butoxycarbonyl)piperidin-4-yl)butanoic acid 
[4-(1-Boc-Pip)butanoic acid)][245] 
OH
N
Boc
O
 
4 g (19.3mmol) 4-piperidine butanoic acid × HCl were treated with di-tert-butyl 
dicarbonate according to method A.  
Yield: 4.8 g (17.7 mmol), colourless crystals. 
HPLC: 51.9% B (purity: 98%); TLC: Rf 0.78. 
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3) tert-butyl 4-(4-(methylamino)-4-oxobutyl)piperidine-1-carboxylate 
[N-methyl-4-(Boc-Pip)butanamide][245] 
N
H
N
Boc
O
 
1 g (3.69 mmol) intermediate 2 was dissolved in 10 mL EtOAc and treated with 2.5 g 
(36.9 mmol) methylamine × HCl, 2.1 g (5.54 mmol) HBTU and 2.89 mL (16.61 mmol) 
DIPEA. The mixture was stirred at 40 °C for 5 h. The solution was cooled to RT and 
washed trice with 5% KHSO4-solution, once with brine, trice with saturated NaHCO3- 
solution, trice with brine and dried over Na2SO4. The EtOAc phase was dried over 
Na2SO4, filtered, and the solvent was removed in vacuo.  
Yield: 884 mg, colourless oil. 
HPLC: 46.6% B (purity: 95%).  
4) N-methyl-4-(piperidin-4-yl)butanamide × HCl[245] 
N
H
HN O
 
884 mg of intermediate 3 were treated with 1 N HCl in HOAc according to method C.  
Yield: 600 mg (2.71 mmol, 87.4%), white solid. 
HPLC: 19.0% B (purity: 98%); MS calcd: 184.16, found: 185.10 (M+H)+. 
5) (S)-4-(1-(2-(3-bromophenylsulfonamido)-3-(3-
cyanophenyl)propanoyl)piperidin-4-yl)-N-methylbutanamide 
[3-Br-phenylsulfonyl-Phe(3-CN)-4-Pip-N-methylbutanamide][245] 
H
N
CN
Br S
O
N
OO
N
H
O
 
550 mg (1.34 mmol) intermediate 1 was coupled to 326 mg (1.474 mmol) intermediate 
4 according to method I.  
Yield: 500 mg, yellow oil. 
HPLC: 52.5% B (purity: 91%), HPLC 2: 46.1% B; MS calcd: 574.12, found: 575.09 
(M+H)+.
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6) (S)-4-(1-(3-(3-cyanophenyl)-2-(2'-fluorobiphenyl-3-ylsulfonamido)-
propanoyl)-piperidin-4-yl)-N-methylbutanamide 
[2F-biphenyl-3-sulfonyl-Phe(3-CN)-4-Pip-N-methylbutanamide]  
H
N
CN
S
O
N
OO
N
H
O
F
 
50 mg intermediate 5 were treated with 18.2 mg (0.13 mmol) 2-fluorophenylboronic 
acid according to method N.  
Yield: 30 mg (0.051 mmol), yellow oil. 
HPLC 2: 50.6% B (purity: 96.2 %), MS calcd: 590.24, found: 591.22 (M+H)+. 
Additional analogues 7-13 (Table 52) were prepared according to method N, using 
50 mg intermediate 5 and 0.13 mmol (1.5 equiv.) of various substituted phenylboronic 
acids. 
Table 5.2: Synthesis, yield, and analytical characterization of compounds 7-13 having the general 
formula. 
H
N
CN
S
O
N
OO
N
H
O
2
3
R1
4
R2
 
1 R1 R2 
Amount 
boronic acid 
mg 
Yielda 
mg/mmol 
HPLC 
% B, purity % 
MS 
calcd, found (M+H)+ 
7 3-F - 18.2 25/0.042 50.9b, 95.9 590.24, 591.22 
8 4-F - 18.2 40/0.068 51.3b, 96.3 590.24, 591.22 
9 2-Cl 4-Cl 24.9 35/0.055 56.5b, 60.1 640.17, 641.30 
10 2-Cl 3-Cl 24.9 40/0.062 62.9, 71.1 640.17, 641.31 
11 3-Cl 4-Cl 24.9 42/0.065 64.6, 72.4 640.17, n.d. 
12 2-Cl 4-EtO 26.1 30/0.046 64.5, 64.8 650.23, n.d. 
13 2-MeO 4-MeO 23.7 35/0.055 57.5, 90.3 632.27, n.d. 
ayellow to brownish oil, bHPLC 2. 
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14) (S)-4-(1-(2-(2'-fluorobiphenyl-3-ylsulfonamido)-3-(3-(N'-hydroxycarbam-
imidoyl)phenyl)propanoyl)piperidin-4-yl)-N-methylbutanamide 
[2F-biphenyl-3-sulfonyl-Phe(3-OxAm)-4-Pip-N-methylbutanamide] 
H
N
S
O
N
OO
N
H
O
F
NH2N
HO
 
30 mg of the intermediate 6 were converted into hydroxyamidine intermediate 
according to method O. The residue was directly used for the preparation of 
intermediate 22 without further purification. 
Yield: not determined, yellow oil. 
HPLC 2: 41.9% B (purity: 80.1 %). 
Additional analogues 15-21 (Table 5.3) were prepared from intermediates 7-13 using 
method O. 
Table 5.3: Synthesis, yield, and analytical characterization of compounds 15-21 having the general 
formula. 
H
N
S
O
N
OO
N
H
O
2
3
R1
4
R2
NH2N
HO
 
No. R1 R2 
Educt  HPLC 
% B, purity % Intermediate. No. mg 
15 3-F - 7 25 41.8a, 77.9 
16 4-F - 8 40 42.5a, 85.9 
17 2-Cl 4-Cl 9 35 48.2, 50.3 
18 2-Cl 3-Cl 10 40 48.1, 50.5 
19 3-Cl 4-Cl 11 42 48.9, 74.2 
20 2-Cl 4-EtO 12 30 50.7, 60.5 
21 2-MeO 4-MeO 13 35 43.9, 42.9 
aHPLC 2 
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22) (S)-4-(1-(3-(3-(N'-acetoxycarbamimidoyl)phenyl)-2-(2'-fluorobiphenyl-3-
ylsulfonamido)propanoyl)piperidin-4-yl)-N-methylbutanamide 
[2F-biphenyl-3-sulfonyl-Phe(3-AcOxAm)-4-Pip-N-methylbutanamide] 
H
N
S
O
N
OO
N
H
O
F
NH2N
O
O  
The intermediate 14 was acetylated according to method P. The solvent was removed in 
vacuo and the remaining oily crude was used for the synthesis of inhibitor MI-0403 
without further purification. 
Yield: not determined, yellow oil. 
HPLC 2: 46.9% B (purity: 78.5%). 
Additional derivatives 23-29 (Table 5.4) were prepared by an analogous procedure from 
intermediates 15-21. 
Table 5.4: Synthesis, yield, and analytical characterization of compounds 23-29 having the general 
formula. 
H
N
S
O
N
OO
N
H
O
2
3
R1
4
R2
NH2N
O
O  
No. R1 R2 Educt Intermediate No. 
HPLC 
% B, purity % 
23 3-F H 15 47.6a, 62.7 
24 4-F H 16 47.5a, 82.2 
25 2-Cl 4-Cl 17 53.5a, 37.2 
26 2-Cl 3-Cl 18 57.3, 36.1 
27 3-Cl 4-Cl 19 58.6, 70.2 
28 2-Cl 4-EtO 20 59.1, 50.1 
29 2-MeO 4-MeO 21 52.3, 41.7 
*HPLC 2 
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30) (S)-tert-butyl 2-(1-(2-(3-bromophenylsulfonamido)-3-(3-cyanophenyl)-
propanoyl)piperidin-4-yl)ethylcarbamate 
[3-Br-phenylsulfonyl-Phe(3-CN)-4-Pip-Boc-ethylamine][245] 
H
N
CN
O
Br S
OO
N
N
H
Boc
 
800 mg (1.95 mmol) intermediate 1 were coupled to 491 mg (2.15 mmol) tert-butyl 2-
(piperidin-4-yl)ethylcarbamate[78] according to method I. 
Yield: 820 mg (≈ 1.323 mmol), yellow oil. 
HPLC: 64.5% B (purity: 80.5%); MS calcd: 618.15, found: 619.19 (M+H)+. 
31) (S)-tert-butyl 2-(1-(3-(3-cyanophenyl)-2-(2'-fluorobiphenyl-3-ylsulfonamido)-
propanoyl)piperidin-4-yl)ethylcarbamate 
[2F-biphenyl-3-sulfonyl-Phe(3-CN)-4-Pip-Boc-ethylamine] 
H
N
CN
S
O
N
OO
N
H
Boc
F
 
50 mg intermediate 30 were coupled with 17 mg (0.121 mmol) 2-fluorophenylboronic 
acid according to method N. 
Yield: 35 mg (0.055 mmol), yellow oil. 
HPLC: 68.2% B (purity: 90.9%). 
Additional analogues 32-38 (Table 5.5) were prepared according to method N using 
50 mg intermediate 30 and 0.121 mmol (1.5 equiv) of various substituted phenylboronic 
acids. 
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Table 5.5: Synthesis, yield, and analytical characterization of compounds 32-38 having the general 
formula. 
H
N
CN
S
O
N
OO
N
H
2
3
R1
4
R2
Boc
 
No. R1 R2 
Amount 
boronic acid 
mg 
Yielda 
mg 
HPLC 
% B, purity % 
MS 
calcd, found (M+H)+ 
32 3-F - 17 38 68.5, 80.8 634.26, 635.30 
33 4-F - 17 35 68.2, 80.3 634.26, 635.30 
34 2-Cl 4-Cl 23.2 40 74.6, 72.1 684.19, 685.12 
35 2-Cl 3-Cl 23.2 36 74.3, 71.2 684.19, nd. 
36 3-Cl 4-Cl 23.2 30 75.9, 76.2 684.19, 685.20 
37 2-Cl 4-EtO 24.4 35 75.1, 97.4 694.26, nd. 
38 2-MeO 4-MeO 22.1 38 69.5, 75.6 676.29, 677.41 
ayellow to brownish oil 
39) (S)-tert-butyl 2-(1-(2-(2'-fluorobiphenyl-3-ylsulfonamido)-3-(3-(N'-hydroxy-
carbamimidoyl)phenyl)propanoyl)piperidin-4-yl)ethylcarbamate 
[2F-biphenyl-3-sulfonyl-Phe(3-OxAm)-4-Pip-Boc-ethylamine] 
H
N
S
O
N
OO
N
H
Boc
F
NH2N
HO
 
35 mg of the nitrile intermediate 31 were converted into hydroxyamidine according to 
method O. The remaining oily residue was used for the preparation of intermediate 47 
without further purification. 
Yield: not determined, yellow oil. 
HPLC: 51.2% B (purity: 75.2%). 
Additional analogues 40-46 (Table 5.6) were prepared from intermediate 32-38 in 
analogy to compound 39 using method O. 
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Table 5.6: Synthesis, yield, and analytical characterization of compounds 40-46 having the general 
formula. 
H
N
S
O
N
OO
N
H
2
3
R1
4
R2
Boc
NH2N
HO
 
No. R1 R2 Educt HPLC % B, purity % Intermediate. No. mg
40 3-F - 32 38 51.3, 80.8 
41 4-F - 33 35 51.2, 81.9 
42 2-Cl 4-Cl 34 40 58.2, 50.1 
43 2-Cl 3-Cl 35 36 58.1, 50.8 
44 3-Cl 4-Cl 36 30 58.5, 67.2 
45 2-Cl 4-EtO 37 35 57.3, 55.1 
46 2-MeO 4-MeO 38 38 52.2, 52.3 
 
47) (S)-tert-butyl 2-(1-(3-(3-(N'-acetoxycarbamimidoyl)phenyl)-2-(2'-fluorobi-
phenyl-3-ylsulfonamido)propanoyl)piperidin-4-yl)ethylcarbamate 
[2F-biphenyl-3-sulfonyl-Phe(3-AcOxAm)-4-Pip-Boc-ethylamine] 
H
N
S
O
N
OO
N
H
Boc
F
NH2N
O
O  
The intermediate 39 was acetylated with acetic anhydride according to method P. The 
remaining residue was used for the synthesis of intermediate 55 without further 
purification. 
Yield: not determined, yellow oil. 
HPLC: 60% B (purity: 52.4%). 
Additional analogues 48-54 (Table 5.7) were prepared by acetylation of intermediates 
40-46 according to the method P. 
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Table 5.7: Synthesis, yield, and analytical characterization of compounds 48-54 having the general 
formula. 
H
N
S
O
N
OO
N
H
2
3
R1
4
R2
Boc
NH2N
O
O  
No. R1 R2 Educt Intermediate No. 
HPLC 
% B, purity % 
48 3-F H 40 59.9, 54.9 
49 4-F H 41 60.1, 70.3 
50 2-Cl 4-Cl 42 68.9, 69.1 
51 2-Cl 3-Cl 43 68.3, 48.9 
52 3-Cl 4-Cl 44 69.8, 60.1 
53 2-Cl 4-EtO 45 63.7, 30.4 
54 2-MeO 4-MeO 46 63.4, 60.1 
 
55) (S)-tert-butyl 2-(1-(3-(3-carbamimidoylphenyl)-2-(2'-fluorobiphenyl-3-
ylsulfonamido)propanoyl)piperidin-4-yl)ethylcarbamate 
[2F-biphenyl-3-sulfonyl-Phe(3-Am)-4-Pip-Boc-ethylamine] 
H
N
S
O
N
OO
N
H
Boc
F
NH2HN  
The intermediate 47 was reduced by zinc dust in 90% HOAc according to method Q. 
The remaining oily residue was used without further purification for the synthesis of 
inhibitor MI-0433. 
Yield: not determined, colourless oil. 
HPLC: 51.4% B (purity: 76.7%). 
Additional analogues 56-61 (Table 5.8) were prepared by reduction of the intermediates 
48-53 according to method Q. 
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Table 4.5: Synthesis, yield and analytical characterization of compounds 56-61 having the general 
formula. 
H
N
S
O
N
OO
N
H
2
3
R1
4
R2
Boc
NH2HN  
No. R1 R2 Educt Intermediate No. 
HPLC 
% B, purity % 
56 3-F H 48 51.3, 69.5 
57 4-F H 49 51.2, 67.2 
58 2-Cl 4-Cl 50 58.2, 78.2 
59 2-Cl 3-Cl 51 58.1, 66.8 
60 3-Cl 4-Cl 52 58.5, 67.5 
61 2-Cl 4-EtO 53 57.3, 49.9 
 
62) (S)-tert-butyl 2-(1-(3-(3-carbamimidoylphenyl)-2-(2',4'-dimethoxybiphenyl-3-
ylsulfonamido)propanoyl)piperidin-4-yl)ethylcarbamate 
[2,4-dimethoxybiphenyl-3-sulfonyl-Phe(3-Am)-4-Pip-Boc-ethylamine]  
H
N
S
O
N
OO
N
H
Boc
O
NH2HN
O
 
The intermediate 54 was hydrogenated for 48 h according to method F. The catalyst was 
removed by filtration, the solvent was evaporated and the remaining oily residue was 
used for the preparation of inhibitor MI-0439 without further purification. 
Yield: not determined, colourless oil. 
HPLC: 52.2% B (purity: 63.2%). 
63) (S)-tert-butyl 1-(2-(3-bromophenylsulfonamido)-3-(3-cyanophenyl)-propano-
yl)piperidin-4-ylcarbamate 
[3-bromophenylsulfonyl-Phe(3-CN)-4-Pip-NH-Boc][78]  
H
N
CN
O
Br S
OO
N
N
H
Boc
 
200 mg (0.489 mmol) intermediate 1 were coupled to 127.3 mg (0.538 mmol) tert-butyl 
piperidin-4-ylcarbamate (Aldrich) according to method I. 
Yield: 225 mg (≈ 0.38 mmol), yellowish solid. 
HPLC: 62.6% B (purity: 92.3%); MS calcd: 590.1, found: 591.1 (M+H)+. 
Experimental part 
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64) (S)-tert-butyl 1-(3-(3-cyanophenyl)-2-(2',4'-dimethoxybiphenyl-3-ylsulfon-
amido)propanoyl)piperidin-4-ylcarbamate 
[2,4-dimethoxybiphenyl-3-sulfonyl-Phe(3-CN)-4-Pip-NH-Boc] 
H
N
CN
O
S
OO
N
N
H
Boc
O O
 
50 mg intermediate 63 were coupled with 23.1 mg (0.127 mmol) 2,4-di-
methoxyphenylboronic acid according to method N. 
Yield: 50 mg, yellow oil. 
HPLC: 67.4% B (purity: 66.3%). 
65) (S)-N-(1-(4-aminopiperidin-1-yl)-3-(3-cyanophenyl)-1-oxopropan-2-yl)-2',4'-
dimethoxybiphenyl-3-sulfonamide 
[2,4-dimethoxybiphenyl-3-sulfonyl-Phe(3-CN)-4-Pip-NH2] 
H
N
CN
O
S
OO
N
NH2O O
 
50 mg intermediate 64 were deprotected according to method B. The product was 
dissolved in EtOAc, washed twice with saturated NaHCO3-solution and twice with 
brine. The EtOAc phase was dried over Na2SO4, filtered and the solvent was removed 
in vacuo.  
Yield: 38 mg, oil. 
HPLC: 44.5% B (purity: 72.3%). 
66) (S)-tert-butyl 1-(3-(3-cyanophenyl)-2-(2',4'-dichlorobiphenyl-3-
ylsulfonamido)propanoyl)piperidin-4-ylcarbamate 
[2,4-dichlorobiphenyl-3-sulfonyl-Phe(3-CN)-4-Pip-NH-Boc] 
H
N
CN
O
S
OO
N
N
H
Boc
Cl Cl
 
50 mg (0.085 mmol) intermediate 63 were coupled with 24.2 mg (0.127 mmol) 2,4-di-
chlorophenylboronic acid according to method N. 
Yield: 46 mg, yellowish oil. 
HPLC: 74.5% B (purity: 68.8%). 
Experimental part 
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67) (S)-N-(1-(4-aminopiperidin-1-yl)-3-(3-cyanophenyl)-1-oxopropan-2-yl)-2',4'-
dichlorobiphenyl-3-sulfonamide 
[2,4-Dichlorobiphenyl-3-sulfonyl-Phe(3-CN)-4-Pip-NH2] 
H
N
CN
O
S
OO
N
NH2Cl Cl
 
46 mg intermediate 66 were deprotected according to method B. The product was 
dissolved in EtOAc and washed twice with saturated NaHCO3-solution and twice with 
brine. The EtOAc phase was dried over Na2SO4, filtered, and the solvent was removed 
in vacuo.  
Yield: 38 mg, yellow oil. 
HPLC: 49.9% B (purity: 90.2%). 
68) (S)-N-(1-(4-(2-aminoethyl)piperidin-1-yl)-3-(3-cyanophenyl)-1-oxopropan-2-
yl)-2',4'-dimethoxybiphenyl-3-sulfonamide 
[2,4-dimethoxybiphenyl-3-sulfonyl-Phe(3-CN)-4-Pip-ethylamine]  
H
N
CN
S
O
N
OO
NH2OO
 
50 mg intermediate 38 were deprotected according to method B. The product was 
dissolved in EtOAc, washed twice with saturated NaHCO3-solution, twice with brine 
and dried over Na2SO4. The EtOAc phase was filtered and the solvent was removed in 
vacuo. 
Yield: 42 mg, yellowish oil. 
HPLC: 46.1% B (purity: 78.5%). 
69) (S)-N-(1-(4-(2-aminoethyl)piperidin-1-yl)-3-(3-cyanophenyl)-1-oxopropan-2-
yl)-2',4'-dichlorobiphenyl-3-sulfonamide 
[2,4-dichlorobiphenyl-3-sulfonyl-Phe(3-CN)-4-Pip-ethylamine] 
H
N
CN
S
O
N
OO
NH2ClCl
 
50 mg intermediate 34 were deprotected according to method B. The product was 
dissolved in EtOAc, washed twice with saturated NaHCO3-solution, twice with brine 
Experimental part 
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and dried over Na2SO4. The EtOAc phase was filtered and the solvent was removed in 
vacuo.  
Yield: 40 mg, brownish oil. 
HPLC: 50.9% B (purity: 79.5%). 
70) (S)-3-(3-cyanophenyl)-2-(3-nitrophenylsulfonamido)propanoic acid 
[3-NO2-phenylsulfonyl-Phe(3-CN)-OH][78]  
H
N
CN
O2N S
O
OH
OO
 
1.034 g (5.436 mmol) H-Phe(3-CN)-OH were dissolved in a mixture of ACN and water 
and treated with 1.325 g (5.980 mmol) 3-nitrophenylsulfonyl chloride according to 
method M, whereby 1 N NaOH (≈ 6mL) was used instead of DIPEA to set the pH to 8-
9. 
Yield: 1.246 g (3.319 mmol; 61.1%), yellowish solid. 
HPLC: 45.9% B; MS calcd: 375.05, found: 374.09 (M-H)-, 376.10 (M+H)+. 
71) (S)-tert-butyl 2-(1-(3-(3-cyanophenyl)-2-(3-nitrophenylsulfonamido)-
propanoyl)piperidin-4-yl)ethylcarbamate 
[3-NO2-phenylsulfonyl-Phe(3-CN)-4-Pip-Boc-ethylamine][78]  
H
N
CN
O
O2N S OO
N
N
H
Boc
 
1 g (2.664 mmol) intermediate 70 was coupled with 0.67 g (2.93 mmol) tert-butyl 2-
(piperidin-4-yl)ethylcarbamate according to method I. 
Yield: 1.225 g (2.09 mmol; 78.5%), orange solid. 
HPLC: 61.4% B (purity: 96.5%); MS calcd: 585.23, found: 586.21 (M+H)+.  
Experimental part 
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72) (S)-tert-butyl 2-(1-(2-(3-aminophenylsulfonamido)-3-(3-cyanophenyl)-
propanoyl)piperidin-4-yl)ethylcarbamate 
[3-NH2-phenylsulfonyl-Phe(3-CN)-4-Pip-Boc-ethylamine][78]  
H
N
CN
O
H2N S OO
N
N
H
Boc
 
1.225 g (2.09 mmol) intermediate 71 were reduced using zinc dust in 90% acetic cid 
according to method Q. 
Yield: 1.05 g (1.889 mmol; 90.4%), orange solid. 
HPLC: 51.9% B (purity: 95.5%); MS calcd: 555.25, found: 556.21 (M+H)+. 
73) Benzyl 3-amino-3-oxopropylcarbamate-(S)-tert-butyl 2-(1-(2-(3-aminophenyl-
sulfonamido)-3-(3-cyanophenyl)propanoyl)piperidin-4-yl)ethylcarbamate 
[Cbz-βAla-3-NH-phenylsulfonyl-Phe(3-CN)-4-Pip-Boc-ethylamine][78]  
H
N
CN
O
N
H
S
OO
N
N
H
Boc
O
N
H
Cbz
 
300 mg (0.539 mmol) intermediate 72 were coupled with 109.5 mg (0.491 mmol) Cbz-
βAla-OH according to method L. 
Yield: 300 mg, yellow oil. 
HPLC: 63.7% B (purity: 95.33%). 
74) (S)-benzyl 3-(3-(N-(1-(4-(2-aminoethyl)piperidin-1-yl)-3-(3-cyanophenyl)-1-
oxopropan-2-yl)sulfamoyl)phenylamino)-3-oxopropylcarbamate × TFA 
[Cbz-βAla-3-NH-phenylsulfonyl-l-Phe(3-CN)-4-Pip-ethylamine × TFA] 
H
N
CN
O
N
H
S
OO
N
NH2
O
N
H
Cbz
 
300 mg of intermediate 73 were deprotected with TFA according to method B.  
Yield: 250 mg, yellow solid. 
HPLC: 43.2% B (purity: 95.8%); MS calcd: 660.25, found: 661.28 (M+H)+. 
Experimental part 
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75) (S)-tert-butyl 1-(3-(3-cyanophenyl)-2-(3-nitrophenylsulfonamido)propanoyl)-
piperidin-4-ylcarbamate 
[3-NO2-phenylsulfonyl-Phe(3-CN)-4-Pip-NH-Boc]  
H
N
CN
O
O2N S OO
N
N
H
Boc
 
600 mg (1.59 mmol) intermediate 70 were coupled with 416.1 mg (1.76 mmol) tert-
butyl piperidin-4-ylcarbamate × HCl according to method I.  
Yield: 800 mg, orange solid. 
HPLC: 59.2% B (purity: 93.9%). 
76) (S)-tert-butyl 1-(2-(3-aminophenylsulfonamido)-3-(3-cyanophenyl)-
propanoyl)piperidin-4-ylcarbamate 
[3-NH2-phenylsulfonyl-Phe(3-CN)-4-Pip-NH-Boc] 
H
N
CN
O
H2N S OO
N
N
H
Boc
 
800 mg (≈ 1.434 mmol) intermediate 75 was reduced with zinc dust in 90% HOAc 
according to method Q. 
Yield: 660 mg, orange oil. 
HPLC: 49.02% B (purity: 83.8%), MS calcd: 527.22, found: 528.21 (M+H)+. 
77) Benzyl 3-amino-3-oxopropylcarbamate-(S)-tert-butyl 1-(2-(3-aminophenyl-
sulfonamido)-3-(3-cyanophenyl)propanoyl)piperidin-4-ylcarbamate 
[Cbz-βAla-3-NH-phenylsulfonyl-Phe(3-CN)-4-Pip-NH-Boc]  
H
N
CN
O
S
OO
N
N
H
Boc
N
H
N
H
O
Cbz
 
660 mg intermediate 76 were coupled with 254 mg (1.14 mmol) Cbz-βAla-OH 
according to method L.  
Yield: 700 mg, yellow oil. 
HPLC: 61.2% B (purity: 85.7%). 
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78) (S)-benzyl 3-(3-(N-(1-(4-aminopiperidin-1-yl)-3-(3-cyanophenyl)-1-oxo-
propan-2-yl)sulfamoyl)phenylamino)-3-oxopropylcarbamate × TFA 
[Cbz-βAla-3-NH-phenylsulfonyl-Phe(3-CN)-4-Pip-NH2 × TFA]  
H
N
CN
O
S
OO
N
NH2
N
H
N
H
O
Cbz
 
700 mg intermediate 77 were deprotected with TFA according to method B.  
Yield: 600 mg (≈ 0.803 mmol), yellow solid. 
HPLC: 42.4% B (purity: 96.9%); MS calcd: 632.24, found: 633.31 (M+H)+. 
79) (S)-benzyl 3-(3-(N-(3-(3-cyanophenyl)-1-oxo-1-(4-(2-ureidoethyl)piperidin-1-
yl)propan-2-yl)sulfamoyl)phenylamino)-3-oxopropylcarbamate 
[Cbz-βAla-3-NH-phenylsulfonyl-Phe(3-CN)-2-(piperidin-4-yl)Et-urea] [191]  
H
N
N
O
SN
H
O
N
H
Cbz
O O
CN
N
H
O
NH2
 
50 mg (0.065 mmol) intermediate 74 were dissolved in 3 mL DCM, treated with 10 mg 
(0.097 mmol) N-methyl-N-nitrosourea and 18 μl (0.13 mmol) TEA. The mixture was 
stirred at RT overnight and the solvent was removed in vacuo. The remaining residue 
was dissolved in EtOAc, washed trice with saturated NaHCO3-solution and trice with 
brine. The EtOAc phase was dried over Na2SO4, and the solvent was removed in vacuo. 
Yield: 40 mg, oil. 
HPLC: 50.8% B (purity: 71.3%). 
80) (S)-benzyl 3-(3-(N-(3-(3-cyanophenyl)-1-oxo-1-(4-ureidopiperidin-1-yl)-
propan-2-yl)sulfamoyl)phenylamino)-3-oxopropylcarbamate 
[Cbz-βAla-3-NH-phenylsulfonyl-Phe(3-CN)-4-Pip-urea][191] 
H
N
N
O
SN
H
O
N
H
Cbz
O O
CN
N
H
O
NH2
 
The compound 80 was prepared in analogy to the derivative 79 from treating 50 mg 
(0.067 mmol) intermediate 78 with 10.4 mg (0.100 mmol) N-methyl-N-nitrosourea and 
18.7 μl (0.134 mmol) TEA in DCM.  
Yield: 30 mg, oil. 
HPLC: 48.2% B (purity: 80.7%). 
Experimental part 
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81) (S)-benzyl 3-(3-(N-(3-(3-cyanophenyl)-1-(4-(2-(3-methylureido)ethyl)-
piperidin-1-yl)-1-oxopropan-2-yl)sulfamoyl)phenylamino)-3-
oxopropylcarbamate 
[Cbz-βAla-3-NH-phenylsulfonyl-Phe(3-CN)-4-Pip-Et-methylurea][192] 
H
N
N
O
SN
H
O
N
H
Cbz
O O
CN
N
H
O
N
H
 
50 mg intermediate 74 were dissolved in 3 mL DCM, treated with 16.7 mg (0.097 
mmol) N-succinimidyl-N-methylcarbamate[190, 191] and 18 μl (0.13 mmol) TEA. The 
mixture was stirred at RT overnight and the solvent was removed in vacuo. The 
remaining residue was dissolved in EtOAc, washed trice with saturated NaHCO3-
solution and trice with brine. The EtOAc was dried over Na2SO4, filtered and the 
solvent was removed in vacuo. 
Yield: 33 mg, oil. 
HPLC: 51.2% B (purity: 89.9%). 
82) (S)-benzyl 3-(3-(N-(3-(3-cyanophenyl)-1-(4-(3-methylureido)piperidin-1-yl)-1-
oxopropan-2-yl)sulfamoyl)phenylamino)-3-oxopropylcarbamate 
[Cbz-βAla-3-NH-phenylsulfonyl-Phe(3-CN)-4-Pip-methylurea][192]  
H
N
N
O
SN
H
O
N
H
Cbz
O O
CN
N
H
O
N
H
 
The compound 82 was prepared in analogy to the derivative 81 from treating 50 mg 
intermediate 78 with 17.3mg (0.101 mmol) N-succinimidyl-N-methylcarbamate and 
18.7 μl (0.134 mmol) TEA in DCM. 
Yield: 29 mg, yellowish solid. 
HPLC: 50.3% B (purity: 83.9%). 
Additional analogues 83-90 (Table 5.9) were analogous prepared as described for 
compound 81 and 82 according to method R using 50 mg intermediate 74 or 50 mg 
intermediate 78 and various isocyanate derivatives. 
Experimental part 
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Table 5.9: Synthesis, yield, and analytical characterization of compounds 83-90 having the general 
formula. 
H
N
N
O
SN
H
O
N
H
Cbz
O O
CN
H
N
H
N
O
R
n
 
 
91) (S)-N-(3-(3-cyanophenyl)-1-(4-(2-(3-methylureido)ethyl)piperidin-1-yl)-1-
oxopropan-2-yl)-2',4'-dimethoxybiphenyl-3-sulfonamide 
[2,4-dimethoxbiphenyl-3-sulfonyl-Phe(3-CN)-4-Pip-Et-methylurea][192]  
H
N
CN
S
O
N
OO
N
H
OO N
H
O
 
40 mg (≈ 0.069 mmol) intermediate 68 were treated with 18 mg (0.104 mmol) N-
succinimidyl-N-methylcarbamate according to the procedure used for the synthesis of 
compound 81. 
Yield: 41 mg, yellowish solid. 
HPLC: 54.4% B (purity: 93.4%). 
No. n R used isocyanates mg/mmol 
Yield 
mg 
HPLC 
% B, purity % 
83 2 Et ethylisocyanate 6.9/0.097 25 53.3, 90.3 
84 0 Et ethylisocyanate 7.2/0.101 30 52.4, 79.8 
85 2 
 
phenyl-isocyanate 
11.6/0.097 40 60.3, 91.6 
86 0 
 
phenyl-isocyanate 
12/0.101 35 58.8, 85.5 
87 2 
 
cyclohexyl-isocyanate 
12.1/0.097 43 62.5, 95.5 
88 0 
 
cyclohexyl-isocyanate 
12.6/0.101 38 60.4, 79.9 
89 2 
 
benzyl-isocyanate 
13/0.097 35 60.2, 86.6 
90 0 
 
benzyl-isocyanate 
13.4/0.101 33 58.8, 80.9 
Experimental part 
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92) (S)-2',4'-dichloro-N-(3-(3-cyanophenyl)-1-(4-(2-(3-methylureido)ethyl)-
piperidin-1-yl)-1-oxopropan-2-yl)biphenyl-3-sulfonamide 
[2,4-dichlorobiphenyl-3-sulfonyl-Phe(3-CN)-4-Pip-Et-methylurea][192] 
H
N
CN
S
O
N
OO
N
H
ClCl N
H
O
 
40 mg (≈ 0.068 mmol) intermediate 69 were treated with 18 mg (0.102 mmol) N-
succinimidyl-N-methylcarbamate as described for the synthesis of intermediate 81. 
Yield: 40 mg, yellowish solid. 
HPLC: 60.7% B (purity: 87.7%). 
93) (S)-N-(3-(3-cyanophenyl)-1-(4-(3-cyclohexylureido)piperidin-1-yl)-1-oxo-
propan-2-yl)-2',4'-dimethoxybiphenyl-3-sulfonamide 
[3-(2,4-dimethoxybiphenyl-3-sulfonyl-Phe(3-CN)-4-Pip-Chxu] 
H
N
CN
O
S
OO
N
N
H
O O N
H
O
 
38 mg (≈ 0.069 mmol) intermediate 65 were treated with 13 μl (0.104 mmol) 
cyclohexyl isocyanate according to method R.  
Yield: 40 mg, yellow oil. 
HPLC: 63.9.5% B (purity: 59.9%). 
94) (S)-2',4'-dichloro-N-(3-(3-cyanophenyl)-1-(4-(3-cyclohexylureido)piperidin-1-
yl)-1-oxopropan-2-yl)biphenyl-3-sulfonamide 
[3-(2,4-dichlorobiphenyl-3-sulfonyl-Phe(3-CN)-4-Pip-Chxu] 
H
N
CN
O
S
OO
N
N
H
Cl Cl N
H
O
 
34 mg (≈ 0.061 mmol) intermediate 67 were treated with 12 μl (0.092 mmol) 
cyclohexylisocyanate according to method R. 
Yield: 36 mg, yellow oil. 
HPLC: 70.5% B (purity: 76.3%). 
Experimental part 
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95) (S)-benzyl 3-(3-(N-(3-(3-(N'-hydroxycarbamimidoyl)phenyl)-1-oxo-1-(4-(2-
ureidoethyl)piperidin-1-yl)propan-2-yl)sulfamoyl)phenylamino)-3-oxopropyl-
carbamate 
[Cbz-βAla-3-NH-phenylsulfonyl-Phe(3-OxAm)-4-Pip-Et-urea] 
H
N
N
O
SN
H
O
N
H
Cbz
O O
N
H
O
NH2
NH2N
HO
 
40 mg of the nitrile intermediate 79 were converted into hydroxyamidine using method 
O. The solvent was removed in vacuo and the remaining residue was used for the 
synthesis of intermediate 111 without further purification.  
Yield: not determined, yellow oil. 
HPLC: 38.7% B (purity: 85.7%). 
Additional analogues 96-110 (Table 5.10) were prepared by treating the intermediates 
80-94 according to method O. 
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Table 5.10: Synthesis, yield and analytical characterization of compounds 96-110 having the general 
formula. 
H
N
N
O
SR H
N
H
N
O
R1
O O
NH2N
HO
n
 
No. n R R1 
Amount Educt HPLC 
% B, purity % Intermediate No. mg 
96 0 Cbz-βAla-NH H 80 30 37.4, 89.6 
97 2 Cbz-βAla-NH Me 81 33 41.1, 80.2 
98 0 Cbz-βAla-NH Me 82 29 38.3, 91.7 
99 2 Cbz-βAla-NH Et 83 25 41.6, 89 
100 0 Cbz-βAla-NH Et 84 30 40.2, 89.9 
101 2 Cbz-βAla-NH 85 40 47.7, 90.7 
102 0 Cbz-βAla-NH 86 35 46.5, 70.4 
103 2 Cbz-βAla-NH 87 43 48.9, 85.3 
104 0 Cbz-βAla-NH 88 38 47.2, 80.7 
105 2 Cbz-βAla-NH 89 35 47.3, 69.7 
106 0 Cbz-βAla-NH 90 33 46.5, 71.4 
107 2 
OO
 
Me 91 41 41.8, 90.1 
108 2 
ClCl  
Me 92 40 46.6, 91.5 
109 0 
OO
 
 
93 40 48.7, 85.6 
110 0 
ClCl   
94 36 53.6, 89.2 
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111) (S)-benzyl 3-(3-(N-(3-(3-(N'-acetoxycarbamimidoyl)phenyl)-1-oxo-1-(4-(2-
ureidoethyl)piperidin-1-yl)propan-2-yl)sulfamoyl)phenylamino)-3-
oxopropylcarbamate 
[Cbz-βAla-3-NH-phenylsulfonyl-Phe(3-AcOxAm)-4-Pip-Et-urea] 
H
N
N
O
SN
H
O
N
H
Cbz
O O
N
H
O
NH2
NH2N
O
O  
The intermediate 95 was acetylated according to method P. The remaining residue was 
used for the synthesis of compound 227 without further purification. 
Yield: not determined, dark yellow oil with salts. 
HPLC: 45.9% B (purity: 69%). 
Additional analogues 112-126 (Table 5.11) were prepared by treating the intermediates 
96-110 according to method P. 
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Table 5.11: Synthesis, yield and analytical characterization of compounds 112-126 having the general 
formula.  
H
N
N
O
SR H
N
H
N
O
R1
O O
NH2N
O
n
O  
No. n R R1 
Educt 
Intermediate No. 
HPLC 
% B, purity % 
112 0 Cbz-βAla-NH H 96 44.9, 53.1 
113 2 Cbz-βAla-NH Me 97 49.3, 67.6 
114 0 Cbz-βAla-NH Me 98 47.2, 52.9 
115 2 Cbz-βAla-NH Et 99 50.1, 70.9 
116 0 Cbz-βAla-NH Et 100 49.1, 74.4 
117  2 Cbz-βAla-NH 101 57.8, 77.1 
118 0 Cbz-βAla-NH 102 56.6, 55.6 
119  2 Cbz-βAla-NH 103 57.6, 69.5 
120 0 Cbz-βAla-NH 104 57.0, 53.5 
121 2 Cbz-βAla-NH 105 56.3, 67.7 
122 0 Cbz-βAla-NH 106 55.3, 45.6 
123 2 
OO
 
Me 107 48.9, 59.5 
124 2 
ClCl  
Me 108 55.6, 55.2 
125 0 
OO
 
 
109 60.4, 56.6 
126 0 
ClCl   
110 66.4, 39.3 
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127) (S)-benzyl 3-(3-(N-(1-(4-(2-(3-benzylureido)ethyl)piperidin-1-yl)-3-(3-
carbamimidoylphenyl)-1-oxopropan-2-yl)sulfamoyl)phenylamino)-3-
oxopropylcarbamate 
[Cbz-βAla-3-NH-phenylsulfonyl-Phe(3-Am)-4-Pip-Et-Bzlu] 
H
N
O
N
H
S
O O
N
N
H
N
H
ON
H
O
NH2HN
Cbz
 
The intermediate 121 was reduced by zinc dust in 90% HOAc according to method Q. 
Compound 127 was used for the synthesis of inhibitor MI_0446 without further 
purification. 
Yield: not determined, light brown oil. 
HPLC: 47.3% B (purity: 75%). 
128) (S)-benzyl 3-(3-(N-(1-(4-(3-benzylureido)piperidin-1-yl)-3-(3-carbamimidoyl-
phenyl)-1-oxopropan-2-yl)sulfamoyl)phenylamino)-3-oxopropylcarbamate 
[Cbz-βAla-3-NH-phenylsulfonyl-Phe(3-Am)-4-Pip-Bzlu] 
H
N
O
N
H
S
O O
N
N
H
N
H
ON
H
O
NH2HN
Cbz
 
The intermediate 122 was reduced by zinc dust in 90% HOAc according to method Q. 
Compound 128 was used for the synthesis of inhibitor MI_0446 without further 
purification. 
Yield: not determined, light brown oil. 
HPLC: 46.1% B (purity: 82%). 
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129) (S)-benzyl 3-(3-(N-(1-(4-aminopiperidin-1-yl)-3-(3-(N'-hydroxycarbam-
imidoyl)phenyl)-1-oxopropan-2-yl)sulfamoyl)phenylamino)-3-oxopropyl-
carbamate 
[Cbz-βAla-3-NH-phenylsulfonyl-Phe(3-OxAm)-4-Pip-NH2] 
H
N
O
S
OO
N
NH2
N
H
N
H
O
Cbz
NH2N
HO
 
50 mg (0.067 mmol) intermediate 78 were converted into hydroxyamidine using 
method O. The solvent was removed in vacuo and the remaining residue was used for 
the synthesis of intermediate 130 without further purification.  
Yield: not determined, yellowish oil. 
HPLC: 32.7% B (purity: 95.7%). 
130) (S)-benzyl 3-(3-(N-(3-(3-(N'-acetoxycarbamimidoyl)phenyl)-1-(4-amino-
piperidin-1-yl)-1-oxopropan-2-yl)sulfamoyl)phenylamino)-3-oxopropyl-
carbamate 
[Cbz-βAla-3-NH-phenylsulfonyl-Phe(3-OxAm)-4-Pip-NH2] 
H
N
O
S
OO
N
NH2
N
H
N
H
O
Cbz
NH2N
O
O  
The intermediate 129 was acetylated according to method P. The remaining residue was 
used for the synthesis of inhibitor MI-0458 without further purification. 
Yield: not determined, yellow oil. 
HPLC: 39.845.9% B (purity: 70.2%). 
Experimental part 
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5.4.2 Synthesis of arginine derivatives 
131) (S)-2-(3-nitrophenylsulfonamido)-5-(3-(3,3,4,6,7-pentamethyl-1,3-dihydro-
isobenzofuran-5-ylsulfonyl)guanidino)pentanoic acid 
[3-NO2-phenylsulfonyl-Arg(Pbf)-OH] 
H
N
O
O2N S OO
OH
HN
HN NH
Pbf  
750 mg (1.758 mmol) H-Arg(Pbf)-OH were dissolved in a mixture of dioxane and 
water and treated with 428.5 mg (1.934 mmol) 3-nitrophenylsulfonyl chloride according 
to method M. 
Yield: 1 g (1.635 mmol; 92.9%), yellowish solid. 
HPLC: 55.7% B; MS calcd: 611.17, found: 611.97 (M+H)+. 
132) (S)-N-methyl-4-(1-(2-(3-nitrophenylsulfonamido)-5-(3-(3,3,4,6,7-pentamethyl-
1,3-dihydroisobenzofuran-5-ylsulfonyl)guanidino)pentanoyl)piperidin-4-
yl)butanamide 
[3-NO2-phenylsulfonyl-Arg(Pbf)-4-Pip-N-methylbutanamide] 
H
N
O
O2N S OO
N
HN
HN NH
Pbf
N
H
O
 
300 mg (0.49 mmol) intermediate 131 were coupled with 118.9 mg (0.539 mmol) 
intermediate 4 according to method I. 
Yield: 327 mg, yellow oil. 
HPLC: 56.4% B (purity: 87%). 
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133) (S)-4-(1-(2-(3-aminophenylsulfonamido)-5-(3-(3,3,4,6,7-pentamethyl-1,3-
dihydroisobenzofuran-5-ylsulfonyl)guanidino)pentanoyl)piperidin-4-yl)-N-
methylbutanamide 
[3-NH2-phenylsulfonyl-Arg(Pbf)-4-Pip-N-methylbutanamide] 
H
N
O
H2N S OO
N
HN
HN NH
Pbf
N
H
O
 
208 mg intermediate 132 was reduced by zinc dust in 90% HOAc according to method 
Q. 
Yield: 168 mg (≈ 0.225 mmol), yellowish crystals. 
HPLC: 47.9% B (purity: 95%). 
134) (S)-tert-butyl 3-(3-(N-(1-(4-(4-(methylamino)-4-oxobutyl)piperidin-1-yl)-1-
oxo-5-(3-(3,3,4,6,7-pentamethyl-1,3-dihydroisobenzofuran-5-ylsulfonyl)-
guanidino)pentan-2-yl)sulfamoyl)phenylamino)-3-oxopropylcarbamate 
[Boc-βAla-3-NH-phenylsulfonyl-Arg(Pbf)-4-Pip-N-methylbutanamide] 
H
N
O
N
H
S
OO
N
HN
HN NH
Pbf
N
H
ON
H
Boc
O
 
125 mg (0.167 mmol) intermediate 133 were coupled with 31.6 mg (0.167 mmol) Boc-
β-alanine according to method L. 
Yield: 125 mg, brown oil. 
HPLC: 58.2% B (purity: 91%). 
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5.4.3 Synthesis of propargylglycine derivatives their precursors 
135) 3-(2,2,2-trifluoroacetamido)propanoic acid 
[Tfa-βAla-OH][238] 
H
N
O
OHF3C
O  
9.5 g (0.106 mmol) β-alanine was acylated according to method G. 
Yield: 17.7 g (0.097 mmol; 91.7%), white powder. 
TLC (4:1:1) Rf: 0.42, MS calcd: 185.03, MS found: 184.05 (M-H)-. 
136) 3-(3-(2,2,2-trifluoroacetamido)propanamido)benzenesulfonic acid 
[Tfa-βAla-NH-phenylsulfonic acid] 
H
N
O
H
N S
O
O
OH
F3C
O  
1 g (5.402 mmol) intermediate 135 was coupled with 1.03 g (5.942 mmol) metanilic 
acid (dissolved in DMF in presence of 1 equiv NMM) according to method L. 
Yield: 1.6 g (4.702 mmol 87%), yellow powder. 
HPLC 2: 27.3% B (purity: 92%); MS calcd: 340.03, found: 339.04 (M-H)-. 
137) 3-(3-(2,2,2-trifluoroacetamido)propanamido)benzene-1-sulfonyl chloride 
[Tfa-βAla-3-NH-phenylsulfonylchloride][78]  
H
N
O
H
N S
O
O
Cl
F3C
O  
500 mg (1.427 mmol) intermediate 136 were dissolved in 10 mL dry acetone and 
treated with 227 μl (1.62 mmol) TEA, 325 mg (1.764 mmol) cyanuric chloride and 
21 mg (0.081 mmol) 18-crown-6. The mixture was stirred and heated under reflux for 
20 h. The solvent was removed and the residue was dissolved in DCM and extracted 
with water. The organic phase was dried over Na2SO4, filtered and the solvent was 
removed in vacuo. 
Yield: 500 mg, brown oil. 
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138) (S)-2-(3-(3-(2,2,2-trifluoroacetamido)propanamido)phenylsulfonamido)pent-
4-ynoic acid 
[Tfa-βAla-3-NH-phenylsulfonyl-Pra-OH]  
H
N
O
N
H
S
OO
OH
O
N
H
F3C
O
 
208.5 mg (1.39 mmol) H-L-Pra-OH × HCl were dissolved in a mixture of ACN and 
water in presence of 483 μl (2.78 mmol) DIPEA (pH ≈ 8.5-9). This mixture was treated 
with 500 mg (1.39 mmol) intermediate 137 according to method M and the pH was 
maintained at 8.5-9 with DIPEA. 
Yield: 525 mg (≈ 1.205 mmol), brown solid. 
HPLC 2: 33.13% B (purity: 75%); MS calcd: 435.37, found: 434.08 (M-H)-. 
139) (S)-N-methyl-4-(1-(2-(3-(3-(2,2,2-trifluoroacetamido)propanamido)-
phenylsulfonamido)pent-4-ynoyl)piperidin-4-yl)butanamide 
[Tfa-βAla-3-NH-phenylsulfonyl-Pra-4-Pip-N-methylbutanamide] 
H
N
O
N
H
S
OO
N
O
N
H
O
N
H
O
F3C
 
500 mg (1.15 mmol) intermediate 138 were coupled with 279.2 mg (1.265 mmol) 
intermediate 4 according to method I. 
Yield: 500 mg, brown oil. 
HPLC 2: 39.3% B (purity: 75%), MS calcd: 601.22, found: 602.11 (M+H)+. 
140) (S)-N-methyl-4-(1-(5-(pyridin-3-yl)-2-(3-(3-(2,2,2-trifluoroacetamido)-
propanamido)phenylsulfonamido)pent-4-ynoyl)piperidin-4-yl)butanamide 
[Tfa-βAla-3-NH-phenylsulfonyl-Pra-5-(pyridin-3-yl)-4-Pip-N-methylbutanamide] 
H
N
O
N
H
S
OO
N
O
N
H
O
N
HN
F3C
O
 
0.33 mg (0.001 mmol, 0.025 equiv) CuI, 46.5 μl (0.332 mmol, 8 equiv) TEA, 8.5 mg 
(0.041 mmol) 3-iodopyridine and 1.2 mg (0.001 mmol, 0.025 equiv) 
tetrakis(triphenylphosphine)palladium (0) were suspended in 3 mL ACN under argon. 
The stirred mixture was heated under reflux. After 1 h, 25 mg (0.041 mmol) of 
intermediate 139 dissolved in 1.5 mL ACN were added. The mixture was refluxed 
under argon for additional 18 h. After centrifugation, the supernatant was evaporated. 
The remaining residue was dissolved in EtOAc and washed trice with brine. The EtOAc 
was dried over Na2SO4, filtered and the solvent was removed in vacuo. 
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Yield: 20 mg, brown oil. 
HPLC: 36.8% B (purity: 55%), MS calcd: 678.24, found: 679.20 (M+H)+. 
141) tert-butyl 5-iodopyridin-2-ylcarbamate 
[2-(Boc-amino)-5-iodopyridine][246] 
N
I
H
N
Boc
 
500 mg (2.27 mmol) 5-iodopyridin-2-amine were slowly added to a solution of 
545.6 mg (2.49 mmol) (Boc)2O in distilled tert-butanol (0.169 mmol/mL) and the 
mixture was stirred at 25 °C for 24 h. The solvent was evaporated and the remaining 
residue was dissolved in EtOAc, washed trice with 5% KHSO4-solution and trice with 
brine. The EtOAc phase was dried over Na2SO4, filtered and the solvent was removed 
in vacuo. 
Yield: 710 mg (2.22 mmol; 98%), yellowish crystals. 
HPLC: 48.3% B, TLC (4:1:1) Rf 0.9 MS calcd: 320.00, found: 320.98 (M+H)+. 
142) (S)-tert-butyl 5-(5-(4-(4-(methylamino)-4-oxobutyl)piperidin-1-yl)-5-oxo-4-(3-
(3-(2,2,2-trifluoroacetamido)propanamido)phenylsulfonamido)pent-1-ynyl)-
pyridin-2-ylcarbamate 
[Tfa-βAla-3-NH-phenylsulfonyl-Pra-5-(6-Boc-aminopyridin-3-yl)-4-Pip-N-
methylbutanamide] 
H
N
O
N
H
S
OO
N
O
N
H
O
N
HN
N
H
F3C
O
Boc
 
25 mg intermediate 139 were coupled with 13.3 mg (0.041 mmol) compound 141 
according to the Sonogashira protocol described for the synthesis of analogue 140. 
Yield: 21 mg, brown oil. 
HPLC: 53.7% B (purity: 64%). 
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143) (S)-4-(1-(5-(6-aminopyridin-3-yl)-2-(3-(3-(2,2,2-trifluoroacetamido)propan-
amido)phenylsulfonamido)pent-4-ynoyl)piperidin-4-yl)-N-methylbutanamide 
[Tfa-βAla-3-NH-phenylsulfonyl-Pra-5-(6-aminopyridin-3-yl)-4-Pip-N-
methylbutanamide] 
H
N
O
N
H
S
OO
N
O
N
H
O
N
HN
H2N
F3C
O
 
The crude intermediate 142 was deprotected in a mixture of DCM and TFA (1:1, v/v) 
for 1 h. The solvent was evaporated and the remaining residue was used for the 
synthesis of inhibitor MI-0408 without further purification. 
Yield: not determined, brown oil. 
HPLC: 36.7% B (purity: 85%), MS calcd: 693.26, found: 694.13 (M+H)+. 
5.4.4 Synthesis of D-phenylglycine derivatives 
144) (R)-methyl 2-amino-2-phenylacetate × HCl[204] 
NH2
H3CO
O  
3.44 mL (47.31 mmol) thionyl chloride were added in portions to 13.5 mL (327 mmol) 
MeOH at -10 °C and stirred for 10 min. 2 g (13.23 mmol) D-phenylglycine were added 
to the thionyl chloride solution. The mixture was stirred at -10 °C for 30 min and at RT 
for additional 24 h. The solvent was concentrated in vacuo to a volume of 5 mL. After 
addition of 3 mL MeOH the product was crystallized at 4 °C. The product was filtered 
and dried in vacuo. 
Yield: 2.5 g (12.39 mmol; 93.7%), white powder.  
HPLC: 17.35% B.  
145) (R)-methyl 2-(3-cyanobenzamido)-2-phenylacetate 
N
H
H3CO
O
O
CN  
1.09 g (7.44 mmol) 3-cyanobenzoic acid was coupled with 1.5 g (7.44 mmol) 
intermediate 144 according to method L.  
Yield: 1.8 g (6.12 mmol; 82.2%), white solid. 
HPLC: 49.5% B. 
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146) (R)-2-(3-cyanobenzamido)-2-phenylacetic acid  
N
H
HO
O
O
CN  
1.8 g (6.12 mmol) intermediate 145 were dissolved in a mixture of dioxane and water 
(1:1, 10 mL/mmol) and saponified using 10 mL 1 N NaOH. The pH was adjusted to 12 
with 1 N NaOH and the mixture was stirred at RT for 3 h (HPLC control). After 
completion of the reaction, the mixture was acidified by 5% KHSO4-solution and 
extracted trice with EtOAc. The organic phase was collected, washed trice with brine, 
dried over Na2SO4, filtered and the solvent was removed in vacuo. 
Yield: 1.6 g (5.71 mmol; 93.2%), white solid. 
HPLC: 41.7% B (purity: 98%). 
147) (R)-2-(3-(N'-hydroxycarbamimidoyl)benzamido)-2-phenylacetic acid  
N
H
HO
O
O
N NH2
HO
 
1 g (3.57 mmol) of the nitrile 146 was converted into hydroxyamidine according to 
method O. The remaining residue was used for the synthesis of intermediate 148 
without further purification.  
Yield: not determined, white powder. 
HPLC: 24.8% B (purity: 94%). 
148) (R)-2-(3-(N'-acetoxycarbamimidoyl)benzamido)-2-phenylacetic acid  
N
H
HO
O
O
N NH2
O
O  
The crude intermediate 147 was acetylated according to method P. The residue was 
used for the synthesis of intermediate 149 without further purification.  
Yield: not determined, white solid. 
HPLC: 34.6% B (purity: 85%). 
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149) (R)-2-(3-carbamimidoylbenzamido)-2-phenylacetic acid × TFA 
N
H
HO
O
O
HN NH2  
The crude intermediate 148 was hydrogenated according to method F and purified by 
preparative HPLC. 
Yield: 820 g (1.99 mmol; 55.7%), white lyophilized solid. 
HPLC: 24.8% B, MS calcd: 297.11, found: 298.31 (M+H)+. 
150) (R)-tert-butyl 4-(2-(3-cyanobenzamido)-2-phenylacetyl)piperazine-1-
carboxylate  
N
H
N
O
O
CN
N
Boc
 
350 mg (1.25 mmol) intermediate 146 were coupled with 255.9 mg (1.373 mmol) Boc-
piperazine according to method L. 
Yield: 500 mg (1.115 mmol), yellow oil. 
HPLC: 58.4% B (purity: 87%). 
151) (R)-3-cyano-N-(2-oxo-1-phenyl-2-(piperazin-1-yl)ethyl)benzamide × HCl 
N
H
N
O
O
CN
HN
 
500 mg intermediate 150 were deprotected according to method C. 
Yield: 400 mg (1.039 mmol), yellow oil. 
HPLC: 30.9% B (purity: 75%). 
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152) (R)-3-cyano-N-(2-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-2-oxo-1-
phenylethyl)benzamide  
N
H
N
O
O
CN
N
N
 
50 mg (0.178 mmol) intermediate 146 were coupled with 21.6 μl (0.178 mmol) 1-(1-
methylpiperidin-4-yl)piperazine according to method L. 
Yield: 35 mg, yellowish solid. 
HPLC: 29.1% B (purity: 66.2%); MS calcd: 445.25, found: 446.20 (M+H)+. 
Additional analogues 153-155 (Table 5.12) were prepared by coupling 50 mg 
intermediate 146 with 0.178 mmol (1.0 equiv) of various piperazine derivatives 
according to method L.  
Table 5.12: Synthesis, yield and analytical characterization of compounds 153-155 having the general 
formula.  
N
H
N
O
O
CN
N
R
 
No. R used piperazine  mg 
Yielda
mg 
HPLC 
% B, purity % 
MS  
calcd, found (M+H)+ 
153 N
 
1-(pyridin-4-yl)piperazine 
29.1 40 35.6,  425.19, 426.11 
154 N  
dimethyl-3-(piperazin-1-
yl)propan-1-amine 
30.5 
50 29.3,  433.25, 434.01 
155 NC
 
4-piperazine-1-yl-benzonitrile 
33.3 55 57.1,  449.19, 450.40 
ayellow oil 
156) (R)-tert-butyl 3-(4-(2-(3-cyanobenzamido)-2-phenylacetyl)piperazin-1-yl)-3-
oxopropylcarbamate  
N
H
N
O
O
CN
NN
H
Boc
O
 
150 mg intermediate 151 were coupled with 73.7 mg (0.389 mmol) Boc-βAla-OH 
according to method J. 
Yield: 165 mg, yellow oil. 
HPLC: 51.2% B (purity: 58%); MS calcd: 519.25, found: 541.80 (M+Na)+. 
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157) (R)-tert-butyl 2-(4-(2-(3-cyanobenzamido)-2-phenylacetyl)piperazin-1-yl)-2-
oxoethylcarbamate  
N
H
N
O
O
CN
N
OH
N
Boc
 
100 mg intermediate 151 were coupled with 45.5 mg (0.259 mmol) Boc-Gly-OH 
according to method L. 
Yield: 80 mg, yellow oil. 
HPLC: 50.2% B (purity: 70%). 
158) (R)-3-(N'-hydroxycarbamimidoyl)-N-(2-(4-(1-methylpiperidin-4-yl)-
piperazin-1-yl)-2-oxo-1-phenylethyl)benzamide  
N
H
O
O
N
N
N
NH2N
HO
 
35 mg nitrile intermediate 152 were converted into the hydroxyamidine according to 
method O. The solvent was removed in vacuo and the residue was used for the synthesis 
of intermediate 164 without further purification. 
Yield: not determined, yellow oil. 
HPLC: 17.1% B (purity: 80.2%). 
Additional hydroxyamidine derivatives 159-163 (Table 5.13) were prepared from 
intermediates 153-157 as described for compound 158. 
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Table 5.13: Synthesis, yield and analytical characterization of compounds 159-163 having the general 
formula.  
N
H
O
O
N
N
R
N NH2
HO
 
No. R 
Educt HPLC 
% B, purity % Intermediate. No. mg 
159 N 153 40 23.7, 89.4 
160 N  
154 50 18.6, 75 
161* 
H2N
NHO
 
155 55 27.3, 83.2 
162 
N
H
Boc
O
 
156 165 36.8, 80 
163 
OH
N
Boc  
157 80 34.8, 90 
*6 equiv (50 mg, 0.732 mmol) NH2OH × HCl and 6 equiv (127 μl, 0.732 mmol) DIPEA were used to 
convert both nitrile groups. 
164) (R)-3-(N'-acetoxycarbamimidoyl)-N-(2-(4-(1-methylpiperidin-4-yl)-piperazin-
1-yl)-2-oxo-1-phenylethyl)benzamide  
N
H
O
O
N
N
N
NH2N
O
O  
The crude intermediate 158 was acetylated according to method P. The remaining 
residue was used for the synthesis of inhibitor MI-0416 without further purification. 
Yield: not determined, yellow oil. 
HPLC: 24.8% B (purity: 61%). 
Additional analogues 165-169 (Table 5.14) were prepared by acetylation of the 
intermediates 159-163 as described for analogue 164. 
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Table 5.14: Synthesis, yield and analytical characterization of compounds 165-169 having the general 
formula. 
N
H
O
O
N
N
R
N NH2
O
O  
No. R Educt: Intermediate No. HPLC % B, purity % 
165 N 159 31.1, 65.3 
166 N 160 27.1, 75.1 
167* 
H2N
NO
O
161 40.9, 65.6 
168 
N
H
Boc
O
162 45.2, 78.3 
169 
OH
N
Boc
163 42.1, 64.5 
*6 equiv acetic anhydride were used for acetylation of both hydroxyamidine groups. 
170) (R)-tert-butyl 3-(4-(2-(3-carbamimidoylbenzamido)-2-phenylacetyl)-
piperazin-1-yl)-3-oxopropylcarbamate  
N
H
N
O
O
NN
H
Boc
O
NH2HN  
Intermediate 168 was hydrogenated according to method F. The solvent was removed in 
vacuo and the residue was used for the synthesis of inhibitor MI-0429 without further 
purification. 
Yield: not determined, yellow oil. 
HPLC: 36.8% B (purity: 50%). 
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171) (R)-tert-butyl 2-(4-(2-(3-carbamimidoylbenzamido)-2-phenylacetyl)-
piperazin-1-yl)-2-oxoethylcarbamate  
N
H
N
O
O
N
OH
N
Boc
NH2HN  
Compound 171 was prepared from the intermediate 169 as decribed for the analogue 
170 according to method F. 
Yield: not determined, yellow oil. 
HPLC: 34.8% B (purity: 60%). 
172) (R)-methyl 2-(5-chlorothiophene-2-carboxamido)-2-phenylacetate 
N
H
O
O
H3CO S
Cl
 
150 mg (0.744 mmol) intermediate 144 were coupled with 120.9 mg (0.744 mmol) 5-
chlorothiophene-2-carboxylic acid according to method L.  
Yield: 195 mg (0.629 mmol; 84.6%), yellow solid. 
HPLC: 57.3% B (purity: 80%); MS calcd: 309.02, found: 310.00 (M+H)+. 
173) (R)-2-(5-chlorothiophene-2-carboxamido)-2-phenylacetic acid 
N
H
O
O
HO S
Cl
 
300 mg intermediate 172 were saponified according to method H. 
Yield: 250 mg, yellow crystallized product. 
HPLC: 49.1% B (purity: 75%); MS calcd: 295.01, found: 296.01 (M+H)+. 
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5.4.5 Synthesis of antranilamide derivatives and precursors 
174) 4-((tert-butoxycarbonylamino)methyl)benzoic acid 
HNHO
O
Boc
 
5 g (33.07 mmol) 4-(aminomethyl)benzoic acid were protected using (Boc)2O according 
to method A.  
Yield: 8 g, yellow powder. 
HPLC: 43.2% B (purity: 98%). 
175) Methyl 2-(4-((tert-butoxycarbonylamino)methyl)benzamido)-4,5-
dimethoxybenzoate 
O
O
OCH3
OH
N
O
Boc
NH
 
500 mg intermediate 174 were coupled with 462.3 mg (2.19 mmol) methyl 2-amino-
4,5-dimethoxybenzoate according to method L.Yield: 510 g, oil. 
HPLC: 65.9% B (purity: 80%); MS calcd: 444.19, found: 889.11 (2M+H)+. 
176) 2-(4-((tert-butoxycarbonylamino)methyl)benzamido)-4,5-dimethoxybenzoic 
acid 
O
O
OH
OH
N
O
Boc
NH
 
300 mg intermediate 175 were saponified according to method H. 
Yield: 275 mg, white solid. 
HPLC: 57.7% B (purity: 72%); MS calcd: 430.17, found: 431.01 (M+H)+. 
177) Methyl 2-(4-(aminomethyl)benzamido)-4,5-dimethoxybenzoate× HCl 
O
O
OCH3
O
H2N
O
NH
 
150 mg intermediate 175 were deprotected according to method C.Yield: 120 mg, white 
solid. 
HPLC: 36.9% B (purity: 75%); MS calcd: 344.14, found: 345.01 (M+H)+. 
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178) tert-butyl 4-(2-(benzylcarbamoyl)-4,5-dimethoxyphenylcarbamoyl)-
benzylcarbamate 
O
O
N
H
NH O
H
N
O
Boc
 
100 mg intermediate 176 were coupled with 27.85 μl (0.255 mmol) benzylamine 
according to method L. 
Yield: 110 mg, yellow oil. 
HPLC: 65.9% B (purity: 73%); MS calcd: 519.24, found: 520.36 (M+H)+. 
179) 2-(4-(Aminomethyl)benzamido)-N-benzyl-4,5-dimethoxybenzamide × HCl  
O
O
N
H
NH O
H2N
O
 
110 mg intermediate 178 were deprotected according to method C. 
Yield: 90 mg, white solid. 
HPLC: 42% B (purity: 99%); MS calcd: 419.18, found: 420.22 (M+H)+. 
180) tert-butyl 4-(4,5-dimethoxy-2-(phenethylcarbamoyl)phenylcarbamoyl)-
benzylcarbamate 
O
O
N
H
NH O
H
N
O
Boc
 
100 mg intermediate 176 were coupled with 32 μl (0.255 mmol) phenylethylamine 
according to method L. 
Yield: 110 mg, yellow oil. 
HPLC: 68.9% B (purity: 45%). 
181) 2-(4-(Aminomethyl)benzamido)-4,5-dimethoxy-N-phenethylbenzamide 
O
O
N
H
NH O
H2N
O
 
100 mg (0.187 mmol) intermediate 180 were deprotected according to method C. 
Yield: 80 mg, white powder. 
HPLC: 42.7% B (purity: 40%). 
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5.4.6 Synthesis of substrate analogue inhibitors and precursors 
182) Diethyl 2,2-bis(2-(pyridin-4-yl)ethyl)malonate[228] 
NN
COOEtEtOOC  
1 g (41.6 mmol) sodium hydride was dissolved in 75 mL absolute ethanol at 0 °C and 
treated with 3.75 mL (23.4 mmol) diethyl malonate. The mixture was heated to 80 °C 
and stirred for 30 min. The mixture was cooled to RT, treated with 2.71 g (25.74 mmol) 
4-vinylpyridine and stirred under reflux for 3 h. The solvent was removed in vacuo and 
1 g of the residue was purified by preparative HPLC. 
Yield: 0.7 g (1.89 mmol), yellow oil. 
HPLC: 21% B; MS calcd: 370.17, found: 371.07 (M+H)+. 
183) 4-(Pyridin-4-yl)-2-(2-(pyridin-4-yl)ethyl)butanoic acid × 2 TFA[229] 
NN
COOH  
700 mg (1.89 mmol) intermediate 182 were dissolved in a mixture of 4 mL dioxane and 
water (1:1, v/v) and heated to 80 °C. 2 mL 3 N NaOH were added in several portions 
over a period of 3 h and the mixture was stirred at 95 °C for 4 h (HPLC control). An 
additional 2 mL 3 N NaOH were added and stirring was continued at 95 °C for 
additional 4 h. The residue was cooled to RT, neutralized with 1 N HCl and the solvent 
was evaporated. The product was purified by preparative HPLC and lyophilized from 
80% tert-butanol. 
Yield: 407 mg (0.82 mmol, 43.4%), white crystallized product. 
HPLC: 12% B (purity: 100%); MS calcd: 270.14, found: 271.14 (M+H)+. 
184) 2-Amino-2-benzyl-3-phenylpropanenitrile[231, 232, 247] 
NH2
CN
 
8.558 g (160 mmol) NH4Cl and 7.105 g (145 mmol) NaCN were dissolved in 20 mL 
water and treated with 10 mL ammonia. To this mixture, 10.52 g (50 mmol) 1,3-
diphenylpropan-2-one (Aldrich) dissolved in 10 mL MeOH were added in several 
portions. The mixture was stirred at 50 °C for 8 h and the reaction was controlled by 
HPLC. An additional 1.337 g (25 mmol) NH4Cl, 1.225 g (25 mmol) NaCN and 3 mL 
ammonia were dissolved in 5 mL water and added to the reaction mixture. Stirring was 
continued at 50 °C for additional 24 h. The mixture was concentrated in vacuo to a 
small volume. The residue was acidified with 1 N HCl and extracted trice with EtOAc 
to remove the hydrophobic impurities. The water phase was used for the synthesis of 
intermediate 185. 
HPLC: 38.96% B; MS calcd: 236.13, found: 119.19 (M+2H)2+. 
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185) 2-Amino-2-benzyl-3-phenylpropanoic acid × TFA 
[H-Dbzg-OH × TFA][231, 232, 247] 
NH2
COOH
 
25 mL 32% HCl were added to the water phase of intermediate 184 and the mixture was 
stirred under refluxe for 48 h. The mixture was concentrated in vacuo, the residue was 
treated with water and evaporated. This procedure was repeated several times to remove 
HCl. 1 g of the residue was purified by preparative HPLC, and the product was 
lyophilized from 80% tert-butanol. 
Yield: 1.3 g (3.52 mmol), yellow solid. 
HPLC: 31.5% B; MS calcd: 255.13, found: 256.11 (M+H)+. 
186) 1,5-Diphenylpentan-3-one[248] 
O
 
9.8 g (41.8 mmol) trans,trans-dibenzylideneacetone were dissolved in 500 mL EtOAc 
and treated with 100 mg catalyst (10%, m/m Pd/C). The mixture was hydrogenated at 
RT for 24 h. The catalyst was removed by filtration, the solvent was evaporated, and the 
product was purified by preparative HPLC. 
Yield: 9.95 g (41.75 mmol 99.9%), colourless oil. 
HPLC: 71.3% B; MS calcd: 238.14, found: 239.12 (M+H)+. 
187) 2-Amino-2-phenethyl-4-phenylbutanenitrile[231, 232, 247] 
CN
NH2  
2 g (8.39 mmol) of compound 186 were converted to intermediate 185 in analogy to the 
synthesis of derivative 184. 
HPLC: 45.8% B; MS calcd: 264.16, found: 265.18 (M+H)+. 
188) 2-amino-2-phenethyl-4-phenylbutanoic acid × TFA 
[H-Dpheg-OH × TFA] 
COOH
NH2  
Intermediate 187 was hydrolysed with HCl as described for the preparation of 
compound 185.  
1 g of the residue was purified by preparative HPLC and the product was lyophilized 
from 80% tert-butanol. 
Yield: 470 mg (1.183 mmol), yellow solid. 
HPLC: 41.1% B; MS calcd: 283.16, found: 284.13 (M+H)+. 
Experimental part 
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189) 2-phenethyl-4-phenyl-2-(2,2,2-trifluoroacetamido)butanoic acid 
[Tfa-Dpheg-OH] 
COOH
NH
OF3C  
100 mg (0.251 mmol) intermediate 188 were protected using trifluroacetic anhydride 
according to method G. 
Yield: 92 mg (0.242 mmol; 96.6%), yellowish oil. 
HPLC: 67.7% B (purity: 100%). 
190) 2-(benzyloxycarbonylamino)-2-phenethyl-4-phenylbutanoic acid 
[Cbz-Dpheg-OH] 
COOH
HN
Cbz  
120 mg (0.317 mmole) intermediate 188 were protected using Cbz-OSu according to 
method D. 
Yield: 125 mg (0.299 mmol; 94.4%), yellow solid. 
HPLC: 70.5% B (purity: 99.8%). 
191) 2-benzyl-3-phenyl-2-(2,2,2-trifluoroacetamido)propanoic acid 
[Tfa-Dbzg-OH] 
NH
COOH
F3C O  
300 mg (0.812 mmol) intermediate 185 were protected using trifluroacetic anhydride 
according to method G. 
Yield: 270 mg (0.769 mmol; 94.7%), yellow oil. 
HPLC: 65.3% B (purity: 99.3%). 
192) (S)-tert-butyl 2-(4-cyanobenzylcarbamoyl)pyrrolidine-1-carboxylate 
[Boc-Pro-4-cyanobenzylamide][249]  
N
O
Boc
H
N CN
 
5 g (23.23 mmol) Boc-Pro-OH were coupled with 4.31 g (25.55 mmol) 
4-cyanobenzylamine × HCl according to method L. 
Yield: 7.11 g, oil. 
HPLC: 47.1% B (purity: 99.2%). 
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193) (S)-N-(4-cyanobenzyl)pyrrolidine-2-carboxamide × HCl 
[H-Pro-4-cyanobenzylamide × HCl] 
HN
O HN CN
 
1.5 g (4.553 mmol) intermediate 192 were deprotected according to method C. 
Yield: 1.15 g (4.328 mmol; 95.1%), beige solid. 
HPLC: 22.3% B (purity: 100%). 
194) (S)-N-(4-carbamimidoylbenzyl)pyrrolidine-2-carboxamide × 2 HCl 
[H-Pro-(4-Am)benzylamide × 2 HCl][221, 249] 
HN
O H
N NH2
NH
 
1 g (2.28 mmol) Cbz-Pro-(4-acetylhydroxyamidine)benzylamide (provided by Prof. Dr. 
Steinmetzer) were dissolved in 100 mL 90% HOAc and treated with 25 mg Pd/C. The 
mixture was stirred at RT for 48 h under hydrogen atmosphere. The catalyst was 
removed by filtration and the solvent was evaporated. The residue was dissolved in 1 N 
HCl and the solution was concentrated in vacuo. The remaining residue was dissolved 
again in water and evaporated.This procedure was repeated three times. The product 
was lyophilized from water. 
Yield: 700 mg (2.19 mmol; 96.1%), beige solid. 
HPLC: 11.8% B; TLC: Rf 0.10; MS calcd: 246.15, found: 247.14 (M+H)+. 
195) (S)-N-(4-cyanobenzyl)-1-(2-phenethyl-4-phenyl-2-(2,2,2-trifluoroacetamido)-
butanoyl)pyrrolidine-2-carboxamide 
[Tfa-Dpheg-N-Pro-4-cyanobenzylamide]  
N
O
H
N
CN
O
HNTfa
 
85 mg (0.224 mmol) intermediate 189 were coupled with 65.5 mg (0.246 mmol) 
intermediate 193 according to method K. 
Yield: 110 mg, brown oil. 
HPLC: 71.5% B (purity: 35%); MS calcd: 590.25, found: 591.29 (M+H)+.  
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196) (S)-N-(4-(N'-hydroxycarbamimidoyl)benzyl)-1-(2-phenethyl-4-phenyl-2-
(2,2,2-trifluoroacetamido)butanoyl)pyrrolidine-2-carboxamide 
[Tfa-Dpheg-Pro-(4-OxAm)-benzylamide] 
N
O
H
N
O
HNTfa
N
NH2
HO
 
110 mg (0.186 mmol) of the nitrile 195 were converted into the hydroxyamidine 
according to method O and used for the synthesis of intermediate 197 without further 
purification. 
Yield: not determined, brown oil. 
HPLC: 53.07% B (purity: 55%). 
197) (S)-N-(4-(N'-acetoxycarbamimidoyl)benzyl)-1-(2-phenethyl-4-phenyl-2-(2,2,2-
trifluoroacetamido)butanoyl)pyrrolidine-2-carboxamide 
[Tfa-DPheg-Pro-(4-AcOxAm)-benzylamide] 
N
O
H
N
O
HNTfa
N
NH2
O
O
 
0.186 mmol intermediate 196 was acetylated according to method P. The solvent was 
removed in vacuo (temperature of the water bath < 35 °C) and the residue was used for 
the synthesis of inhibitor MI-0457 without further purification. 
Yield: not determined, brown oil. 
HPLC: 64.1% (purity: 45%). 
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198) (S)-1-(2-benzyl-3-phenyl-2-(2,2,2-trifluoroacetamido)propanoyl)-N-(4-
cyanobenzyl)pyrrolidine-2-carboxamide 
[Tfa-Dbzg-Pro-4-cyanobenzylamide] 
N
H
NOO
NH
CN
Tfa
 
250 mg (0.712 mmol) intermediate 191 were coupled with 208 mg (0.783 mmol) 
intermediate 193 according to method K. 
Yield: 300 mg, brown oil. 
HPLC: 67.7% B (purity: 59%); MS calcd: 562.22, found: 563.21 (M+H)+. 
199) (S)-1-(2-benzyl-3-phenyl-2-(2,2,2-trifluoroacetamido)propanoyl)-N-(4-(N'-
hydroxycarbamimidoyl)benzyl)pyrrolidine-2-carboxamide 
[Tfa-Dbzg-Pro-(4-OxAm)benzylamide] 
N
H
NOO
NHTfa
NH2
N
HO
 
300 mg (0.533 mmol) of the nitrile 198 were converted into hydroxyamidine according 
to method O and used for the synthesis of intermediate 200 without further purification. 
Yield: not determined, brown oil. 
HPLC: 48.3% B (purity: 59%). 
200) (S)-N-(4-(N'-acetoxycarbamimidoyl)benzyl)-1-(2-benzyl-3-phenyl-2-(2,2,2-
trifluoroacetamido)propanoyl)pyrrolidine-2-carboxamide 
[Tfa-Dbzg-Pro-(4-AcOxAm)benzylamide] 
N
H
NOO
NHTfa
NH2
N
O
O
 
Intermediate 199 were acetylated according to method P and used for the synthesis of 
inhibitor MI-0456 without further purification. 
Yield: not determined, brown oil. 
HPLC: 59.5% B (purity: 52%). 
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201) (S)-benzyl 3-(2-(4-cyanobenzylcarbamoyl)pyrrolidine-1-carbonyl)-1,5-
diphenylpentan-3-ylcarbamate 
[Cbz-Dpheg-Pro-4-cyanobenzylamide] 
N
O
H
N
CN
O
HNCbz
 
100 mg (0.239 mmol) intermediate 190 were coupled with 70 mg (0.263 mmol) 
intermediate 193 according to method K. 
Yield: 120 mg, brown oil. 
HPLC: 72.5% B (purity: 40%). 
202) (S)-benzyl 3-(2-(4-(N'-hydroxycarbamimidoyl)benzylcarbamoyl)-pyrrolidine-
1-carbonyl)-1,5-diphenylpentan-3-ylcarbamate 
[Cbz-Dpheg-Pro-(4-OxAm)benzylamide] 
N
O
H
N
O
HNCbz
NH2
N
HO
 
120 mg (0.191 mmol) of the nitrile 201 were converted into hydroxyamidine according 
to method O and used for the synthesis of intermediate 203 without further purification. 
Yield: not determined, brown oil. 
HPLC: 54.4% B (purity: 50%). 
Experimental part 
136 
 
203) (S)-benzyl 3-(2-(4-(N'-acetoxycarbamimidoyl)benzylcarbamoyl)-pyrrolidine-
1-carbonyl)-1,5-diphenylpentan-3-ylcarbamate 
[Cbz-Dpheg-Pro-(4-AcOxAm)benzylamide] 
N
O
H
N
O
HNCbz
NH2
N
O
O
 
0.191 mmol intermediate 202 were acetylated according to method P and used for the 
synthesis of inhibitor MI-0458 without further purification. 
Yield: not determined, brown oil. 
HPLC: 65.1% B (purity: 35%). 
204) (R)-2-(tert-butoxycarbonylamino)-4-phenylbutanoic acid 
[Boc-D-hPhe-OH] 
H
N
OH
O
Boc
 
100 mg (0.558 mmol) H-D-hPhe-OH were Boc-protected according to method A. 
Yield: 150 mg (0.537 mmol; 96.2%), white solid. 
HPLC: 53.1% B (purity: 96%). 
205) (R)-2-(tert-butoxycarbonylamino)-4-(4-hydroxyphenyl)butanoic acid 
[Boc-D-hTyr-OH] 
OH
H
N
OH
O
Boc
 
100 mg (0.364 mmol) H-D-hTyr-OH × HBr (Iris) were Boc-protected according to 
method A (HPLC control). An additional 19.7 mg (0.091mmol, 0.25 equiv) of di-tert.-
butylpyrocarbonate were added at 0 °C and the mixture was stirred for additional 2 h. 
Yield: 100 mg (0.339 mmol; 93%), white solid. 
HPLC: 41.3% B (purity: 80%). 
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206) tert-butyl (S)-1-((S)-2-(4-carbamimidoylbenzylcarbamoyl)pyrrolidin-1-yl)-1-
oxo-4-phenylbutan-2-ylcarbamate 
[Boc-hPhe-Pro-4-Amba] 
N
O
H
N
NH2
HN
NH
O
Boc  
39.8 mg (0.142 mmol) Boc-hPhe-OH were coupled with 50 mg (0.157 mmol) 
intermediate 194 according to method I. The solvent was removed in vacuo and the 
residue was used for the synthesis of inhibitor MI-0464 without further purification. 
Yield: not determined, yellow oil. 
HPLC: 42.3% B (purity: 70%). 
Additional N-protected amino acids were coupled with 50 mg (0.157 mmol) 
intermediate 194 according to method I and provided analogues 207-210 (Table 5.15). 
Table 5.15: Synthesis, yield and analytical characterization of compounds 205-208 having the general 
formula. 
N
O HN NH2
NH
R
 
No. R Educts: mg/mmol 
HPLC 
% B, purity % 
207 
HN
O
Boc
Boc-Phe-OH 
37.9/0.142 39.5, 89.3 
208 
HN
O
Boc
Boc-D-Phe-OH 
37.9/0.142 
40.5, 90 
 
209 
NH
O
Boc
Intermediate 204 
Boc-D-hPhe-OH 
39.8/0.142 
43.5, 87.4 
210 
O
NH
Cbz
N
H
H2N
NH
Cbz-D-Arg-OH × HCl 
49.2/0.142 28.0, 79,3 
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211) tert-butyl (R)-1-((S)-1-(4-carbamimidoylbenzylamino)-1-oxopropan-2-
ylamino)-1-oxo-4-phenylbutan-2-ylcarbamate 
[Boc-D-hPhe-Ala-4-Amba] 
NH
O
Boc
N
H
HN
O
NH2
NH  
57.6 mg (0.206 mmol) Boc-D-hPhe-OH (204) were coupled with 50 mg (0.227 mmol) 
H-Ala-4-Amba × 2 HCl (provided by Dr. Frank Sielaff) according to method I. The 
solvent was removed in vacuo and the residue was used for the synthesis of inhibitor 
MI-0469 without further purification. 
Yield: not determined, yellow oil. 
HPLC: 41.02% B (purity: 81.8%). 
212) tert-butyl (R)-1-((S)-1-(4-carbamimidoylbenzylamino)-1-oxopropan-2-
ylamino)-4-(4-hydroxyphenyl)-1-oxobutan-2-ylcarbamate 
[Boc-D-hTyr-Ala-4-Amba] 
HO
NH
O
Boc
N
H
HN
O
NH2
NH  
26.8 mg (0.09 mmol) Boc-D-hTyr-OH (205) were coupled with 22 mg (0.099 mmol) 
H-Ala-4-Amba × 2 HCl according to method I. The solvent was removed in vacuo and 
the residue was used for the synthesis of inhibitor MI-0470 without further purification. 
Yield: not determined, yellow oil. 
HPLC: 41.02% B (purity: 55%). 
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5.5 Synthesis of inhibitors 
213) (S)-4-(1-(3-(3-carbamimidoylphenyl)-2-(2'-fluorobiphenyl-3-ylsulfonamido)-
propanoyl)piperidin-4-yl)-N-methylbutanamide × TFA 
[2F-biphenyl-3-sulfonyl-Phe(3-Am)-4-Pip-N-methylbutanamide × TFA]  
(MI-0403) 
H
N
S
O
N
OO
N
H
O
F
NH2HN  
The intermediate 22 was converted into the amidine according to method Q. The 
product was purified by preparative HPLC and lyophilized from 80% tert-butanol.  
Yield: 23 mg (0.032 mmol), white powder. 
HPLC: 45.3% B; TLC: Rf 0.87; MS calcd: 607.26, found: 608.18 (M+H)+. 
Additional analogues 214-219 (Table 5.16) were prepared from intermediates 23-28 
using method Q. 
Table 5.16: Synthesis, yield and analytical characterization of compounds 214-219 having the general 
formula. 
H
N
S
O
N
OO
N
H
O
2
3
R1
4
R2
NH2HN  
No. R1 R2 
Educt 
Intermediate 
No. 
Yielda 
mg/mmol 
HPLC
% B 
TLC 
Rf 
MS 
calcd, found (M+H)+ 
214 
MI-0404 3-F - 23 15/0.021 45.4 0.86 607.26, 608.23 
215 
MI-0405 4-F - 24 29/0.04 44.6 0.85 607.26, 608.17 
216 
MI-0406 2-Cl 4-Cl 25 15/0.019 48.6 0.84 657.19, 658.16
 
217 
MI-0440 2-Cl 3-Cl 26 17/0.022 48 0.85 657.19, 658.41 
218 
MI-0442 3-Cl 4-Cl 27 26/0.034 48.7 0.85 657.19, 658.41 
219 
MI-0412 2-Cl 4-EtO 28 15/0.019 50.06 0.78 667.26, 668.38 
aAll final inhibitors were obtained as white powder after lyophilization. 
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220) (S)-4-(1-(3-(3-carbamimidoylphenyl)-2-(2',4'-dimethoxybiphenyl-3-
ylsulfonamido)propanoyl)piperidin-4-yl)-N-methylbutanamide × TFA  
[2,4dimethoxybiphenyl-3-sulfonyl-Phe(3-Am)-4-Pip-N-methylbutan-
amide × TFA] (MI-0438) 
H
N
S
O
N
OO
N
H
O
O
NH2HN
O
 
The crude intermediate 29 were hydrogenated according to method F, the product was 
purified by preparative HPLC and lyophilized from 80% tert-butanol.  
Yield: 14 mg (0.018 mmol), white powder. 
HPLC: 43.9% B; TLC: Rf 0.83; MS calcd: 649.29, found: 650.39 (M+H)+. 
221) (S)-3-(3-(4-(2-aminoethyl)piperidin-1-yl)-2-(2'-fluorobiphenyl-3-ylsulfon-
amido)-3-oxopropyl)benzimidamide × 2 TFA 
[2F-biphenyl-3-sulfonyl-Phe(3-Am)-4-Pip-ethylamine × 2 TFA] (MI-0433) 
H
N
S
O
N
OO
NH2F
NH2HN  
The crude intermediate 55 was deprotected according to method B.  
Yield: 17 mg (0.022 mmol), white powder. 
HPLC: 24% B; TLC: Rf 0.73; MS calcd: 551.24, MS found: 552.29 (M+H)+. 
Additional analogues 222-228 (Table 5.17) were prepared from intermediates 56-62 
using method B. 
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Table 5.17: Synthesis, yield, and analytical characterization of compounds 222-228 having the general 
formula. 
H
N
S
O
N
OO
NH2
2
3
R1
4
R2
NH2HN  
No. R1 R2 
Educt 
Intermediate 
No. 
Yielda 
mg/mmol 
HPLC
% B 
TLC 
Rf 
MS 
calcd, found (M+H)+ 
222 
MI-0431 3-F - 56 18/0.023 34.3 0.72 551.24, 552.31 
223 
MI-0434 4-F - 57 12/0.015 34.6 0.73 551.24, 552.22  
224 
MI-0432 2-Cl 4-Cl 58 18/0.022  39.4 0.74 601.17, 602.21 
225 
MI-0441 2-Cl 3-Cl 59 13/0.016 39.7 0.74 601.17, 602.11
 
226 
MI-0443 3-Cl 4-Cl 60 15/0.018 40.8 0.75 601.27, 602.10 
227 
MI-0413 2-Cl 4-EtO 61 14/0.019 41 0.75 611.23, 612.32 
228 
MI-0439 2-MeO 4-MeO 62 20/0.024 36.1 0.71 593.27, 594.41
 
aAll final inhibitors were obtained as white powder after lyophilization. 
229) (S)-3-amino-N-(3-(N-(3-(3-carbamimidoylphenyl)-1-oxo-1-(4-(2-ureidoethyl)-
piperidin-1-yl)propan-2-yl)sulfamoyl)phenyl)propanamide × 2 TFA  
[H-βAla-3-NH-phenylsulfonyl-Phe(3-Am)-4-Pip-Et-urea × 2 TFA] (MI-0449) 
H
N
N
O
SN
H
O
H2N O O
N
H
O
NH2
NH2HN  
0.057 mmol intermediate 111 were hydrogenated according to method F. 
Yield: 12 mg (0.015 mmol), white powder. 
HPLC: 23.4% B; TLC: Rf 0.55; MS calcd: 586.27, found: 587.41 (M+H)+. 
Additional analogues 230-238 (Table 5.18) were prepared by hydrogenation of the 
intermediates 112-120 using method F. 
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Table 5.18: Synthesis, yield and analytical characterization of compounds 230-238 having the general 
formula. 
H
N
N
O
SN
H
O
H2N H
N
H
N
O
R
n
O O
NH2HN  
No. n R 
Educt 
Intermediate 
No. 
Yielda 
mg/mmol 
HPLC
% B 
TLC
Rf 
MS 
calcd, found (M+H)+ 
230 
MI-0451 0 H 112 13/0.017 20.3 0.54 558.24, 559.31 
231 
MI-0436 2 Me 113 13/0.016 24.4 0.63 600.28, 601.22
  
232 
MI-0450 0 Me 114 12/0.015 21.3 0.59 572.25, 573.30 
233 
MI-0437 2 Et 115 14/0.017 26.2 0.66 614.27, 615.41 
234 
MI-0452 0 Et 116 19/0.023 23.7 0.59 586.27, 587.31 
235 
MI-0444 2  
117 15/0.017 32.2 0.67 662.27, 663.40 
236 
MI-0454 0  
118 17/0.020 30.4 0.71 634.27, 635.61 
237 
MI-0445 2  
119 20/0.022 34.1 0.67 668.35, 669.51 
238 
MI-0453 0  
120 19/0.022 31.7 0.65 640.35, 641.32 
awhite powder after lyophilization 
239) (S)-3-(2-(2',4'-dimethoxybiphenyl-3-ylsulfonamido)-3-(4-(2-(3-methylureido)-
ethyl)piperidin-1-yl)-3-oxopropyl)benzimidamide × TFA  
[2,4-Dimethoxybiphenyl-3-sulfonyl-Phe(3-Am)-4-Pip-Et-methylurea × TFA] 
(MI-0460) 
H
N
O
S
OO
N
O O
NH2HN
N
H
N
H
O
 
0.064 mmol intermediate 123 was reduced by zinc dust in 90% HOAc according to 
method Q. 
Yield: 14 mg (0.018 mmol), white powder. 
HPLC: 41.4% B; TLC: Rf 0.84; MS calcd: 650.29, found: 651.42 (M+H)+. 
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Additional analogues 240-242 (Table 5.19) were prepared by reduction of intermediates 
124-126 using method Q. 
Table 5.19: Synthesis, yield and analytical characterization of compounds 240-242 having the general 
formula. 
H
N
N
O
SR H
N
H
N
O
R1
O O
NH2HN
n
 
No. n R R1 
Educt 
Intermediate 
No. 
Yielda 
mg/mmol
HPLC 
% B 
TLC 
Rf 
MS 
calcd, found 
(M+H)+ 
240 
MI-0461 2 
ClCl  
Me 124 13/0.017 46.4 0.85 658.19, 659.37 
241 
MI-0462 0 OO
 
125 25/0.031 48.7 0.85 690.32, 691.51 
242 
MI-0463 0 
ClCl  
126 13/0.016 53.5 0.87 698.22, 700.28 
aslight yellowish powder after lyophilization 
243) (S)-3-amino-N-(3-(N-(1-(4-(2-(3-benzylureido)ethyl)piperidin-1-yl)-3-(3-
carbamimidoylphenyl)-1-oxopropan-2-yl)sulfamoyl)phenyl)propanamide × 2 
TFA 
[H-βAla-3-NH-phenylsulfonyl-Phe(3-Am)-4-Pip-Et-Bzlu × 2 TFA] (MI-0446) 
H
N
N
O
SN
H
O
H2N O O
N
H
O
N
H
NH2HN  
The intermediate 127 was deprotected according to method E, purified by preparative 
HPLC and lyophilized from 80% tert-butanol. 
Yield: 11 mg (0.012 mmol), white powder. 
HPLC: 31.6% B; TLC: Rf 0.66; MS calcd: 676.32, found. 677.41 (M+H)+. 
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244) (S)-3-amino-N-(3-(N-(1-(4-(3-benzylureido)piperidin-1-yl)-3-(3-carbam-
imidoylphenyl)-1-oxopropan-2-yl)sulfamoyl)phenyl)propanamide × 2 TFA  
[H-βAla-3-NH-phenylsulfonyl-Phe(3-Am)-4-Pip-Bzlu × 2 TFA] (MI-0455) 
H
N
N
O
SN
H
O
H2N O O
N
H
O
N
H
NH2HN  
The intermediate 128 was deprotected as described for the synthesis of inhibitor MI-
0446 (method E). 
Yield: 14 mg (0.016 mmol), white powder. 
HPLC: 30.1% B; TLC: Rf 0.71; MS calcd: 648.28, found: 649.71 (M+H)+. 
245) (S)-3-amino-N-(3-(N-(1-(4-aminopiperidin-1-yl)-3-(3-carbamimidoylphenyl)-
1-oxopropan-2-yl)sulfamoyl)phenyl)propanamide × 3 TFA  
[H-βAla-3-NH-phenylsulfonyl-Phe(3-Am)-4-Pip-NH2 × 3 TFA] (MI-0458) 
H
N
O
S
OO
N
NH2
N
H
H2N
O
NH2HN  
The intermediate 130 were hydrogenated according to method F. The solvent was 
removed in vacuo, the product was purified by preparative HPLC and lyophilized from 
80% tert-butanol. 
Yield: 40mg (0.047), white powder. 
HPLC: 17.5% B; TLC: Rf 0.54; MS calcd: 515.23, found: 516.31 (M+H)+.  
246) (S)-4-(1-(2-(3-aminophenylsulfonamido)-5-guanidinopentanoyl)piperidin-4-
yl)-N-methylbutanamide × 2 TFA  
[3-NH2-phenylsulfonyl-Arg-4-Pip-N-methylbutanamide × 2 TFA] (MI-0401) 
H
N
O
H2N S OO
N
HN
H2N NH
N
H
O
 
The crude intermediate 133 was deprotected using 90% TFA. The mixture was stirred 
for 2 h. The solvent was removed in vacuo, the product was purified by preparative 
HPLC and lyophilized from 80% tert-butanol. 
Yield: 45 mg (0.622 mmol), white powder. 
HPLC: 24.9% B; TLC: Rf 0.75; MS calcd: 495.26, found: 496.2 (M+H)+. 
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247) (S)-4-(1-(2-(3-(3-aminopropanamido)phenylsulfonamido)-5-guanidino-
pentanoyl)piperidin-4-yl)-N-methylbutanamide × 2 TFA  
[H-βAla-3-NH-phenylsulfonyl-Arg-4-Pip-N-methylbutanamide × 2 TFA] 
(MI-0402) 
H
N
O
N
H
S
OO
N
HN
H2N NH
N
H
OH2N
O
 
The crude intermediate 134 was deprotected and purified as described for the synthesis 
of inhibitor 246. 
Yield: 68 mg (0.086 mmol), white powder. 
HPLC: 24.1% B; TLC: Rf 0.68; MS calcd: 566.30, found: 567.21 (M+H)+. 
248) (S)-4-(1-(2-(3-(3-aminopropanamido)phenylsulfonamido)-5-(pyridin-3-
yl)pent-4-ynoyl)piperidin-4-yl)-N-methylbutanamide × 2 TFA  
[H-βAla-3-NH-phenylsulfonyl-Pra-5-(pyridin-3-yl)-4-Pip-N-methylbutanamide × 
2 TFA] (MI-0407) 
H
N
O
N
H
S
OO
N
O
H2N O
N
HN
 
The crude intermediate 140 was deprotected according to method H, the product was 
purified by preparative HPLC and lyophilized from 80 % tert-butanol. 
Yield: 7 mg (0.009 mmol), slight yellowish powder. 
HPLC: 27.6% B; TLC: Rf 0.77; MS calcd: 582.26, found: 583.1 (M+H)+. 
249) (S)-4-(1-(2-(3-(3-aminopropanamido)phenylsulfonamido)-5-(6-aminopyridin-
3-yl)pent-4-ynoyl)piperidin-4-yl)-N-methylbutanamide × 2 TFA 
[H-βAla-3-NH-phenylsulfonyl-Pra-5-(6-aminopyridin-3-yl)-4-Pip-N-methyl-
butanamide × 2 TFA] (MI-0408)  
H
N
O
N
H
S
OO
N
O
H2N O
N
HN
H2N  
The Tfa-group of intermediate 143 was removed by 1 N NaOH according to method H. 
Yield: 15 mg (0.018 mmol), slight yellowish powder. 
HPLC: 26.6% B; TLC: Rf 0.56; MS calcd: 597.27, found: 598.22 (M+H)+. 
Experimental part 
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250) (R)-3-carbamimidoyl-N-(2-oxo-1-phenyl-2-(4-phenylpiperazin-1-yl)ethyl)-
benzamide × TFA  
[(3-Am)benzoyl-D-Phg-4-phenylpiperazin-1-yl × TFA] (MI-0415) 
N
H
O
O
HN NH2
N
N
 
50 mg (0.121 mmol) intermediate 149 were coupled with 19.6 mg (0.121 mmol) 1-
phenylpiperazine according to method I. The product was purified by preparative HPLC 
and lyophilized from 80 % tert-butanol. 
Yield: 30 mg (0.054 mmol), white powder. 
HPLC: 38.2% B; TLC: Rf 0.81; MS calcd: 441.22, found: 442.4 (M+H)+. 
Additional analogues 251-254 (Table 5.20) were prepared by coupling 50 mg (0.121 
mmol) intermediate 149 with (0.121 mmol, 1.0 equiv) of various piperazine derivatives 
using method I. 
Table 5.20: Synthesis, yield and analytical characterization of inhibitors 251-254 having the general 
formula. 
N
H
O
O
HN NH2
R
N
N
 
No. R 
Educt piperazine 
derivative 
 mg 
Yielda 
mg/mmol 
HPLC
% B 
TLC 
Rf 
MS 
calcd, found (M+H)+ 
251 
MI-0418 NC  
4-(piperazin-1-
yl)benzonitrile 22.7 21/0.037 41.2 0.80 466.21, 467.41 
252 
MI-0420 O
O
 
1-Cbz-piperazine 
26.6 13/0.021 43.7 0.85 499.22, 500.01 
253 
MI-0421 HO  
1-(4-hydroxy-
phenyl)-piperazine 
21.6 
25/0.044 25.6 0.81 457.20, 458.30 
254 
MI-0426  
1-benzyl-
piperazine 
21.3 
17/0.03 29.1 0.76 455.23, 456.22 
awhite powder after lyophilization 
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255) (R)-3-carbamimidoyl-N-(2-oxo-1-phenyl-2-(4-(pyridin-2-yl)piperazin-1-yl)-
ethyl)benzamide × 2 TFA  
[(3-Am)benzoyl-D-Phg-4-(pyridin-2-yl)piperazin-1-yl × 2 TFA] (MI-0422) 
N
H
O
O
HN NH2
N
N
N
 
50 mg (0.121 mmol) intermediate 149 were coupled with 19.3 μl (0.121 mmol) 1-(2-
Pyr)piperazine according to method J, and the product was purified by preparative 
HPLC and lyophilized from water. 
Yield: 30 mg (0.045 mmol), slight yellowish powder. 
HPLC: 23.9% B; TLC: Rf 0.79; MS calcd: 442.21, found: 443.22 (M+H)+. 
256) (R)-3-carbamimidoyl-N-(2-(4-(2-cyanoethyl)piperazin-1-yl)-2-oxo-1-phenyl-
ethyl)benzamide × 2 TFA  
[(3-Am)benzoyl-D-Phg-4-(CN-Et)piperazin-1-yl × 2 TFA] (MI-0423) 
N
H
O
O
HN NH2
N
N
NC
 
50 mg (0.121 mmol) intermediate 149 were coupled with 16.8 mg (0.121 mmol) 3-
piperazinopropionitrile as described for the synthesis of compound 255 (method J). 
Yield: 15 mg (0.023 mmol), slight yellowish powder. 
HPLC: 20.5% B; TLC: Rf 0.79; MS calcd: 418.21, found: 419.41 (M+H)+. 
257) (R)-3-carbamimidoyl-N-(2-oxo-1-phenyl-2-(4-(pyrimidin-2-yl)piperazin-1-yl)-
ethyl)benzamide × TFA  
[(3-Am)benzoyl-D-Phg-4-(pyrimidin-2-yl)piperazin-1-yl × TFA] (MI-0427) 
N
H
O
O
N
N
HN NH2
N
N
 
The product 257 (MI-0427) was prepared from 50 mg (0.121 mmol) intermediate 149 
and 19.9 mg (0.121 mmol) 2-(piperazin-1-yl)pyrimidine as described for the synthesis 
of compound 255 (method J). 
Yield: 10 mg (0.018 mmol), yellowish powder. 
HPLC: 31.1% B; TLC: Rf 0.79; MS calcd: 443.21, found: 444.11 (M+H)+. 
Experimental part 
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258) (R)-3-carbamimidoyl-N-(2-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-2-oxo-
1-phenylethyl)benzamide × 3 TFA  
[(3-Am)benzoyl-D-Phg-4-(1-Me-Pip)piperazin-1-yl × 3 TFA] (MI-0416) 
N
H
O
O
N
N
N
NH2HN  
The intermediate 164 was hydrogenated according to method method F. 
Yield: 23 mg (0.029 mmol), white powder. 
HPLC: 17.1% B; TLC: Rf 0.71; MS calcd: 462.27, found: 463.41 (M+H)+. 
Additional analogues 259-261 (Table 5.21) were prepared from intermediates 165-167 
by hydrogenation according to method F. 
Table 5.21: Synthesis, yield and analytical characterization of inhibitors 259-261 having the general 
formula. 
N
H
O
O
N
N
R
HN NH2  
No. R 
Educt 
Intermediate 
No. 
Yielda 
mg/mmol 
HPLC 
% B 
TLC 
Rf 
MS 
calcd, found (M+H)+ 
259 
MI-0417 N
165 23/0.034 23.2 0.71 442.21, 443.51 
260 
MI-0424 N  
166 30/0.038 21.8 0.70 450.27, 451.32 
261 
MI-0419 H2N
HN
 
167 32/0.045 28.1 0.76 483.24, 484.21 
aAll final inhibitors were obtained as white powder after lyophilization. 
Experimental part 
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262) (R)-N-(2-(4-(3-aminopropanoyl)piperazin-1-yl)-2-oxo-1-phenylethyl)-3-
carbamimidoylbenzamide × 2 TFA  
[(3-Am)benzoyl-D-Phg-4-(β-Ala)piperazin-1-yl × 2 TFA] (MI-0429) 
N
H
N
O
O
NH2N
O
NH2HN  
The intermediate 170 was deprotected by TFA according to method B. 
Yield: 55 mg (0.083 mmol), white powder. 
HPLC: 20.2% B; TLC: Rf 0.64; MS calcd: 436.22, found: 437.28 (M+H)+. 
263) (R)-N-(2-(4-(2-aminoacetyl)piperazin-1-yl)-2-oxo-1-phenylethyl)-3-carbam-
imidoylbenzamide × 2 TFA  
[(3-Am)benzoyl-D-Phg-4-(Gly)piperazin-1-yl × 2 TFA] (MI-0430) 
N
H
N
O
O
N
O
H2N
NH2HN  
The intermediate 171 were deprotected by TFA according to the method B. 
Yield: 55 mg (0.085 mmol), white powder. 
HPLC: 19.1% B; TLC: Rf 0.62; MS calcd: 422.21, found: 423.23 (M+H)+. 
264) (R)-3-carbamimidoyl-N-(2-(4-(2-guanidinoacetyl)piperazin-1-yl)-2-oxo-1-
phenylethyl)benzamide × 2 TFA  
[(3-Am)benzoyl-D-Phg-4-(2-guanidinoacetyl)piperazin-1-yl × 2 TFA] (MI-0435) 
N
H
N
O
O
N
H
N
O
NH2HN
H2N
NH
 
25 mg (0.038 mmol) of inhibitor 263 were converted into the analogous guanidine 
derivative according to method S. 
Yield: 25 mg (0.036 mmol), white powder. 
HPLC: 20.8% B; TLC: Rf 0.71; MS calcd: 464.23, found: 465.37 (M+H)+. 
Experimental part 
150 
 
265) (R)-5-chloro-N-(2-oxo-1-phenyl-2-(4-(pyridin-4-yl)piperazin-1-yl)ethyl)-
thiophene-2-carboxamide × TFA  
[5-Cl-thiophene-2-carboxyl-D-Phg-4-(pyridin-4-yl)piperazin-1-yl × TFA] (MI-
0423) 
N
H
O
O
N S
Cl
N
N
 
50mg (0.169 mmol) intermediate 173 were coupled with 27.59 mg (0.169 mmol) 1-
(pyridin-4-yl)piperazine according to method L. 
Yield: 15 mg (0.027 mmol), white powder. 
 HPLC: 41.8% B; TLC: Rf 0.92; MS calcd: 440.11, found: 441.72 (M+H)+. 
266) Methyl 2-(4-(guanidinomethyl)benzamido)-4,5-dimethoxybenzoate × TFA 
(MI-0409) 
O
O
OCH3
OH
N
O
NH
NH2
HN
 
60 mg of the amine intermediate 177 were converted into the guanidine according to 
method S. 
Yield: 52.2 mg (0.123 mmol), white powder. 
HPLC: 40.3% B; TLC: Rf 0.92; MS calcd: 386.16, found. 387 (M+H)+. 
267) N-benzyl-2-(4-(guanidinomethyl)benzamido)-4,5-dimethoxybenzamide × 
TFA (MI-0410) 
O
O
N
H
NH O
H
N
O
H2N
NH
 
90 mg of the amine intermediate 179 were converted into the guanidine according to 
method S. 
Yield: 105 mg (0.182 mmol), white powder. 
HPLC: 43.1% B; TLC: Rf 0.84; MS calcd: 461.21, found: 462.22 (M+H)+. 
Experimental part 
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268) 2-(4-(Guanidinomethyl)benzamido)-4,5-dimethoxy-N-phenethylbenzamide × 
TFA (MI-0411)  
O
O
N
H
NH O
H
N
O
H2N
NH
 
70 mg of the amine 181 were converted into the guanidine according to method S. 
Yield: 21 mg (0.036 mmol), white powder. 
HPLC: 45.2 % B; TLC: Rf 0.86; MS calcd: 475.22, found: 476.21 (M+H)+. 
269)  (S)-N-(4-carbamimidoylbenzyl)-1-(4-(pyridin-4-yl)-2-(2-(pyridin-4-yl)ethyl)-
butanoyl)pyrrolidine-2-carboxamide × 3 TFA  
[4-(Pyridin-4-yl)-2-(2-(pyridin-4-yl)ethyl)butanoyl-)-Pro-(4-Amba) × 3 TFA] 
(MI-0400) 
N
O HNON
N
NH
NH2
 
100 mg (0.201 mmol) intermediate 183 were coupled with 70.6 mg (0.221 mmol) 
intermediate 194 according to method I. 
Yield: 115 mg (0.137 mmol), white powder. 
HPLC: 16.5% B; TLC: Rf 0.6; MS calcd: 498.27, found: 499.25 (M+H)+. 
270) (S)-N-(4-carbamimidoylbenzyl)-1-(2-phenethyl-4-phenyl-2-(2,2,2-trifluoro-
acetamido)butanoyl)pyrrolidine-2-carboxamide × TFA  
[Tfa-Dpheg-Pro-(4-Amba) × TFA] (MI-0457) 
N
O
H
N
O
HNTfa
NH
NH2
 
The intermediate 197 was hydrogenated according to method F. 
Yield: 69 mg (0.096 mmol), white powder. 
HPLC: 53.2% B; TLC: Rf 0.88; MS calcd: 607.28, found: 608.31, (M+H)+. 
Experimental part 
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271) (S)-1-(2-benzyl-3-phenyl-2-(2,2,2-trifluoroacetamido)propanoyl)-N-(4-
carbamimidoylbenzyl)pyrrolidine-2-carboxamide × TFA  
[Tfa-Dbzg-Pro-(4-Amba) × TFA] (MI-0456) 
N
H
NOO
NHTfa
NH2
NH
 
The intermediate 200 was hydrogenated according to method F. 
Yield: 133 mg (0.192 mmol), white powder. 
HPLC: 48.3% B; TLC: Rf 0.83; MS calcd: 579.25, found. 580.22 (M+H)+. 
272) (S)-1-(2-amino-2-phenethyl-4-phenylbutanoyl)-N-(4-carbamimidoylbenzyl)-
pyrrolidine-2-carboxamide × 2 TFA  
[H-Dpheg-Pro-(4-Amba) × 2 TFA] (MI-0459) 
N
O
H
N
O
H2N
NH2
NH
 
The intermediate 203 was hydrogenated according to method F. 
Yield: 57 mg (0.077 mmol), white powder.  
HPLC: 37.7% B; TLC: Rf 0.81; MS calcd: 511.29, found. 512.28 (M+H)+. 
273) (S)-1-((S)-2-amino-4-phenylbutanoyl)-N-(4-carbamimidoylbenzyl)-
pyrrolidine-2-carboxamide × 2 TFA  
[H-hPhe-Pro-4-Amba × 2 TFA] (MI-0464) 
N
O
H
N
NH2
HN
NH2
O
(S)-1-((S)-2-amino-4-phenylbutanoyl)-N -(4-carbamimidoylbenzyl)pyrrolidine-2-carboxamide  
The intermediate 206 was deprotected by TFA according to method B. 
Yield: 35 mg (0.055 mmol), white powder. 
HPLC: 25.1% B; TLC: Rf 0.75; MS calcd: 407.23, found: 408.29 (M+H)+. 
Experimental part 
153 
 
Additional analogues 274-278 (Table 5.22) were prepared from deprotecting the 
intermediates 207-209, 211, 212 according to method B. 
Table 5.22: Synthesis, yield and analytical characterization of inhibitors 274-278 having the general 
formula. 
N
H NH2
NH
P2
P3
 
No. P3 P2 
Educt 
Intermediate 
No. 
Yielda 
mg/mmol 
HPLC 
% B 
TLC 
Rf 
MS 
calcd, found (M+H)+ 
274 
MI-0465 H-Phe Pro 207 53/085 22.3 0.74 393.22, 394.12 
275 
MI-0466 H-D-Phe Pro 208 39/0.63 23.6 0.77 393.22, 394.29 
276 
MI-0467 H-D-hPhe Pro 209 35/0.055 26.3 0.79 407.23, 408.37 
277 
MI-0469 H-D-hPhe Ala 211 45/0.074 24.8 0.75 381.22, 382.43 
278 
MI-0470 H-D-hTyr Ala 212 20/0.032 18.9 0.72 397.22, 398.22 
awhite powder after lyophilization 
279) (S)-1-((R)-2-amino-5-guanidinopentanoyl)-N-(4-carbamimidoylbenzyl)-
pyrrolidine-2-carboxamide × 3 TFA  
[H-D-Arg-Pro-4-Amba × 3 TFA] (MI-0468) 
N
O H
N NH2
NH
O
NH2
N
H
H2N
NH
 
Intermediate 210 was deprotected according to method E, purified by preparative HPLC 
and lyophilized from 80% tert-butanol. 
Yield: 49 mg (0.066 mmol), white powder. 
HPLC: 14.6% B; TLC: Rf 0.2; MS calcd: 402.25, found. 403.51 (M+H)+. 
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